<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Interventions for acne scars - Abdel Hay, R - 2016 | Cochrane Library</title> <meta content="Interventions for acne scars - Abdel Hay, R - 2016 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011946.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Interventions for acne scars - Abdel Hay, R - 2016 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011946.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD011946.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Interventions for acne scars" name="citation_title"/> <meta content="Rania Abdel Hay" name="citation_author"/> <meta content="Faculty of Medicine, Cairo University" name="citation_author_institution"/> <meta content="raniamounir@kasralainy.edu.eg" name="citation_author_email"/> <meta content="Khalid Shalaby" name="citation_author"/> <meta content="Ain Shams University" name="citation_author_institution"/> <meta content="Hesham Zaher" name="citation_author"/> <meta content="Faculty of Medicine, Cairo University" name="citation_author_institution"/> <meta content="Vanessa Hafez" name="citation_author"/> <meta content="Cairo University" name="citation_author_institution"/> <meta content="Ching‐Chi Chi" name="citation_author"/> <meta content="Sandra Dimitri" name="citation_author"/> <meta content="Ain Shams University" name="citation_author_institution"/> <meta content="Ashraf F Nabhan" name="citation_author"/> <meta content="Ain Shams University" name="citation_author_institution"/> <meta content="Alison M Layton" name="citation_author"/> <meta content="Harrogate and District NHS Foundation Trust" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="4" name="citation_issue"/> <meta content="10.1002/14651858.CD011946.pub2" name="citation_doi"/> <meta content="2016" name="citation_date"/> <meta content="2016/04/03" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011946.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011946.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011946.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="*Needles; Acne Vulgaris [*complications]; Atrophy; Catheter Ablation [*methods]; Chemexfoliation [adverse effects, *methods]; Cicatrix [pathology, *therapy]; Cosmetic Techniques [instrumentation]; Dermal Fillers [*therapeutic use]; Hypertrophy; Laser Therapy [adverse effects, *methods]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011946.pub2&amp;doi=10.1002/14651858.CD011946.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011946.pub2&amp;doi=10.1002/14651858.CD011946.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011946.pub2&amp;doi=10.1002/14651858.CD011946.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011946.pub2&amp;doi=10.1002/14651858.CD011946.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011946.pub2&amp;doi=10.1002/14651858.CD011946.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011946.pub2&amp;doi=10.1002/14651858.CD011946.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011946.pub2&amp;doi=10.1002/14651858.CD011946.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011946.pub2&amp;doi=10.1002/14651858.CD011946.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011946.pub2&amp;doi=10.1002/14651858.CD011946.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011946.pub2&amp;doi=10.1002/14651858.CD011946.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011946.pub2&amp;doi=10.1002/14651858.CD011946.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011946.pub2&amp;doi=10.1002/14651858.CD011946.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011946.pub2&amp;doi=10.1002/14651858.CD011946.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011946.pub2&amp;doi=10.1002/14651858.CD011946.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011946.pub2&amp;doi=10.1002/14651858.CD011946.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011946.pub2&amp;doi=10.1002/14651858.CD011946.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011946.pub2&amp;doi=10.1002/14651858.CD011946.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011946.pub2&amp;doi=10.1002/14651858.CD011946.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011946.pub2&amp;doi=10.1002/14651858.CD011946.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011946.pub2&amp;doi=10.1002/14651858.CD011946.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011946.pub2&amp;doi=10.1002/14651858.CD011946.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011946.pub2&amp;doi=10.1002/14651858.CD011946.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011946.pub2&amp;doi=10.1002/14651858.CD011946.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="bzu3XIhG";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD011946\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD011946\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011946\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011946\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","zh_HANT","ru","hr","pl","fr","fa","ms"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD011946.pub2",title:"Interventions for acne scars",firstPublishedDate:"Apr 3, 2016 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Skin Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=bzu3XIhG&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011946.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011946.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD011946.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD011946.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011946.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD011946.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;Abstract&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Laienverständliche Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;Plain language summary&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD011946.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD011946.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD011946.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD011946.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>12560 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD011946.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011946.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011946.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011946.pub2/full#CD011946-abs-0005"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011946.pub2/full#CD011946-sec-0169"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011946.pub2/full#CD011946-sec-0036"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011946.pub2/full#CD011946-sec-0037"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011946.pub2/full#CD011946-sec-0044"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011946.pub2/full#CD011946-sec-0045"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011946.pub2/full#CD011946-sec-0082"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011946.pub2/full#CD011946-sec-0163"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011946.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011946.pub2/appendices#CD011946-sec-0179"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011946.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011946.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD011946.pub2/media/CDSR/CD011946/table_n/CD011946StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD011946.pub2/media/CDSR/CD011946/table_n/CD011946StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011946.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011946.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011946.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD011946.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD011946.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD011946.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2016 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Interventions for acne scars</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011946.pub2/information#CD011946-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Rania Abdel Hay</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011946.pub2/information#CD011946-cr-0003">Khalid Shalaby</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011946.pub2/information#CD011946-cr-0004">Hesham Zaher</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011946.pub2/information#CD011946-cr-0005">Vanessa Hafez</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011946.pub2/information#CD011946-cr-0006">Ching‐Chi Chi</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011946.pub2/information#CD011946-cr-0007">Sandra Dimitri</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011946.pub2/information#CD011946-cr-0008">Ashraf F Nabhan</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011946.pub2/information#CD011946-cr-0009">Alison M Layton</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/information/en#CD011946-sec-0187">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 03 April 2016 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD011946.pub2">https://doi.org/10.1002/14651858.CD011946.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD011946-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011946-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011946-abs-0004">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011946-abs-0013">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD011946-abs-0003">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD011946-abs-0002">繁體中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD011946-abs-0001" lang="en"> <section id="CD011946-sec-0001"> <h3 class="title" id="CD011946-sec-0001">Background</h3> <p>Acne scarring is a frequent complication of acne and resulting scars may negatively impact on an affected person's psychosocial and physical well‐being. Although a wide range of interventions have been proposed, there is a lack of high‐quality evidence on treatments for acne scars to better inform patients and their healthcare providers about the most effective and safe methods of managing this condition. This review aimed to examine treatments for atrophic and hypertrophic acne scars, but we have concentrated on facial atrophic scarring. </p> </section> <section id="CD011946-sec-0002"> <h3 class="title" id="CD011946-sec-0002">Objectives</h3> <p>To assess the effects of interventions for treating acne scars.</p> </section> <section id="CD011946-sec-0003"> <h3 class="title" id="CD011946-sec-0003">Search methods</h3> <p>We searched the following databases up to November 2015: the Cochrane Skin Group Specialised Register, the Cochrane Central Register of Controlled Trials (CENTRAL) in the Cochrane Library (2015, Issue 10), MEDLINE (from 1946), EMBASE (from 1974), and LILACS (from 1982). We also searched five trials registers, and checked the reference lists of included studies and relevant reviews for further references to randomised controlled trials. </p> </section> <section id="CD011946-sec-0004"> <h3 class="title" id="CD011946-sec-0004">Selection criteria</h3> <p>We include randomised controlled trials (RCTs) which allocated participants (whether split‐face or parallel arms) to any active intervention (or a combination) for treating acne scars. We excluded studies dealing only or mostly with keloid scars. </p> </section> <section id="CD011946-sec-0005"> <h3 class="title" id="CD011946-sec-0005">Data collection and analysis</h3> <p>Three review authors independently extracted data from each of the studies included in this review and evaluated the risks of bias. We resolved disagreements by discussion and arbitration supported by a method expert as required. Our primary outcomes were participant‐reported scar improvement and any adverse effects serious enough to cause participants to withdraw from the study. </p> </section> <section id="CD011946-sec-0006"> <h3 class="title" id="CD011946-sec-0006">Main results</h3> <p>We included 24 trials with 789 adult participants aged 18 years or older. Twenty trials enrolled men and women, three trials enrolled only women and one trial enrolled only men. We judged eight studies to be at low risk of bias for both sequence generation and allocation concealment. With regard to blinding we judged 17 studies to be at high risk of performance bias, because the participants and dermatologists were not blinded to the treatments administered or received; however, we judged all 24 trials to be at a low risk of detection bias for outcome assessment. We evaluated 14 comparisons of seven interventions and four combinations of interventions. Nine studies provided no usable data on our outcomes and did not contribute further to this review's results. </p> <p>For our outcome 'Participant‐reported scar improvement' in one study fractional laser was more effective in producing scar improvement than non‐fractional non‐ablative laser at week 24 (risk ratio (RR) 4.00, 95% confidence interval (CI) 1.25 to 12.84; n = 64; very low‐quality evidence); fractional laser showed comparable scar improvement to fractional radiofrequency in one study at week eight (RR 0.78, 95% CI 0.36 to 1.68; n = 40; very low‐quality evidence) and was comparable to combined chemical peeling with skin needling in a different study at week 48 (RR 1.00, 95% CI 0.60 to 1.67; n = 26; very low‐quality evidence). In a further study chemical peeling showed comparable scar improvement to combined chemical peeling with skin needling at week 32 (RR 1.24, 95% CI 0.87 to 1.75; n = 20; very low‐quality evidence). Chemical peeling in one study showed comparable scar improvement to skin needling at week four (RR 1.13, 95% CI 0.69 to 1.83; n = 27; very low‐quality evidence). In another study, injectable fillers provided better scar improvement compared to placebo at week 24 (RR 1.84, 95% CI 1.31 to 2.59; n = 147 moderate‐quality evidence). </p> <p>For our outcome ‘Serious adverse effects’ in one study chemical peeling was not tolerable in 7/43 (16%) participants (RR 5.45, 95% CI 0.33 to 90.14; n = 58; very low‐quality evidence). </p> <p>For our secondary outcome ‘Participant‐reported short‐term adverse events’, all participants reported pain in the following studies: in one study comparing fractional laser to non‐fractional non‐ablative laser (RR 1.00, 95% CI 0.94 to 1.06; n = 64; very low‐quality evidence); in another study comparing fractional laser to combined peeling plus needling (RR 1.00, 95% CI 0.86 to 1.16; n = 25; very low‐quality evidence); in a study comparing chemical peeling plus needling to chemical peeling (RR 1.00, 95% CI 0.83 to 1.20; n = 20; very low‐quality evidence); in a study comparing chemical peeling to skin needling (RR 1.00, 95% CI 0.87 to 1.15; n = 27; very low‐quality evidence); and also in a study comparing injectable filler and placebo (RR 1.03, 95% CI 0.10 to 11.10; n = 147; low‐quality evidence). </p> <p>For our outcome ‘Investigator‐assessed short‐term adverse events’, fractional laser (6/32) was associated with a reduced risk of hyperpigmentation than non‐fractional non‐ablative laser (10/32) in one study (RR 0.60, 95% CI 0.25 to 1.45; n = 64; very low‐quality evidence); chemical peeling was associated with increased risk of hyperpigmentation (6/12) compared to skin needling (0/15) in one study (RR 16.00, 95% CI 0.99 to 258.36; n = 27; low‐quality evidence). There was no difference in the reported adverse events with injectable filler (17/97) compared to placebo (13/50) (RR 0.67, 95% CI 0.36 to 1.27; n = 147; low‐quality evidence). </p> </section> <section id="CD011946-sec-0007"> <h3 class="title" id="CD011946-sec-0007">Authors' conclusions</h3> <p>There is a lack of high‐quality evidence about the effects of different interventions for treating acne scars because of poor methodology, underpowered studies, lack of standardised improvement assessments, and different baseline variables. </p> <p>There is moderate‐quality evidence that injectable filler might be effective for treating atrophic acne scars; however, no studies have assessed long‐term effects, the longest follow‐up being 48 weeks in one study only. Other studies included active comparators, but in the absence of studies that establish efficacy compared to placebo or sham interventions, it is possible that finding no evidence of difference between two active treatments could mean that neither approach works. The results of this review do not provide support for the first‐line use of any intervention in the treatment of acne scars. </p> <p>Although our aim was to identify important gaps for further primary research, it might be that placebo and or sham trials are needed to establish whether any of the active treatments produce meaningful patient benefits over the long term. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD011946-abs-0005" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011946-abs-0005">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD011946-abs-0006">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD011946-abs-0012">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011946-abs-0014">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD011946-abs-0011">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD011946-abs-0009">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ms#CD011946-abs-0015">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD011946-abs-0010">Polski</a> </li> <li class="section-language"> <a class="" href="full/ru#CD011946-abs-0008">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD011946-abs-0007">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD011946-abs-0005" lang="en"> <h3>Treatment for acne scars</h3> <p><b>Review question</b> </p> <p>Which treatments are effective for acne scars?</p> <p><b>Background</b> </p> <p>Acne scars may have a damaging effect on a person's physical, mental, and social well‐being. Although a wide range of treatments are used, there is a lack of high‐quality evidence on which are the most effective for acne scars. </p> <p>This review aimed to better inform patients and healthcare providers about the most effective and safe methods to manage this problem. We have examined treatments for atrophic scars (depressions in the skin surface) and hypertrophic scars (lumpy scars that stick out from the skin surface) in acne but have concentrated on facial atrophic scarring. Our main outcomes of interest were participant‐reported scar improvement and any adverse effects serious enough to cause participants to withdraw from the study. </p> <p><b>Study characteristics</b> </p> <p>We include 24 randomised controlled trials (RCTs) with 789 people with acne scars (from searches up to November 2015). Twenty‐one RCTs (706 people) enrolled both men and women, three RCTs (75 people) enrolled only women and one RCT (eight people) enrolled only men. Most of the studies we included (21 RCTs with 744 people) enrolled people with atrophic acne scars. One RCT enrolled 20 individuals with mixed atrophic and hypertrophic acne scars. </p> <p><b>Key results</b> </p> <p>There is insufficient evidence from trials to support fractional laser for treatment of acne. However, this management approach is adopted by some in clinical practice for the treatment of acne scarring. </p> <p>For our outcome 'Participant‐reported scar improvement' fractional laser was more effective in producing scar improvement change than non‐fractional non‐ablative laser. Fractional radiofrequency showed similar scar improvement to fractional laser. Chemical peeling showed similar scar improvement to both fractional laser and skin needling. Combined chemical peeling with skin needling showed similar scar improvement to fractional laser and to deep chemical peeling. Injectable fillers provided better scar improvement compared to placebo. </p> <p>Our outcome ‘Serious adverse effects’ was reported in one study, showing that chemical peeling was not tolerable in 16% of those taking part. Other outcomes, ‘Participant‐reported' and 'Investigator‐assessed' adverse events in the short term (less than 24 weeks), were more or less acceptable by those taking part and by investigators and did not reveal a big difference between the studied interventions. </p> <p>Four out of six of our comparisons were completely inconclusive and they were of very low‐quality evidence. There is a lack of studies that establish efficacy of treatments compared to placebo or sham interventions, and it is possible that finding no evidence of difference between two active treatments could mean that neither is very useful. </p> <p>We did not identify any trials that examined treatment for acne scars on the back.</p> <p>The results of this review do not support the first‐line use of any intervention in the treatment of acne scars, and no studies provided evidence to confirm that any short‐term benefit will translate to long‐term effects. </p> <p><b>Quality of the evidence</b> </p> <p>We rated the quality of the evidence for several outcomes as very low to moderate. The lower quality evidence for treatments was mostly because there were few people in the studies, making the results less precise, and there was a lack of blinding (people knew the treatment they were receiving). </p> <p>Future studies should consider adopting patient‐reported outcomes as a primary measure. There should be a set of core outcome measures reported in all RCTs for treating acne scars, and outcomes should be evaluated several months after the treatment has been done. Lack of reporting of serious side effects was one of the research gaps found in this review. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD011946-sec-0169" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD011946-sec-0169"></div> <h3 class="title" id="CD011946-sec-0170">Implications for practice</h3> <section id="CD011946-sec-0170"> <p>Overall, our review found that knowledge gaps predominate over robust evidence for the treatment of acne scars. Only 24 RCTs met our inclusion criteria, with a total of 789 participants. Imprecision due to small numbers of participants led us to downgrade the quality of evidence for several of our comparisons. The small numbers of participants in many studies are not easily remedied due to the fact that most studies are unfunded or minimally funded. In the context that most interventions were investigated by a single RCT, it is difficult to draw meaningful conclusions about efficacy and adverse effects, particularly long‐term effects or delayed events. </p> <p>The results of this review do not provide sufficient evidence to support the first‐line use of any intervention in the treatment of acne scars, and the relative safety of the different interventions has not been adequately determined. </p> <p>There is moderate‐quality evidence that injectable fillers improve atrophic acne scars; however, the impermanence of their effect and their minimal utility for fine sharply‐depressed scars (e.g. box‐car and ice‐pick scars) from the clinical point of view should be also considered. Use of non‐fractional non‐ablative laser, fractional laser, fractional radiofrequency, chemical peeling, skin needling, and combined needling with chemical peeling in acne scars is given only limited support, based on evidence from our review. </p> <p>There is no high‐quality evidence to determine the effects or the safety of subcision, combined fractional laser with PRP, combined fractional laser with punch elevation, and combined microdermabrasion plus ALA‐PDT in acne scars. </p> <p>There are no RCTs to determine which should be the gold standard treatment against which other treatments should be measured. The utility of full‐face treatment methods for treating atrophic acne scars, whether by laser ablation and thermal destruction (e.g. fully ablative CO₂ resurfacing), mechanical means (e.g. dermabrasion), or chemical dissolution (e.g. phenol peel) have fallen into disfavour due to the attendant protracted post‐treatment down time and relatively elevated risk of long‐term adverse effects, such as scar or hypopigmentation. </p> <p>The nine studies in ‘Studies awaiting classification’ may alter the conclusions of the review when they are assessed in future updates of this review. </p> </section> <h3 class="title" id="CD011946-sec-0171">Implications for research</h3> <section id="CD011946-sec-0171"> <p>Our review has highlighted a need for further RCTs to improve the evidence base for most interventions in acne scars. See <a href="#CD011946-tbl-0009">Table 2</a> in which we have identified a lack of a validated standardised improvement scale for all the comparisons listed. </p> <section id="CD011946-sec-0172"> <h5 class="title">Study design</h5> <p>Within‐individual studies may be considered more appropriate than parallel‐group studies, as they reduce the between‐person variance present in parallel studies. Active acne leading to new scar formation may interfere with trials of any design, as does the tendency of some scars to improve spontaneously over time. However some institutional review boards (notably in the USA) find within‐individual studies trials objectionable on ethical grounds, and recruitment into such trials is also difficult. </p> <p>Trials should include a power calculation and recruit sufficient participants to avoid problems with imprecision due to being underpowered. </p> </section> <section id="CD011946-sec-0173"> <h5 class="title">Population</h5> <p>Studies should include adults with atrophic or hypertrophic acne scars subdivided by severity and individual scar type. Populations with acne scars on the back should be included. Future trials should collect baseline variables (participant demographics, acne lesions and extent, skin phototype, scar duration, and depth of scars) to ensure that they are balanced. </p> </section> <section id="CD011946-sec-0174"> <h5 class="title">Intervention</h5> <p>Future studies should include active interventions such as: fractional laser, non‐fractional non‐ablative laser, radiofrequency, microdermabrasion, needling, subcision, punch excision, chemical peeling, injectable fillers, autologous bone marrow stem‐cell transplant, or combined therapy versus placebo or no treatment for atrophic acne scars. For hypertrophic acne scars, future studies should include: Intralesional steroid, low‐level light therapy, cryotherapy, pulsed dye laser, silicone gel, imiquimod, 5‐fluorouracil, interferon, bleomycin, surgery, or combined therapy versus placebo or no treatment. </p> <p>Recommended comparisons should include investigation of the following benefits or disadvantages: </p> <p> <ul id="CD011946-list-0061"> <li> <p>fractional laser (which has fewer side effects) versus non‐fractional ablative laser (which has more side effects) </p> </li> <li> <p>fractional laser (as an expensive tool) versus needling or chemical peeling (as economic tools) </p> </li> <li> <p>fractional laser versus microdermabrasion or versus injectable fillers</p> </li> <li> <p>fractional laser (which has fewer side effects) versus subcision or punch excision (which has more side effects) </p> </li> <li> <p>chemical peeling versus needling or injectable fillers or microdermabrasion</p> </li> <li> <p>needling versus microdermabrasion or subcision or punch excision or fillers</p> </li> <li> <p>injectable fillers versus autologous bone marrow stem‐cell transplants</p> </li> <li> <p>low‐level light therapy versus pulsed dye laser or cryotherapy (as an economic tool)</p> </li> <li> <p>Intralesional steroid (as an economic and practical tool) versus pulsed dye laser, low‐level light therapy or 5‐fluorouracil or bleomycin </p> </li> </ul> </p> </section> <section id="CD011946-sec-0175"> <h5 class="title">Blinding</h5> <p>Participants, clinical investigators and outcome assessors should be blinded to the treatment allocated. </p> </section> <section id="CD011946-sec-0176"> <h5 class="title">Outcomes</h5> <p>The outcomes of a trial should be prospectively declared in a clinical trial database, including the nature and timing of the primary outcome. Outcomes must include a validated standardised improvement scale assessed by both participants and investigators in the short term (in about six months) and in the long term (at least one year), to determine the treatment effect. Outcomes should also include adverse events serious or severe enough to have caused participants’ withdrawal from the study, as well as less serious adverse events reported by both participants and investigators in the short term (within one month) and in the long term (within six months). Equally important are participant satisfaction, and an assessment of quality of life, as well as a measure of post‐procedure down time assessed in days. </p> </section> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD011946-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD011946-sec-0036"></div> <div class="table" id="CD011946-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Fractional laser versus non‐fractional non‐ablative laser for acne scars</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Fractional laser versus non‐fractional non‐ablative laser for acne scars</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with acne scars<br/> <b>Settings:</b> hospital‐based<br/> <b>Intervention:</b> fractional laser versus non‐fractional non‐ablative laser </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Fractional laser versus non‐fractional non‐ablative laser</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participant‐reported scar improvement (long‐term)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not measured</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participant‐reported scar improvement (short‐term)</b> <br/> N of participants with &gt; 50% improvement in acne scars<br/> Follow‐up: mean 6 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>94 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>375 per 1000</b> <br/> (117 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 4</b> <br/> (1.25 to 12.84) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Investigator‐assessed adverse events (short‐term) Hyperpigmentation</b> <br/> N of participants with adverse events<br/> Follow‐up: mean 4 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>312 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>188 per 1000</b> <br/> (78 to 453) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.6</b> <br/> (0.25 to 1.45) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participant‐assessed adverse events (short‐term) Burning</b> <br/> N of participants with adverse events<br/> Follow‐up: mean 4 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>1000 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>1000 per 1000</b> <br/> (940 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1</b> <br/> (0.94 to 1.06) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participant satisfaction</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not measured</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not measured</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded by one level because of unclear allocation concealment and blinding of participant and personnel.<br/> <sup>2</sup>Downgraded two levels for very serious imprecision because the optimal information size (OIS) is not met (should be 5600) and the CI is extremely wide.<br/> <sup>3</sup>Downgraded two levels for very serious imprecision because the optimal information size (OIS) is not met (should be around 1200), very small sample size, and the 95% CI around the estimate of effect includes both no effect and appreciable harm.<br/> <sup>4</sup>Downgraded two levels for very serious imprecision because the optimal information size (OIS) is not met, very small sample size, and the 95% CI around the estimate of effect includes both no effect and appreciable harm. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD011946-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Fractional laser versus radiofrequency for acne scars</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Fractional laser versus radiofrequency for acne scars</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with acne scars<br/> <b>Settings:</b> hospital‐based<br/> <b>Intervention:</b> fractional laser versus radiofrequency </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Fractional laser versus radiofrequency</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participant‐reported scar improvement (long‐term)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not measured</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participant‐reported scar improvement (short‐term)</b> <br/> N of participants with &gt; 50% improvement in acne scars<br/> Follow‐up: mean 8 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>450 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>351 per 1000</b> <br/> (162 to 756) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.78</b> <br/> (0.36 to 1.68) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011946-bbs2-0021" title="RongsaardN , RummaneethornP . Comparison of a fractional bipolar radiofrequency device and a fractional erbium‐doped glass 1,550‐nm device for the treatment of atrophic acne scars: a randomized split‐face clinical study. Dermatologic Surgery2014;40(1):14‐21. [PUBMED: 24267397] ">Rongsaard 2014</a> reported a mean improvement of 2.89 for the fractional laser and 2.74 for the radiofrequency </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Investigator‐assessed adverse events (short‐term)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear whether the reported higher events (erythema, oedema, PIH) with the laser are participant‐ or investigator‐assessed </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participant‐assessed adverse events (short‐term)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>More pain with fractional laser was noticed, <a href="./references#CD011946-bbs2-0021" title="RongsaardN , RummaneethornP . Comparison of a fractional bipolar radiofrequency device and a fractional erbium‐doped glass 1,550‐nm device for the treatment of atrophic acne scars: a randomized split‐face clinical study. Dermatologic Surgery2014;40(1):14‐21. [PUBMED: 24267397] ">Rongsaard 2014</a> and <a href="./references#CD011946-bbs2-0024" title="ZhangZ , FeiY , ChenX , LuW , ChenJ . Comparison of a fractional microplasma radio frequency technology and carbon dioxide fractional laser for the treatment of atrophic acne scars: a randomized split‐face clinical study. Dermatologic Surgery2013;39(4):559‐66. [PUBMED: 23379344] ">Zhang 2013</a> reported higher incidence of positive adverse events with fractional laser </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participant satisfaction</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011946-bbs2-0024" title="ZhangZ , FeiY , ChenX , LuW , ChenJ . Comparison of a fractional microplasma radio frequency technology and carbon dioxide fractional laser for the treatment of atrophic acne scars: a randomized split‐face clinical study. Dermatologic Surgery2013;39(4):559‐66. [PUBMED: 23379344] ">Zhang 2013</a> reported that 30/33 and 31/33 of participants were satisfied with laser and radiofrequency respectively with no significant difference </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not measured</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded by one level because of unclear allocation concealment and high blinding of participant and personnel.<br/> <sup>2</sup>Downgraded two levels for very serious imprecision because the optimal information size (OIS) is not met (should be around 620) and the 95% CI around the estimate of effect includes both no effect and appreciable benefit. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD011946-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Fractional laser versus combined chemical peeling plus needling for acne scars</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Fractional laser versus combined chemical peeling plus needling for acne scars</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with acne scars<br/> <b>Settings:</b> hospital‐based<br/> <b>Intervention:</b> fractional laser versus combined chemical peeling plus needling </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Fractional laser versus combined chemical peeling plus needling</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participant‐reported scar improvement (long‐term)</b> <br/> N of participants with &gt; 50% improvement in acne scars<br/> Follow‐up: mean 12 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>692 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>692 per 1000</b> <br/> (415 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1</b> <br/> (0.6 to 1.67) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participant‐reported scar improvement (short‐term)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not measured</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Investigator‐assessed adverse events (short‐term)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not measured</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participant‐assessed adverse events (short‐term)</b> <br/> N of participants with adverse events<br/> Follow‐up: mean 4 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>1000 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>1000 per 1000</b> <br/> (860 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1</b> <br/> (0.86 to 1.16) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participant satisfaction</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not measured</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not measured</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded by one level for high risk of bias regarding blinding of participants and personnel.<br/> <sup>2</sup>Downgraded two levels for very serious imprecision because the optimal information size (OIS) is not met (should be around 200), very small sample size, and the 95% CI around the estimate of effect includes both no effect and appreciable benefit.<br/> <sup>3</sup>Downgraded two levels for very serious imprecision because the optimal information size (OIS) is not met, very small sample size, and the 95% CI around the estimate of effect includes both no effect and appreciable harm. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD011946-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Chemical peeling versus placebo or no treatment for acne scars</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Chemical peeling versus placebo or no treatment for acne scars</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with acne scars<br/> <b>Settings:</b> out‐patient<br/> <b>Intervention:</b> chemical peeling versus placebo or no treatment </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Chemical peeling versus placebo or no treatment</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participant‐reported scar improvement (long‐term)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not measured</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participant‐reported scar improvement (short‐term)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not measured</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Investigator‐assessed adverse events (short‐term)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not measured</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participant‐assessed adverse events (short‐term)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Burning sensation and deep erythema were reported following frosting in some cases from the chemical peeling </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participant satisfaction</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not measured</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not measured</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious or severe adverse events</b> <br/> N of participants with positive severe adverse events<br/> Follow‐up: mean 6 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> <br/> (0 to 0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 5.45</b> <br/> (0.33 to 90.14) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7/43 participants experienced serious adverse events with chemical peel but 0/15 in the placebo group </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded one level for high risk of attrition bias.<br/> <sup>2</sup>Downgraded two levels for very serious imprecision because the optimal information size (OIS) is far from met, extremely wide CI, due to low occurrence of events in control group and small sample size. 95% CI around the estimate of effect includes both no effect and appreciable harm. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD011946-tbl-0005"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Chemical peeling versus combined chemical peeling plus any active intervention for acne scars</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Chemical peeling versus combined chemical peeling plus any active intervention for acne scars</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with acne scars<br/> <b>Settings:</b> hospital‐based<br/> <b>Intervention:</b> chemical peeling versus combined chemical peeling plus any active intervention </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Chemical peeling versus combined chemical peeling plus any active intervention</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participant‐reported scar improvement (long‐term)</b> <br/> N of participants with &gt; 50% improvement in acne scars<br/> Follow‐up: mean 8 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>800 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>992 per 1000</b> <br/> (696 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.24</b> <br/> (0.87 to 1.75) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participant‐reported scar improvement (short‐term)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not measured</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Investigator‐assessed adverse events (short‐term)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not measured</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participant‐assessed adverse events (short‐term)</b> <br/> N of participants with adverse events<br/> Follow‐up: mean 4 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>1000 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>1000 per 1000</b> <br/> (830 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1</b> <br/> (0.83 to 1.2) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participant satisfaction</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not measured</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not measured</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded by one level due to high risk of bias with regard to blinding of participants and personnel.<br/> <sup>2</sup>Downgraded two levels for very serious imprecision because the optimal information size (OIS) is not met (should be around 100), very small sample size, and the 95% CI around the estimate of effect includes both no effect and appreciable benefit.<br/> <sup>3</sup>Downgraded two levels for very serious imprecision because the optimal information size (OIS) is not met, very small sample size, and the 95% CI around the estimate of effect includes both no effect and appreciable harm. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD011946-tbl-0006"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Chemical peeling versus needling for acne scars</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Chemical peeling versus needling for acne scars</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with acne scars<br/> <b>Settings:</b> hospital‐based<br/> <b>Intervention:</b> chemical peeling versus needling </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Chemical peeling versus needling</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participant‐reported scar improvement (long‐term)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not measured</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participant‐reported scar improvement (short‐term)</b> <br/> N of participants with &gt; 50% improvement in acne scars<br/> Follow‐up: mean 1 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>667 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>747 per 1000</b> <br/> (460 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.13</b> <br/> (0.69 to 1.83) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Investigator‐assessed adverse events (short‐term)</b> <br/> N of participants with adverse events<br/> Follow‐up: mean 4 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 16</b> <br/> (0.99 to 258.36) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>27<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>6/12 participants experienced adverse events with chemical peel</p> <p>but 0/15 with needling</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> <br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> <br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participant‐assessed adverse events (short‐term)</b> <br/> N of participants with positive adverse events<br/> Follow‐up: mean 4 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>1000 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>1000 per 1000</b> <br/> (870 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1</b> <br/> (0.87 to 1.15) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Patient satisfaction</b> <br/> N of satisfied participants<br/> Follow‐up: mean 4 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>667 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>747 per 1000</b> <br/> (460 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.13</b> <br/> (0.69 to 1.83) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not measured</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded by one level due to high risk of bias regarding blinding of participants and personnel.<br/> <sup>2</sup>Downgraded two levels for very serious imprecision because the optimal information size (OIS) is not met (should be around 250), very small sample size, and the 95% CI around the estimate of effect includes both no effect and appreciable benefit.<br/> <sup>3</sup>Downgraded two levels for very serious imprecision because the optimal information size (OIS) is not met, very small sample size, extremely wide CI, and the 95% CI around the estimate of effect includes both no effect and appreciable harm.<br/> <sup>4</sup>Downgraded two levels for very serious imprecision because the optimal information size (OIS) is not met, very small sample size, and the 95% CI around the estimate of effect includes both no effect and appreciable harm. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD011946-tbl-0007"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Injectable fillers versus placebo or no treatment for acne scars</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Injectable fillers versus placebo or no treatment for acne scars</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with acne scars<br/> <b>Settings:</b> outpatient<br/> <b>Intervention:</b> injectable fillers versus placebo or no treatment </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Injectable fillers versus placebo or no treatment</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participant‐assessed scar improvement (long‐term)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not measured</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participant‐reported scar improvement (short‐term)</b> <br/> N of participants with &gt; 50% improvement in acne scars<br/> Follow‐up: mean 6 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>420 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>773 per 1000</b> <br/> (550 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.84</b> <br/> (1.31 to 2.59) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>147<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011946-bbs2-0020" title="MunavalliGS , SmithS , MaslowskiJM , WeissRA . Successful treatment of depressed, distensible acne scars using autologous fibroblasts: a multi‐site, prospective, double blind, placebo‐controlled clinical trial. Dermatologic Surgery2013;39(8):1226‐36. [PUBMED: 23566237] ">Munavalli 2013</a> reported 43% vs 18% improvement with the dermal filler and placebo respectively </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participant satisfaction</b> <br/> N of satisfied participants<br/> Follow‐up: mean 6 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>520 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>848 per 1000</b> <br/> (640 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.63</b> <br/> (1.23 to 2.15) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>147<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participant‐reported adverse events (short‐term)</b> <br/> N of participants with positive adverse events<br/> Follow‐up: mean 4 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>20 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>21 per 1000</b> <br/> (2 to 222) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.03</b> <br/> (0.1 to 11.1) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>147<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Investigator‐assessed adverse events (short‐term)</b> <br/> N of participants with positive adverse events<br/> Follow‐up: mean 4 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>260 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>174 per 1000</b> <br/> (94 to 330) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.67</b> <br/> (0.36 to 1.27) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>147<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011946-bbs2-0020" title="MunavalliGS , SmithS , MaslowskiJM , WeissRA . Successful treatment of depressed, distensible acne scars using autologous fibroblasts: a multi‐site, prospective, double blind, placebo‐controlled clinical trial. Dermatologic Surgery2013;39(8):1226‐36. [PUBMED: 23566237] ">Munavalli 2013</a> reported comparable incidence of events with dermal filler and placebo </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not measured</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded one level for imprecision because the optimal information size (OIS) is not met (should be around 300), although the sample size is not that small.<br/> <sup>2</sup>Downgraded two levels for very serious imprecision because the optimal information size (OIS) is not met (should be around 1500), small sample size, and the 95% CI around the estimate of effect includes both no effect and appreciable harm.<br/> <sup>3</sup>Downgraded two levels for very serious imprecision because the optimal information size (OIS) is not met, and the 95% CI around the estimate of effect includes both no effect and appreciable harm. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD011946-sec-0037" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD011946-sec-0037"></div> <p>A description of key medical terms can be found in <a href="./appendices#CD011946-sec-0180">Appendix 1</a>. </p> <section id="CD011946-sec-0038"> <h3 class="title" id="CD011946-sec-0038">Description of the condition</h3> <section id="CD011946-sec-0039"> <h4 class="title">Acne and its prevalence</h4> <p>Acne vulgaris is a chronic inflammatory condition of the pilosebaceous unit (<a href="./references#CD011946-bbs2-0072" title="FabbrociniG , AnnunziataMC , D'ArcoV , DeVitaV , LodiG , MaurielloMC , et al. Acne scars: pathogenesis, classification and treatment. Dermatology Research and Practice2010;2010:893080. [PUBMED: 20981308] ">Fabbrocini 2010</a>; <a href="./references#CD011946-bbs2-0108" title="WilliamsHC , DellavalleRP , GarnerS . Acne vulgaris. Lancet2012;379(9813):361‐72. [MEDLINE: 21880356] ">Williams 2012</a>). It is notable for open or closed comedones or both and for inflammatory lesions including papules, pustules, or nodules (<a href="./references#CD011946-bbs2-0106" title="StraussJS , KrowchukDP , LeydenJJ , LuckyAW , ShalitaAR , SiegfriedEC , et al. Guidelines of care for acne vulgaris management. Journal of the American Academy of Dermatology2007;56(4):651‐63. [MEDLINE: 17276540] ">Strauss 2007</a>). Acne vulgaris is among the top 10 most prevalent conditions worldwide (<a href="./references#CD011946-bbs2-0086" title="HayRJ , JohnsNE , WilliamsHC , BolligerIW , DellavalleRP , MargolisDJ , et al. The global burden of skin disease in 2010: an analysis of the prevalence and impact of skin conditions. Journal of Investigative Dermatology2014;134(6):1527‐34. [MEDLINE: 24166134] ">Hay 2014</a>), and it is one of the most common skin conditions. Some degree of acne affects almost all adolescents between 15 and 17 years of age (<a href="./references#CD011946-bbs2-0066" title="CollierCN , HarperJC , CafardiJA , CantrellWC , WangW , FosterKW , et al. The prevalence of acne in adults 20 years and older. Journal of the American Academy of Dermatology2007;58(1):56‐9. [MEDLINE: 17945383] ">Collier 2007</a>; <a href="./references#CD011946-bbs2-0108" title="WilliamsHC , DellavalleRP , GarnerS . Acne vulgaris. Lancet2012;379(9813):361‐72. [MEDLINE: 21880356] ">Williams 2012</a>). Up to 80% of adolescents and up to 5% of adults experience acne (<a href="./references#CD011946-bbs2-0091" title="JacobCI , DoverJS , KaminerMS . Acne scarring: a classification system and review of treatment options. Journal of the American Academy of Dermatology2001;45(1):109–17. [MEDLINE: 11423843] ">Jacob 2001</a>). </p> <p>The impact of acne on the quality of life can be profound (<a href="./references#CD011946-bbs2-0068" title="DalgardF , GielerU , HolmJO , BjertnessE , HauserS . Self‐esteem and body satisfaction among late adolescents with acne: results from a population survey. Journal of the American Academy of Dermatology2009;59(5):746‐51. [MEDLINE: 19119094] ">Dalgard 2009</a>). Compared to people without acne, individuals with acne are at a higher risk of experiencing depression and anxiety, especially in those whose quality of life has been affected (<a href="./references#CD011946-bbs2-0070" title="DumanH , TopalIO , KocaturkE , DumanMA . Evaluation of anxiety, depression, and quality of life in patients with acne vulgaris, and quality of life in their families. Dermatologica Sinica In press. [DOI: 10.1016/j.dsi.2015.07.002] ">Duman 2015</a>). They are more likely to have lower self esteem and lower body satisfaction and may be at an increased risk of suicide attempts (<a href="./references#CD011946-bbs2-0101" title="PurvisD , RobinsonE , MerryS , WatsonP . Acne, anxiety, depression and suicide in teenagers: a cross‐sectional survey of New Zealand secondary school students. Journal of Paediatrics and Child Health2006;42(12):793‐6. [PUBMED: 17096715] ">Purvis 2006</a>). Optimal treatments may significantly improve the appearance, quality of life, and self esteem of affected people (<a href="./references#CD011946-bbs2-0101" title="PurvisD , RobinsonE , MerryS , WatsonP . Acne, anxiety, depression and suicide in teenagers: a cross‐sectional survey of New Zealand secondary school students. Journal of Paediatrics and Child Health2006;42(12):793‐6. [PUBMED: 17096715] ">Purvis 2006</a>). </p> <p>It is important for dermatologists to be aware of a condition known as dysmorphophobia or body dysmorphic disorder, which can affect people with acne and acne scars. It is characterised by a distressing and excessive preoccupation with a slight or imagined defect of a physical feature and may significantly damage psychosocial functioning and decrease the quality of life of those affected (<a href="./references#CD011946-bbs2-0067" title="ConradoLA , HounieAG , DinizJB , FossaluzaV , TorresAR , MiguelEC , et al. Body dysmorphic disorder among dermatologic patients: prevalence and clinical features. Journal of the American Academy of Dermatology2010;63(2):235‐43. [MEDLINE: 20561712] ">Conrado 2010</a>; <a href="./references#CD011946-bbs2-0085" title="GuptaR , HuynhM , GinsburgIH . Body dysmorphic disorder. Seminars in Cutaneous Medicine and Surgery2013;32(2):78‐82. [MEDLINE: 24049964] ">Gupta 2013</a>). </p> </section> <section id="CD011946-sec-0040"> <h4 class="title">Acne scars: aetiology, pathology, and prevalence</h4> <p>Scarring, as a physical disfigurement, is a frequent complication of acne. The psychological impact of scarring can be profound; scars can occur as a result of damage to the skin during the healing of active acne (<a href="./references#CD011946-bbs2-0100" title="PatelMJ , AntonyA , DoT , HindsG , SachsD , JVoorhees , et al. Atrophic acne scars may arise from both inflammatory and non‐inflammatory acne lesions. 2010 Annual Meeting of the Society for Investigative Dermatology Atlanta, GA United States. Conference Start: 20100505 Conference End: 20100508. Journal of Investigative Dermatology2010;130(Suppl 1s):S58. [EMBASE: 70123028] ">Patel 2010</a>). Although active acne can persist for a decade or more, acne scars may persist for a lifetime (<a href="./references#CD011946-bbs2-0110" title="JordanR , CumminsCCL , BurlsA , SeukeranDDC . Laser resurfacing for facial acne scars. Cochrane Database of Systematic Reviews2000, Issue 3. [DOI: 10.1002/14651858.CD001866] ">Jordan 2000</a>). One publication (<a href="./references#CD011946-bbs2-0093" title="LaytonAM , HendersonCA , CunliffeWJ . A clinical evaluation of acne scarring and its incidence. Clinical and Experimental Dermatology1994;19(4):303‐8. [MEDLINE: 7955470] ">Layton 1994</a>) on the prevalence of acne scarring suggests that the type and extent of scarring correlates with the site and severity of previous acne and duration of acne before effective treatment. Facial scarring affects both sexes equally and occurs in up to 95% of cases (<a href="./references#CD011946-bbs2-0093" title="LaytonAM , HendersonCA , CunliffeWJ . A clinical evaluation of acne scarring and its incidence. Clinical and Experimental Dermatology1994;19(4):303‐8. [MEDLINE: 7955470] ">Layton 1994</a>). </p> <p>Several classifications and scales have been proposed for facial acne scarring (<a href="./references#CD011946-bbs2-0069" title="DrenoB , KhammariA , OrainN , NorayC , Mérial‐KienyC , MéryS , et al. ECCA grading scale: an original validated acne scar grading scale for clinical practice in dermatology. Dermatology2007;214(1):46‐51. [PUBMED: 17191047] ">Dreno 2007</a>; <a href="./references#CD011946-bbs2-0079" title="GoodmanGJ , BaronJA . Postacne scarring: a qualitative global scarring grading system. Dermatologic Surgery2006;32(12):1458‐66. [MEDLINE: 17199653] ">Goodman 2006a</a>; <a href="./references#CD011946-bbs2-0080" title="GoodmanGJ , BaronJA . Postacne scarring‐‐a quantitative global scarring grading system. Journal of Cosmetic Dermatology2006;5(1):48‐52. [MEDLINE: 17173571] ">Goodman 2006b</a>). </p> <p>Often, scarring is the consequence of severe inflammatory nodulocystic acne, but it may also be the product of superficial inflamed lesions or the squeezing or picking of lesions with the fingernails (<a href="./references#CD011946-bbs2-0100" title="PatelMJ , AntonyA , DoT , HindsG , SachsD , JVoorhees , et al. Atrophic acne scars may arise from both inflammatory and non‐inflammatory acne lesions. 2010 Annual Meeting of the Society for Investigative Dermatology Atlanta, GA United States. Conference Start: 20100505 Conference End: 20100508. Journal of Investigative Dermatology2010;130(Suppl 1s):S58. [EMBASE: 70123028] ">Patel 2010</a>). There are three general types of acne scars, depending on hyperproliferation or loss of collagen: hypertrophic scars, keloid scars or atrophic scars. A person might have one or more types occurring in the same skin area (<a href="./references#CD011946-bbs2-0063" title="Basta‐JuzbasicA . Current therapeutic approach to acne scars. Acta Dermatovenerologica Croatica2010;18(3):171‐5. [MEDLINE: 20887698] ">Basta‐Juzbasic 2010</a>; <a href="./references#CD011946-bbs2-0096" title="MaibachHI , GorouhiF . Evidence Based Dermatology. 2. Shelton, CT: People's Medical Publishing House, 2011. [1607950391] ">Maibach 2011</a>). </p> <p>Atrophic scars are seen in almost 80% to 90% of patients (<a href="./references#CD011946-bbs2-0100" title="PatelMJ , AntonyA , DoT , HindsG , SachsD , JVoorhees , et al. Atrophic acne scars may arise from both inflammatory and non‐inflammatory acne lesions. 2010 Annual Meeting of the Society for Investigative Dermatology Atlanta, GA United States. Conference Start: 20100505 Conference End: 20100508. Journal of Investigative Dermatology2010;130(Suppl 1s):S58. [EMBASE: 70123028] ">Patel 2010</a>). These scars present clinically as indentations in the skin due to loss of collagen and destructive inflammation in the deep dermis with subsequent contraction (<a href="./references#CD011946-bbs2-0091" title="JacobCI , DoverJS , KaminerMS . Acne scarring: a classification system and review of treatment options. Journal of the American Academy of Dermatology2001;45(1):109–17. [MEDLINE: 11423843] ">Jacob 2001</a>). Atrophic scars may be further classified into ice pick scars (V‐shaped epithelial tracts with a sharp margin that can extend deeper in the skin), boxcar scars (a round to oval scar with sharp vertical sides that can extend deeper in the skin), or rolling scars (irregular scars with a rolling or undulating shape that may reach up to 5 mm in diameter) occurring in 60% to 70%, 20% to 30%, and 15% to 25% of patients respectively (<a href="./references#CD011946-bbs2-0091" title="JacobCI , DoverJS , KaminerMS . Acne scarring: a classification system and review of treatment options. Journal of the American Academy of Dermatology2001;45(1):109–17. [MEDLINE: 11423843] ">Jacob 2001</a>). These three scar types are usually seen in the same person, making it difficult to differentiate between them (<a href="./references#CD011946-bbs2-0012" title="LeeDH , ChoiYS , MinSU , YoonMY , SuhDH . Comparison of a 585‐nm pulsed dye laser and a 1064‐nm Nd:YAG laser for the treatment of acne scars: a randomized split‐face clinical study. Journal of the American Academy of Dermatology2009;60(5):801‐7. [PUBMED: 19217691] ">Lee 2009</a>; <a href="./references#CD011946-bbs2-0095" title="LevyLL , ZeichnerJA . Management of acne scarring, part II: a comparative review of non‐laser‐based, minimally invasive approaches. American Journal of Clinical Dermatology2012;13(5):331‐40. [MEDLINE: 22849351] ">Levy 2012</a>). </p> <p>Limited morphological classification of scarring has been described and to date there is poor consensus; clinical assessment of scars demonstrates significant variation between assessors (<a href="./references#CD011946-bbs2-0073" title="FinlayAY , TorresV , KangS , BettoliV , DrenoB , GohCL , et al. Classification of acne scars is difficult even for acne experts. Journal of the European Academy of Dermatology and Venereology2013;27(3):391‐3. [PUBMED: 22329412] ">Finlay 2013</a>). The lack of a universally accepted standardised objective quantification or qualitative scoring to estimate the global severity and burden of disease makes comparisons of treatments for scarring challenging. There is some evidence for differences in innate immune responses in those that scar and do not scar (<a href="./references#CD011946-bbs2-0089" title="HollandDB , JeremyAH , RobertsSG , SeukeranDC , LaytonAM , CunliffeWJ . Inflammation in acne scarring: a comparison of the responses in lesions from patients prone and not prone to scar. British Journal of Dermatology2004;150(1):72‐81. [PUBMED: 14746619] ">Holland 2004</a>); this makes it difficult to interpret results between participants. </p> <p>Hypertrophic and keloidal scars show excessive deposition of collagen with reduced collagenase activity (<a href="./references#CD011946-bbs2-0061" title="AlsterTS , TanziEL . Hypertrophic scars and keloids: etiology and management. American Journal of Clinical Dermatology2003;4(4):235‐43. [MEDLINE: 12680802] ">Alster 2003</a>). Individuals with Type IV/V Fitzpatrick skin types are more liable to develop hypertrophic or keloid scars, and both scars predominantly occur on the trunk (<a href="./references#CD011946-bbs2-0064" title="BrownJJ , BayatA . Genetic susceptibility to raised dermal scarring. British Journal of Dermatology2009;161(1):8‐18. [MEDLINE: 19508304] ">Brown 2009</a>). Typically, hypertrophic scars are raised firm pink lesions that remain within the borders of the original site of injury (<a href="./references#CD011946-bbs2-0076" title="GauglitzGG , KortingHC , PavicicT , RuzickaT , JeschkeMG . Hypertrophic scarring and keloids: pathomechanisms and current and emerging treatment strategies. Molecular Medicine2011;17(1‐2):113‐25. [MEDLINE: 20927486] ">Gauglitz 2011</a>). In contrast, keloids appear reddish‐purple and take the form of papules and nodules usually extending beyond the borders of the original wound (<a href="./references#CD011946-bbs2-0076" title="GauglitzGG , KortingHC , PavicicT , RuzickaT , JeschkeMG . Hypertrophic scarring and keloids: pathomechanisms and current and emerging treatment strategies. Molecular Medicine2011;17(1‐2):113‐25. [MEDLINE: 20927486] ">Gauglitz 2011</a>). Keloids do not tend to regress spontaneously and are frequently resistant to treatment and have a high recurrence rate (<a href="./references#CD011946-bbs2-0064" title="BrownJJ , BayatA . Genetic susceptibility to raised dermal scarring. British Journal of Dermatology2009;161(1):8‐18. [MEDLINE: 19508304] ">Brown 2009</a>; <a href="./references#CD011946-bbs2-0072" title="FabbrociniG , AnnunziataMC , D'ArcoV , DeVitaV , LodiG , MaurielloMC , et al. Acne scars: pathogenesis, classification and treatment. Dermatology Research and Practice2010;2010:893080. [PUBMED: 20981308] ">Fabbrocini 2010</a>; <a href="./references#CD011946-bbs2-0012" title="LeeDH , ChoiYS , MinSU , YoonMY , SuhDH . Comparison of a 585‐nm pulsed dye laser and a 1064‐nm Nd:YAG laser for the treatment of acne scars: a randomized split‐face clinical study. Journal of the American Academy of Dermatology2009;60(5):801‐7. [PUBMED: 19217691] ">Lee 2009</a>). </p> <p>The destructive treatments that we consider in this review can worsen keloids (<a href="./references#CD011946-bbs2-0097" title="MutalikS . Treatment of keloids and hypertrophic scars. Indian Journal of Dermatology, Venereology and Leprology2005;71(1):3‐8. [EMBASE: 2005117802] ">Mutalik 2005</a>). We therefore exclude management of keloidal scars from this review, so this will need to be addressed in a separate review. </p> </section> </section> <section id="CD011946-sec-0041"> <h3 class="title" id="CD011946-sec-0041">Description of the intervention</h3> <p>The management of acne scarring includes various types of resurfacing (chemical peels, lasers, dermabrasion); use of injectable fillers; and also surgical methods, such as needling, subcision, punch excision, or punch elevation (<a href="./references#CD011946-bbs2-0063" title="Basta‐JuzbasicA . Current therapeutic approach to acne scars. Acta Dermatovenerologica Croatica2010;18(3):171‐5. [MEDLINE: 20887698] ">Basta‐Juzbasic 2010</a>; <a href="./references#CD011946-bbs2-0065" title="CaoH , YangG , WangY , LiuJ P , SmithCA , LuoH , et al. Complementary therapies for acne vulgaris. Cochrane Database of Systematic Reviews2015, Issue 1. [DOI: 10.1002/14651858.CD009436.pub2] ">Cao 2015</a>; <a href="./references#CD011946-bbs2-0072" title="FabbrociniG , AnnunziataMC , D'ArcoV , DeVitaV , LodiG , MaurielloMC , et al. Acne scars: pathogenesis, classification and treatment. Dermatology Research and Practice2010;2010:893080. [PUBMED: 20981308] ">Fabbrocini 2010</a>). Different factors, e.g. colour, texture, and morphology, can affect the treatment choice for each individual scar (<a href="./references#CD011946-bbs2-0063" title="Basta‐JuzbasicA . Current therapeutic approach to acne scars. Acta Dermatovenerologica Croatica2010;18(3):171‐5. [MEDLINE: 20887698] ">Basta‐Juzbasic 2010</a>). Combining interventions may produce more benefit compared with a single method alone. Complete resolution of acne scars can not be achieved by the currently available treatment modalities (<a href="./references#CD011946-bbs2-0063" title="Basta‐JuzbasicA . Current therapeutic approach to acne scars. Acta Dermatovenerologica Croatica2010;18(3):171‐5. [MEDLINE: 20887698] ">Basta‐Juzbasic 2010</a>). Early effective treatment of acne is probably the best strategy to prevent or limit post‐acne scarring (<a href="./references#CD011946-bbs2-0082" title="GoodmanGJ . Treatment of acne scarring. In: Zouboulis ChristosC , Katsambas AndreasD , Kligman AlbertM editor(s). Pathogenesis and Treatment of Acne and Rosacea. Heidelberg: Springer Berlin, 2014:527‐36. ">Goodman 2014</a>; <a href="./references#CD011946-bbs2-0108" title="WilliamsHC , DellavalleRP , GarnerS . Acne vulgaris. Lancet2012;379(9813):361‐72. [MEDLINE: 21880356] ">Williams 2012</a>). </p> <p>Different interventions for the treatment of acne scars sometimes entail a significant cost (<a href="./references#CD011946-bbs2-0110" title="JordanR , CumminsCCL , BurlsA , SeukeranDDC . Laser resurfacing for facial acne scars. Cochrane Database of Systematic Reviews2000, Issue 3. [DOI: 10.1002/14651858.CD001866] ">Jordan 2000</a>). The costs for the same intervention sometimes vary considerably between different countries or regions. </p> </section> <section id="CD011946-sec-0042"> <h3 class="title" id="CD011946-sec-0042">How the intervention might work</h3> <p>Traditional ablative laser resurfacing removes the epidermis and part of the dermis of the scars, allowing collagen remodeling and re‐epithelialisation (<a href="./references#CD011946-bbs2-0110" title="JordanR , CumminsCCL , BurlsA , SeukeranDDC . Laser resurfacing for facial acne scars. Cochrane Database of Systematic Reviews2000, Issue 3. [DOI: 10.1002/14651858.CD001866] ">Jordan 2000</a>). Patients typically do not need more than one treatment, but the treatment has adverse effects including persistent erythema, hypopigmentation, hyperpigmentation, infections, and scarring. It also has a recovery period (up to two weeks) (<a href="./references#CD011946-bbs2-0082" title="GoodmanGJ . Treatment of acne scarring. In: Zouboulis ChristosC , Katsambas AndreasD , Kligman AlbertM editor(s). Pathogenesis and Treatment of Acne and Rosacea. Heidelberg: Springer Berlin, 2014:527‐36. ">Goodman 2014</a>). Proper training is required for performing ablative laser resurfacing (<a href="./references#CD011946-bbs2-0082" title="GoodmanGJ . Treatment of acne scarring. In: Zouboulis ChristosC , Katsambas AndreasD , Kligman AlbertM editor(s). Pathogenesis and Treatment of Acne and Rosacea. Heidelberg: Springer Berlin, 2014:527‐36. ">Goodman 2014</a>). </p> <p>Non‐ablative laser resurfacing produces dermal thermal injury while preserving the epidermis; this dermal thermal injury promotes collagen remodeling through the formation of new collagen, which leads to an improvement in the scarring (<a href="./references#CD011946-bbs2-0008" title="HedelundL , MoreauKER , BeyerDM , NymannP , HaedersdalM . Fractional nonablative 1,540‐nm laser resurfacing of atrophic acne scars. A randomized controlled trial with blinded response evaluation. Lasers in Medical Science2010;25(5):749‐54. [EMBASE: 2010472544] ">Hedelund 2010</a>). </p> <p>Fractional laser resurfacing acts, as the name indicates, "on regularly‐spaced arrays over a fraction of the skin surface to induce thermal ablation of microscopic columns of epidermal and dermal tissue" (<a href="./references#CD011946-bbs2-0077" title="GoelA , KrupashankarDS , AurangabadkarS , NischalKC , OmprakashHM , MysoreV . Fractional lasers in dermatology‐‐current status and recommendations. Indian Journal of Dermatology, Venereology and Leprology2011;77(3):369‐79. [DOI: 10.4103/0378‐6323.79732] ">Goel 2011</a>). This approach is more effective than non‐ablative resurfacing while providing a faster recovery when compared with ablative resurfacing (<a href="./references#CD011946-bbs2-0060" title="Alexiades‐ArmenakasMR , DoverJS , ArndtKA . The spectrum of laser skin resurfacing: nonablative, fractional, and ablative laser resurfacing. Journal of the American Academy of Dermatology2008;58(5):719‐37; 738‐40. [MEDLINE: 18423256] ">Alexiades‐Armenakas 2008</a>). Fractional and non‐ablative laser resurfacing have become more popular in practice than ablative laser resurfacing, despite a non‐comparable efficacy, probably because of a lower rate of adverse events (<a href="./references#CD011946-bbs2-0060" title="Alexiades‐ArmenakasMR , DoverJS , ArndtKA . The spectrum of laser skin resurfacing: nonablative, fractional, and ablative laser resurfacing. Journal of the American Academy of Dermatology2008;58(5):719‐37; 738‐40. [MEDLINE: 18423256] ">Alexiades‐Armenakas 2008</a>). </p> <p>Chemical peels (employing glycolic acid, phenol, salicylic‐mandelic acid, or trichloroacetic acid) are used in treating small depressed scars but not ice pick or deep boxcar scars (<a href="./references#CD011946-bbs2-0074" title="GargVK , SinhaS , SarkarR . Glycolic acid peels versus salicylic‐mandelic acid peels in active acne vulgaris and post‐acne scarring and hyperpigmentation: a comparative study. Dermatologic Surgery2008;35(1):59‐65. [MEDLINE: 19076192] ">Garg 2008</a>; <a href="./references#CD011946-bbs2-0075" title="GargS , BavejaS . Combination therapy in the management of atrophic acne scars. Journal of Cutaneous and Aesthetic Surgery2014;7(1):18‐23. [MEDLINE: 24761094] ">Garg 2014</a>). A combination of chemical peeling, subcision, and microneedling may result in a better outcome (<a href="./references#CD011946-bbs2-0072" title="FabbrociniG , AnnunziataMC , D'ArcoV , DeVitaV , LodiG , MaurielloMC , et al. Acne scars: pathogenesis, classification and treatment. Dermatology Research and Practice2010;2010:893080. [PUBMED: 20981308] ">Fabbrocini 2010</a>). However, excessive systemic absorption of phenolic chemical peels might increase the risk of cardiac toxicity (<a href="./references#CD011946-bbs2-0092" title="LandauM . Cardiac complications in deep chemical peels. Dermatologic Surgery2007;33(2):190‐3. [MEDLINE: 17300604] ">Landau 2007</a>). </p> <p>Dermabrasion involves the use of tools (e.g. high‐speed brush, diamond cylinder, fraise, or silicon carbide sandpaper) to remove the epidermis or epidermis and part of the dermis. An advantage of the procedure is that it allows the clinician to etch scar edges precisely without thermal injury. It may be effective for some acne scars, but is usually not used for ice pick or deep boxcar scars (<a href="./references#CD011946-bbs2-0082" title="GoodmanGJ . Treatment of acne scarring. In: Zouboulis ChristosC , Katsambas AndreasD , Kligman AlbertM editor(s). Pathogenesis and Treatment of Acne and Rosacea. Heidelberg: Springer Berlin, 2014:527‐36. ">Goodman 2014</a>). Adverse effects include significant pain and a considerable recovery time. Scarring, pigment alterations, and milia formation can also occur with dermabrasion (<a href="./references#CD011946-bbs2-0082" title="GoodmanGJ . Treatment of acne scarring. In: Zouboulis ChristosC , Katsambas AndreasD , Kligman AlbertM editor(s). Pathogenesis and Treatment of Acne and Rosacea. Heidelberg: Springer Berlin, 2014:527‐36. ">Goodman 2014</a>). </p> <p>Skin‐needling procedures may diminish the appearance of acne scars. A needling device is rolled over the surface of the skin to form numerous perforations in the epidermis and dermis, with a goal of stimulating new collagen (<a href="./references#CD011946-bbs2-0001" title="AlamM , HanS , PongprutthipanM , DisphanuratW , KakarR , NodzenskiM , et al. Efficacy of a needling device for the treatment of acne scars: a randomized clinical trial. JAMA Dermatology2014;150(8):844‐9. [PUBMED: 24919799] PongprutthipanM , NodzenskiM , VeledarE , WestD , DubinaM , AlamM , et al. A randomized controlled trial to assess the efficacy of a needling device for the treatment of acne scars. Lasers in Surgery and Medicine2014;46:4. [EMBASE: 71594493] ">Alam 2014</a>). Needling therapy has been associated with improvement of dermatologist‐rated acne scarring (<a href="./references#CD011946-bbs2-0001" title="AlamM , HanS , PongprutthipanM , DisphanuratW , KakarR , NodzenskiM , et al. Efficacy of a needling device for the treatment of acne scars: a randomized clinical trial. JAMA Dermatology2014;150(8):844‐9. [PUBMED: 24919799] PongprutthipanM , NodzenskiM , VeledarE , WestD , DubinaM , AlamM , et al. A randomized controlled trial to assess the efficacy of a needling device for the treatment of acne scars. Lasers in Surgery and Medicine2014;46:4. [EMBASE: 71594493] ">Alam 2014</a>). The advantages of skin needling include low cost, a relatively short recovery period (two to three days), and a very low risk for postinflammatory hyperpigmentation (<a href="./references#CD011946-bbs2-0071" title="FabbrociniG , FardellaN , MonfrecolaA , ProiettiI , InnocenziD . Acne scarring treatment using skin needling. Clinical and Experimental Dermatology2009;34(8):874‐9. [MEDLINE: 19486041] ">Fabbrocini 2009</a>). Skin needling treatment is well tolerated by most people and the pain is minimal (<a href="./references#CD011946-bbs2-0001" title="AlamM , HanS , PongprutthipanM , DisphanuratW , KakarR , NodzenskiM , et al. Efficacy of a needling device for the treatment of acne scars: a randomized clinical trial. JAMA Dermatology2014;150(8):844‐9. [PUBMED: 24919799] PongprutthipanM , NodzenskiM , VeledarE , WestD , DubinaM , AlamM , et al. A randomized controlled trial to assess the efficacy of a needling device for the treatment of acne scars. Lasers in Surgery and Medicine2014;46:4. [EMBASE: 71594493] ">Alam 2014</a>). </p> <p>Punch excision may be an effective treatment for ice pick scars and small (&lt; 3 mm) boxcar scars. A punch biopsy instrument of equal to or slightly greater diameter than the scar is used to incise the tissue to the subcutaneous fat layer and excise the scar (<a href="./references#CD011946-bbs2-0084" title="GrevelinkJM , WhiteVR . Concurrent use of laser skin resurfacing and punch excision in the treatment of facial acne scarring. Dermatologic Surgery1998;24(5):527‐30. [EMBASE: 1998165350] ">Grevelink 1998</a>). It has been associated with good results, but secondary widening of the scar may occur (<a href="./references#CD011946-bbs2-0082" title="GoodmanGJ . Treatment of acne scarring. In: Zouboulis ChristosC , Katsambas AndreasD , Kligman AlbertM editor(s). Pathogenesis and Treatment of Acne and Rosacea. Heidelberg: Springer Berlin, 2014:527‐36. ">Goodman 2014</a>). </p> <p>Punch elevation is best suited for boxcar scars (<a href="./references#CD011946-bbs2-0081" title="GoodmanGJ , BaronJA . The management of postacne scarring. Dermatologic Surgery2007;33(10):1175‐88. [EMBASE: 2007481881] ">Goodman 2007</a>). The scar border is excised, leaving the deepest part of the scar that is adherent to the fat layer. The scar is raised higher than the surrounding skin; it then retracts during healing to become level with the surface (<a href="./references#CD011946-bbs2-0082" title="GoodmanGJ . Treatment of acne scarring. In: Zouboulis ChristosC , Katsambas AndreasD , Kligman AlbertM editor(s). Pathogenesis and Treatment of Acne and Rosacea. Heidelberg: Springer Berlin, 2014:527‐36. ">Goodman 2014</a>). </p> <p>Subcision is used for the management of rolling or depressed scars; a blade inserted parallel to the skin surface is used to cut fibrotic strands tethering the scar to the underlying tissue (<a href="./references#CD011946-bbs2-0091" title="JacobCI , DoverJS , KaminerMS . Acne scarring: a classification system and review of treatment options. Journal of the American Academy of Dermatology2001;45(1):109–17. [MEDLINE: 11423843] ">Jacob 2001</a>). Reported adverse effects include bruising and swelling, bleeding, and infection (<a href="./references#CD011946-bbs2-0059" title="AlamM , OmuraN , KaminerMS . Subcision for acne scarring: technique and outcomes in 40 patients. Dermatologic Surgery2005;31(3):310‐7; 317. [MEDLINE: 15841633] ">Alam 2005</a>). </p> <p>Injectable filler injections used for atrophic scars have been proposed to improve the appearance of acne scars; collagen, autologous fat transfer, and artificial injectable fillers are most commonly used (<a href="./references#CD011946-bbs2-0010" title="KarnikJ , BaumannL , BruceS , CallenderV , CohenS , GrimesP , et al. A double‐blind, randomized, multicenter, controlled trial of suspended polymethylmethacrylate microspheres for the correction of atrophic facial acne scars. Journal of the American Academy of Dermatology2014;71(1):77‐83. [EMBASE: 2014426024] ">Karnik 2014</a>). Their effect lasts from three to 18 months, depending on the type of filler used (<a href="./references#CD011946-bbs2-0010" title="KarnikJ , BaumannL , BruceS , CallenderV , CohenS , GrimesP , et al. A double‐blind, randomized, multicenter, controlled trial of suspended polymethylmethacrylate microspheres for the correction of atrophic facial acne scars. Journal of the American Academy of Dermatology2014;71(1):77‐83. [EMBASE: 2014426024] ">Karnik 2014</a>). </p> <p>Hypertrophic scars are classically treated with intralesional corticosteroid injections (<a href="./references#CD011946-bbs2-0062" title="ArnoAI , GauglitzGG , BarretJP , JeschkeMG . Up‐to‐date approach to manage keloids and hypertrophic scars: a useful guide. Burns2014;40(7):1255‐66. [MEDLINE: 24767715] ">Arno 2014</a>). Using multiple treatment methods gives the maximum potential for success, including earlier use of 5‐fluorouracil (<a href="./references#CD011946-bbs2-0097" title="MutalikS . Treatment of keloids and hypertrophic scars. Indian Journal of Dermatology, Venereology and Leprology2005;71(1):3‐8. [EMBASE: 2005117802] ">Mutalik 2005</a>). Clinical research increasingly supports the use of newer agents (e.g. bleomycin, onion extract, imiquimod, mitomycin C) and laser therapy (pulsed‐dye, fractional) for this type of scar management (<a href="./references#CD011946-bbs2-0078" title="GoldMH , McGuireM , MustoeTA , PusicA , SachdevM , WaibelJ , et al. Updated international clinical recommendations on scar management: part 2‐‐algorithms for scar prevention and treatment. Dermatologic Surgery2014;40(8):825‐31. [MEDLINE: 25068544] ">Gold 2014</a>). </p> </section> <section id="CD011946-sec-0043"> <h3 class="title" id="CD011946-sec-0043">Why it is important to do this review</h3> <p>Acne scars may cause important detrimental effects on a person's physical, mental, and social well‐being (<a href="./references#CD011946-bbs2-0101" title="PurvisD , RobinsonE , MerryS , WatsonP . Acne, anxiety, depression and suicide in teenagers: a cross‐sectional survey of New Zealand secondary school students. Journal of Paediatrics and Child Health2006;42(12):793‐6. [PUBMED: 17096715] ">Purvis 2006</a>). Although a wide range of interventions have been proposed in this field, there is a lack of high‐quality synthesised evidence on interventions for acne scars to better inform caregivers and consumers about the most effective and safe methods to manage this problem. </p> <p>Treatment of acne scars is among the top 10 research priorities for the treatment of acne identified by the Acne Priority Setting Partnership. The Acne Priority Setting Partnership was set up to identify and rank treatment uncertainties by bringing together consumers and professionals who provide care within and beyond the National Health Service (NHS) (<a href="./references#CD011946-bbs2-0094" title="LaytonA , EadyEA , PeatM , WhitehouseH , LevellN , RiddM , et al. Identifying acne treatment uncertainties via a James Lind Alliance Priority Setting Partnership. BMJ Open2015;5(7):e008085. [MEDLINE: 26187120] ">Layton 2015</a>). The National Institute for Health Research (NIHR) Health Technology Assessment (HTA) programme and its initiative to support the current review will use knowledge gaps identified by the review to inform areas of future research. </p> <p>We have built on and expanded the work previously published in a Cochrane review that assessed laser resurfacing for facial acne scars (<a href="./references#CD011946-bbs2-0110" title="JordanR , CumminsCCL , BurlsA , SeukeranDDC . Laser resurfacing for facial acne scars. Cochrane Database of Systematic Reviews2000, Issue 3. [DOI: 10.1002/14651858.CD001866] ">Jordan 2000</a>). We have taken into account the uncertainties identified by that review. </p> <p>Given the physical disfigurement associated with acne vulgaris, along with the potentially profound psychological impact of this skin disorder, we think it is necessary to assess the evidence on the benefits and harms of available treatments for acne scars. We are interested in acne scars on both face and back, but we have concentrated in this review on facial scars. </p> <p>The plans for this review were published in the protocol 'Interventions for acne scars' (<a href="./references#CD011946-bbs2-0109" title="Abdel HayR , ShalabyK , ZaherH , HafezV , ChiC‐C , DimitriS , et al. Interventions for acne scars. Cochrane Database of Systematic Reviews2015, Issue 11. [DOI: 10.1002/14651858.CD011946] ">Abdel Hay 2015</a>) </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD011946-sec-0044" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD011946-sec-0044"></div> <p>To assess the effects of interventions for treating acne scars.</p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD011946-sec-0045" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD011946-sec-0045"></div> <section id="CD011946-sec-0046"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD011946-sec-0047"> <h4 class="title">Types of studies</h4> <p>We include randomised controlled trials (RCTs) allocating participants (whether by split‐face or parallel study designs) to any active intervention (or a combination) for treating acne scars. In multi‐arm trials, we have included all eligible arms. </p> <p>We exclude cluster trials, cross‐over trials, and quasi‐RCTs.</p> </section> <section id="CD011946-sec-0048"> <h4 class="title">Types of participants</h4> <p>People of either gender, all ages, and all ethnic groups who had been diagnosed by a dermatologist or an experienced investigator as having atrophic or hypertrophic acne scars. We include all grades of scar severity. </p> <p>We exclude studies dealing with only or mostly keloid scars, because the destructive treatments that we consider in this review may worsen keloids. </p> </section> <section id="CD011946-sec-0049"> <h4 class="title">Types of interventions</h4> <p>We include all interventions versus an active intervention, placebo, or no treatment. We consider all active interventions, including chemical peeling, dermabrasion and microdermabrasion, laser therapy, radiofrequency, punch techniques and dermal grafting, tissue‐augmenting agents, needling, subcision, intralesional steroid injection, silicone gel, cryotherapy, pulsed dye laser, imiquimod, 5‐fluorouracil, interferon, bleomycin, surgery, or combined therapy. </p> </section> <section id="CD011946-sec-0050"> <h4 class="title">Types of outcome measures</h4> <section id="CD011946-sec-0051"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD011946-list-0001"> <li> <p>Participant‐reported scar improvement: measured by a scar improvement, grading, or severity scale. </p> </li> <li> <p>Participants with adverse effects serious or severe enough to have caused their withdrawal from the study. We define 'serious' adverse effects' as events that pose a threat to a participant's life or functioning whereas 'severe' adverse effects are defined by their intensity. </p> </li> </ol> </p> </section> <section id="CD011946-sec-0052"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD011946-list-0002"> <li> <p>Investigator‐assessed scar improvement: measured by a scar improvement, grading, or severity scale. </p> </li> <li> <p>Participant satisfaction: measured by a participant satisfaction questionnaire.</p> </li> <li> <p>Quality of life: measured by a quality‐of‐life scale, whether global or specific.</p> </li> <li> <p>Participant‐reported adverse events, e.g. pain, erythema, oedema, infection, oozing, crusting, hyperpigmentation, or scarring. </p> </li> <li> <p>Investigator‐assessed adverse events, e.g. erythema, oedema, infection, oozing, crusting, hyperpigmentation, or scarring. </p> </li> <li> <p>Duration, in days, of post‐procedure down time. We defined the down time as the number of days following the procedure during which the participant had oedema and erythema and felt unable or unwilling to go out in public. </p> </li> </ol> </p> <section id="CD011946-sec-0053"> <h6 class="title">Timing of outcomes</h6> <p>We assessed our primary outcome of scar improvement over a time frame of up to 24 weeks (short‐term) and more than 24 weeks (long‐term). </p> <p>We assessed our adverse events outcomes in the short term up to four weeks after the procedure and in the long term more than four weeks after the procedure. </p> </section> </section> </section> </section> <section id="CD011946-sec-0054"> <h3 class="title">Search methods for identification of studies</h3> <p>We aimed to identify all relevant RCTs, regardless of language or publication status (published, unpublished, in press, or in progress). </p> <section id="CD011946-sec-0055"> <h4 class="title">Electronic searches</h4> <p>We searched the following databases up to 18 November 2015:</p> <p> <ul id="CD011946-list-0003"> <li> <p>the Cochrane Skin Group Specialised Register using the following terms: acne and (cicatri* or scar*); </p> </li> <li> <p>the Cochrane Central Register of Controlled Trials (CENTRAL) 2015, Issue 10, in the Cochrane Library using the search strategy in <a href="./appendices#CD011946-sec-0181">Appendix 2</a>; </p> </li> <li> <p>MEDLINE via Ovid (from 1946) using the strategy in <a href="./appendices#CD011946-sec-0182">Appendix 3</a>; </p> </li> <li> <p>EMBASE via Ovid (from 1974) using the strategy in <a href="./appendices#CD011946-sec-0183">Appendix 4</a>; </p> </li> <li> <p>LILACS (Latin American and Caribbean Health Science Information database, from 1982) using the strategy in <a href="./appendices#CD011946-sec-0184">Appendix 5</a>. </p> </li> </ul> </p> <section id="CD011946-sec-0056"> <h5 class="title">Trials registers</h5> <p>We searched the following trials registers on 24 December 2015, using the following terms: "acne" and (cicatri* or scar*). </p> <p> <ul id="CD011946-list-0004"> <li> <p>The ISRCTN registry (<a href="http://www.isrctn.com/" target="_blank">www.isrctn.com/</a>). </p> </li> <li> <p>The US National Institutes of Health Ongoing Trials Register (<a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>). </p> </li> <li> <p>The Australian New Zealand Clinical Trials Registry (<a href="http://www.anzctr.org.au" target="_blank">www.anzctr.org.au</a>). </p> </li> <li> <p>The World Health Organization International Clinical Trials Registry platform (<a href="http://apps.who.int/trialsearch/" target="_blank">apps.who.int/trialsearch</a>). </p> </li> <li> <p>The EU Clinical Trials Register (<a href="https://www.clinicaltrialsregister.eu/" target="_blank">www.clinicaltrialsregister.eu</a>). </p> </li> </ul> </p> </section> </section> <section id="CD011946-sec-0057"> <h4 class="title">Searching other resources</h4> <p>We checked the bibliographies of included trials and review articles for further references to relevant trials. </p> <p>We searched manufacturers' websites for relevant trial information.</p> <p>We contacted trial authors for missing data and information about ongoing trials.</p> <section id="CD011946-sec-0058"> <h5 class="title">Adverse effects</h5> <p>We did not perform a separate search for adverse effects of interventions used for treating acne scars. We considered adverse effects described in the included studies only. </p> </section> </section> </section> <section id="CD011946-sec-0059"> <h3 class="title" id="CD011946-sec-0059">Data collection and analysis</h3> <p>Some of the data collection and analysis section of this review is based on a standard template used by the Cochrane Pregnancy and Childbirth Review Group. </p> <section id="CD011946-sec-0060"> <h4 class="title">Selection of studies</h4> <p>We downloaded all potentially relevant studies identified from the searches into reference management software and removed duplicates. Two review authors independently screened titles and abstracts of studies from literature searches for inclusion in the review and coded them as "retrieve" (eligible, potentially eligible, or unclear) or "do not retrieve". We obtained the full texts of those coded "retrieve", and two review authors independently screened the full texts to identify studies for inclusion. We did not include studies reported as abstracts only, as we could not extract enough information for 'Risk of bias' assessment and completion of the <a href="./references#CD011946-sec-0193" title="">Characteristics of included studies</a> tables. We resolved disagreements by discussion, and if we did not reach consensus a third author made the judgement. </p> <p>We recorded reasons for the exclusion of any ineligible studies in the '<a href="./references#CD011946-sec-0194" title="">Characteristics of excluded studies</a>' tables. </p> <p>We carried out the selection process in sufficient detail to complete a study flow diagram. </p> </section> <section id="CD011946-sec-0061"> <h4 class="title">Data extraction and management</h4> <p>We used the data extraction form available from the Cochrane Skin Group's website and developed a computer database tool to be used for data extraction. We piloted the data extraction form within the review team using a sample of the studies to be reviewed. For eligible studies, two review authors independently extracted the data using the agreed form and then entered the data into Review Manager 5 software (<a href="./references#CD011946-bbs2-0102" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>). We cross‐checked the data for accuracy. We resolved discrepancies through discussion or if required we consulted a third author. When information regarding any of the above was unclear, we contacted the authors of the original reports to elicit further details. </p> </section> <section id="CD011946-sec-0062"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors independently assessed the risk of bias for each study using the criteria outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD011946-bbs2-0088" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). We resolved any disagreement by discussion or with the involvement of a third author. </p> <section id="CD011946-sec-0063"> <h5 class="title">(1) Sequence generation (checking for possible selection bias)</h5> <p>We describe for each included study the method used to generate the allocation sequence in sufficient detail to allow an assessment of whether it should produce comparable groups. </p> <p>We assessed the risk as one of the following:</p> <p> <ul id="CD011946-list-0005"> <li> <p>low (any truly random process, e.g. random number table, computer random number generator);</p> </li> <li> <p>high (non‐random approach, e.g. sequence generated by odd or even date of birth, sequence generated by some rule based on date of admission); or </p> </li> <li> <p>unclear.</p> </li> </ul> </p> </section> <section id="CD011946-sec-0064"> <h5 class="title">(2) Allocation concealment (checking for possible selection bias)</h5> <p>We describe for each included study the method used to conceal the allocation sequence in sufficient detail to determine whether allocation of the intervention could have been foreseen in advance of or during recruitment, or changed after assignment. </p> <p>We assessed the risk as one of the following:</p> <p> <ul id="CD011946-list-0006"> <li> <p>low (e.g. telephone or central randomisation, consecutively‐numbered sealed opaque envelopes); </p> </li> <li> <p>high (open random allocation, unsealed or non‐opaque envelopes); or</p> </li> <li> <p>unclear.</p> </li> </ul> </p> </section> <section id="CD011946-sec-0065"> <h5 class="title">(3) Blinding (checking for possible performance and detection bias)</h5> <p>We describe for each included study the methods used, if any, to blind study participants and personnel from knowledge of which intervention a participant would receive. We assessed blinding separately for performance and detection bias and for different outcomes or classes of outcomes. </p> <p>We assessed the risk as one of the following:</p> <p> <ul id="CD011946-list-0007"> <li> <p>low, high, or unclear for participants;</p> </li> <li> <p>low, high, or unclear for personnel; and</p> </li> <li> <p>low, high, or unclear for outcome assessors.</p> </li> </ul> </p> </section> <section id="CD011946-sec-0066"> <h5 class="title">(4) Incomplete outcome data (checking for possible attrition bias through withdrawals, dropouts, protocol deviations) </h5> <p>We describe for each included study and for each outcome or class of outcomes the completeness of data, including attrition and exclusions from the analysis. We considered both the overall attrition rate (the proportion of participants randomly assigned to the study groups for whom outcome data are not available) and the differential attrition rate (the difference in attrition rates between groups). We considered an overall attrition rate above 20% or a differential attrition rate above 5% as representing a high risk of attrition bias. </p> <p>We state whether attrition and exclusions were reported, the numbers included in the analysis at each stage (compared with the total randomised participants), reasons for attrition or exclusion where reported, and whether missing data were balanced across groups. Where sufficient information was reported or could be supplied by the trial authors, we re‐included missing data in the analyses that we undertook. We assessed risk as one of the following: </p> <p> <ul id="CD011946-list-0008"> <li> <p>low;</p> </li> <li> <p>high; or</p> </li> <li> <p>unclear.</p> </li> </ul> </p> </section> <section id="CD011946-sec-0067"> <h5 class="title">(5) Selective reporting bias</h5> <p>We describe for each included study how we investigated the possibility of selective outcome reporting bias and what we found, on the basis of what was present in the trial registry documents. We wrote to authors to ask for protocols if these were not published. </p> <p>We assessed the risk as follows:</p> <p> <ul id="CD011946-list-0009"> <li> <p>low, where it was clear that all of the study's prespecified outcomes and all expected outcomes of interest to the review were reported; </p> </li> <li> <p>high, where not all of the study's prespecified outcomes were reported, one or more reported primary outcomes were not prespecified, outcomes of interest were reported incompletely and so could not be used, or the study failed to include results of a key outcome that could be expected to be reported; or </p> </li> <li> <p>unclear.</p> </li> </ul> </p> </section> <section id="CD011946-sec-0068"> <h5 class="title">(6) Other sources of bias</h5> <p>We describe for each included study any important concerns that we have about other possible sources of bias, e.g. baseline imbalance and blocked randomisation in unblinded trials. </p> <p>We assessed the risk as one of the following:</p> <p> <ul id="CD011946-list-0010"> <li> <p>low;</p> </li> <li> <p>high; or</p> </li> <li> <p>unclear.</p> </li> </ul> </p> </section> <section id="CD011946-sec-0069"> <h5 class="title">(7) Overall risk of bias</h5> <p>We made explicit judgements about whether studies were at high risk of bias according to the criteria given in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD011946-bbs2-0088" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). With reference to (one) to (six) above, we assessed the likely magnitude and direction of the bias and whether we considered that it was likely to impact on the treatment effects. We explore the impact of the level of bias through undertaking sensitivity analyses. </p> </section> </section> <section id="CD011946-sec-0070"> <h4 class="title">Measures of treatment effect</h4> <section id="CD011946-sec-0071"> <h5 class="title">Dichotomous data</h5> <p>For dichotomous data, we present results as summary risk ratios (RRs) with 95% confidence intervals (CIs). </p> </section> <section id="CD011946-sec-0072"> <h5 class="title">Continuous data</h5> <p>For continuous data, we use the mean difference (MD) if outcomes were measured in the same way across trials. We use the standardised mean difference (SMD) to combine trials that measured the same outcome using different scales. We present change data and endpoint data separately in cases where we used the SMD. </p> </section> </section> <section id="CD011946-sec-0073"> <h4 class="title">Unit of analysis issues</h4> <p>We anticipated that the trials included in this review might randomise either participants or split‐face. We followed the guidance in the C<i>ochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD011946-bbs2-0088" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). We intended to incorporate trials using a split‐face design to approximate a paired analysis using the generic inverse variance method, and to undertake a sensitivity analysis where we had used imputations and to perform meta‐analyses of these trials separately from parallel trials. However paired data were unavailable and we were not able to adjust for the within‐individual variability. We report those studies separately as a RR without a P value or 95% CI. We include two multi‐arm trials in the review, using the two arms that compared different interventions for acne scars. We include these studies as pair‐wise comparisons. </p> </section> <section id="CD011946-sec-0074"> <h4 class="title">Dealing with missing data</h4> <p>For all outcomes, we attempted to conduct analyses on an intention‐to‐treat basis. When there were missing data, we contacted the authors of the study to obtain the relevant missing data (See <a href="#CD011946-tbl-0008">Table 1</a>). We carefully evaluated important numerical data. If we could not obtain missing data for dichotomous outcomes, we considered participants with missing outcome data as treatment failures. We used sensitivity analysis to assess how sensitive results were to reasonable changes in the assumptions that we made. We addressed the potential impact of missing data on the findings of the review in the <a href="#CD011946-sec-0163">Discussion</a> section. </p> <div class="table" id="CD011946-tbl-0008"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Contacted authors</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Contact author</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Contact email</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Reply/did not reply</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011946-bbs2-0025" title="AhmedR , MohammedG , IsmailN , ElakhrasA . Randomized clinical trial of CO₂ LASER pinpoint irradiation technique versus chemical reconstruction of skin scars (CROSS) in treating ice pick acne scars. Journal of Cosmetic and Laser Therapy2014;16(1):8‐13. [EMBASE: 2014075366] ">Ahmed 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mohammed G</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a class="__cf_email__" data-cfemail="0f6b7d5068676e6b6e38384f67607b626e6663216c6062" href="/cdn-cgi/l/email-protection">[email protected]</a></p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Did not reply</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011946-bbs2-0002" title="AsilianA , SalimiE , FaghihiG , DehghaniF , TajmirriahiN , HosseiniSM . Comparison of Q‐Switched 1064‐nm Nd: YAG laser and fractional CO2 laser efficacies on improvement of atrophic facial acne scar. Journal of Research in Medical Sciences2011;16(9):1189‐95. [EMBASE: 2011598154] ">Asilian 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Salimi E</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a class="__cf_email__" data-cfemail="f281ad81939e9b9f9bb28097819796979c86dc9f879bdc9391dc9b80" href="/cdn-cgi/l/email-protection">[email protected]</a></p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Did not reply</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011946-bbs2-0003" title="BernsteinEF , FerreiraM , AndersonD . A pilot investigation to subjectively measure treatment effect and side‐effect profile of non‐ablative skin remodeling using a 532 nm, 2 ms pulse‐duration laser. Journal of Cosmetic &amp; Laser Therapy2001;3(3):137‐41. [EMBASE: 2002362049] ">Bernstein 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bernstein EF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a class="__cf_email__" data-cfemail="f69293849b91838fb69e99829b979f9ad895999b" href="/cdn-cgi/l/email-protection">[email protected]</a></p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Did not reply</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011946-bbs2-0004" title="ChaeWS , SeongJY , JungHN , KongSH , KimMH , SuhHS , et al. Comparative study on efficacy and safety of 1550 nm Er: Glass fractional laser and fractional radiofrequency microneedle device for facial atrophic acne scar. Journal of Cosmetic Dermatology2015;14(2):100‐6. [EMBASE: 2015071568] ">Chae 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Choi YS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a class="__cf_email__" data-cfemail="1f6a6a777b7a6d727e5f777e71727e767331717a6b" href="/cdn-cgi/l/email-protection">[email protected]</a></p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Responded</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011946-bbs2-0005" title="ChoSB , LeeSJ , ChoS , OhSH , ChungWS , KangJM , et al. Non‐ablative 1550‐nm erbium‐glass and ablative 10 600‐nm carbon dioxide fractional lasers for acne scars: a randomized split‐face study with blinded response evaluation. Journal of the European Academy of Dermatology and Venereology2010;24(8):921‐5. [EMBASE: 2010378178] ">Cho 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kim DH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a class="__cf_email__" data-cfemail="fa8e9f88939589c3c8ba929b94979b9396d4949f8e" href="/cdn-cgi/l/email-protection">[email protected]</a></p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Did not reply</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011946-bbs2-0032" title="GadkariR , NayakC . A split‐face comparative study to evaluate efficacy of combined subcision and dermaroller against combined subcision and cryoroller in treatment of acne scars. Journal of Cosmetic Dermatology2014;13(1):38‐43. [PUBMED: 24641604] ">Gadkari 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gadkari R</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a class="__cf_email__" data-cfemail="80e4f2f2e5f3e8ede1e7e1e4ebe1f2e9c0e7ede1e9ecaee3efed" href="/cdn-cgi/l/email-protection">[email protected]</a></p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Did not reply</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011946-bbs2-0008" title="HedelundL , MoreauKER , BeyerDM , NymannP , HaedersdalM . Fractional nonablative 1,540‐nm laser resurfacing of atrophic acne scars. A randomized controlled trial with blinded response evaluation. Lasers in Medical Science2010;25(5):749‐54. [EMBASE: 2010472544] ">Hedelund 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hedelund L</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a class="__cf_email__" data-cfemail="066a636863286e6362636a736862466e69726b676f6a2865696b" href="/cdn-cgi/l/email-protection">[email protected]</a></p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Did not reply</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011946-bbs2-0009" title="HedelundL , HaakCS , Togsverd‐BoK , BoghMK , BjerringP , HaedersdalM . Fractional CO2 laser resurfacing for atrophic acne scars: A randomized controlled trial with blinded response evaluation. Lasers in Surgery and Medicine2012;44(6):447‐52. [EMBASE: 2012412028] ">Hedelund 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hedelund L</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a class="__cf_email__" data-cfemail="472b22292f222307352a69232c" href="/cdn-cgi/l/email-protection">[email protected]</a></p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Did not reply</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011946-bbs2-0010" title="KarnikJ , BaumannL , BruceS , CallenderV , CohenS , GrimesP , et al. A double‐blind, randomized, multicenter, controlled trial of suspended polymethylmethacrylate microspheres for the correction of atrophic facial acne scars. Journal of the American Academy of Dermatology2014;71(1):77‐83. [EMBASE: 2014426024] ">Karnik 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Smith SR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a class="__cf_email__" data-cfemail="5023233d39243810232431332922233d3924383d347e333f3d" href="/cdn-cgi/l/email-protection">[email protected]</a></p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Did not reply</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011946-bbs2-0011" title="KimHJ , KimTG , KwonYS , ParkJM , LeeJH . Comparison of a 1,550 nm Erbium: glass fractional laser and a chemical reconstruction of skin scars (CROSS) method in the treatment of acne scars: a simultaneous split‐face trial. Lasers in Surgery and Medicine2009;41(8):545‐9. [PUBMED: 19639620] ">Kim 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lee JH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a class="__cf_email__" data-cfemail="ec8699848989ac9599849fc28d8f" href="/cdn-cgi/l/email-protection">[email protected]</a></p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Did not reply</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011946-bbs2-0036" title="KimS , ChoKH . Clinical trial of dual treatment with an ablative fractional laser and a nonablative laser for the treatment of acne scars in Asian patients. Dermatologic Surgery2009;35(7):1089‐98. [PUBMED: 19438689] ">Kim 2009a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kim S</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a class="__cf_email__" data-cfemail="6b025f00182b120a03040445080406" href="/cdn-cgi/l/email-protection">[email protected]</a></p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Did not reply</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011946-bbs2-0012" title="LeeDH , ChoiYS , MinSU , YoonMY , SuhDH . Comparison of a 585‐nm pulsed dye laser and a 1064‐nm Nd:YAG laser for the treatment of acne scars: a randomized split‐face clinical study. Journal of the American Academy of Dermatology2009;60(5):801‐7. [PUBMED: 19217691] ">Lee 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Suh DH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a class="__cf_email__" data-cfemail="2c484d494459426c5f4259024d4f02475e" href="/cdn-cgi/l/email-protection">[email protected]</a></p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Did not reply</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011946-bbs2-0013" title="LeeJW , KimBJ , KimMN , MunSK . The efficacy of autologous platelet rich plasma combined with ablative carbon dioxide fractional resurfacing for acne scars: a simultaneous split‐face trial. Dermatologic Surgery2011;37(7):931‐8. [PUBMED: 21635618] ">Lee 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kim BJ</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a class="__cf_email__" data-cfemail="6e0c0b0103040101002e1b00071a0b02400d0140051c" href="/cdn-cgi/l/email-protection">[email protected]</a></p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Did not reply</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011946-bbs2-0017" title="LinknerRV , Jim OnS , HaddicanM , SingerG , Shim‐ChangH . Evaluating the efficacy of photodynamic therapy with 20% aminolevulinic acid and microdermabrasion as a combination treatment regimen for acne scarring: A split‐face, randomized, double‐blind pilot study. Journal of Clinical &amp; Aesthetic Dermatology2014;7(5):32‐5. [PUBMED: 24847407] ">Linkner 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Linkner RV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a class="__cf_email__" data-cfemail="eebc879a8fc0a2878085808b9cae83819b809a9d87808f87c0819c89" href="/cdn-cgi/l/email-protection">[email protected]</a></p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Did not reply</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011946-bbs2-0018" title="ManuskiattiW , IamphonratT , WanitphakdeedechaR , EimpunthS . Comparison of fractional Er:YAG and CO2 lasers in resurfacing of atrophic acne scars in Asians. 31st Annual Conference of the American Society for Laser Medicine and Surgery, ASLMS 2011 Grapevine, TX United States. Conference Start: 20110330 Conference End: 20110403. Lasers in Surgery and Medicine2011;43:938‐939. [EMBASE: 70640237] ManuskiattiW , IamphonratT , WanitphakdeedechaR , EimpunthS . Comparison of fractional erbium‐doped yttrium aluminum garnet and carbon dioxide lasers in resurfacing of atrophic acne scars in Asians. Dermatologic Surgery2013;39(1 Pt 1):111‐20. [EMBASE: 23205717] ">Manuskiatti 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Manuskiatti W</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a class="__cf_email__" data-cfemail="ef98809d8e9f87808188c1828e81af828e87868b8083c18e8cc19b87" href="/cdn-cgi/l/email-protection">[email protected]</a></p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Did not reply</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011946-bbs2-0019" title="MinSU , ChoiYS , LeeDH , YoonMY , SuhDH . Comparison of a long‐pulse Nd:YAG laser and a combined 585/1,064‐nm laser for the treatment of acne scars: a randomized split‐face clinical study. Dermatologic Surgery2009;35(11):1720‐7. [PUBMED: 19250299] ">Min 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Suh DH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a class="__cf_email__" data-cfemail="2a4e4b4f425f446a59445f044b49044158" href="/cdn-cgi/l/email-protection">[email protected]</a></p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Did not reply</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011946-bbs2-0040" title="MohammedG . Randomized clinical trial of CO2 laser pinpoint irradiation technique with/without needling for ice pick acne scars. Journal of Cosmetic and Laser Therapy2013;15(3):177‐82. [EMBASE: 2013337358] ">Mohammed 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mohammed G</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a class="__cf_email__" data-cfemail="e38791bc848b828782d4d4a38b8c978e828a8fcd808c8e" href="/cdn-cgi/l/email-protection">[email protected]</a></p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Did not reply</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011946-bbs2-0020" title="MunavalliGS , SmithS , MaslowskiJM , WeissRA . Successful treatment of depressed, distensible acne scars using autologous fibroblasts: a multi‐site, prospective, double blind, placebo‐controlled clinical trial. Dermatologic Surgery2013;39(8):1226‐36. [PUBMED: 23566237] ">Munavalli 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Munavalli GS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a class="__cf_email__" data-cfemail="4b2c263e252a3d2a2727220b282a39242722252a3820222565282426" href="/cdn-cgi/l/email-protection">[email protected]</a></p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Did not reply</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011946-bbs2-0041" title="NofalE , HelmyA , NofalA , AlakadR , NasrM . Platelet‐rich plasma versus CROSS technique with 100% trichloroacetic acid versus combined skin needling and platelet rich plasma in the treatment of atrophic acne scars: a comparative study. Dermatologic Surgery2014;40(8):864‐73. [PUBMED: 25006854] ">Nofal 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nofal E</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a class="__cf_email__" data-cfemail="4d2c25202c2923222b2c21780d252239202c2421632e2220" href="/cdn-cgi/l/email-protection">[email protected]</a></p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Did not reply</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011946-bbs2-0021" title="RongsaardN , RummaneethornP . Comparison of a fractional bipolar radiofrequency device and a fractional erbium‐doped glass 1,550‐nm device for the treatment of atrophic acne scars: a randomized split‐face clinical study. Dermatologic Surgery2014;40(1):14‐21. [PUBMED: 24267397] ">Rongsaard 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rongsaard N</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a class="__cf_email__" data-cfemail="ee80819e808f9c9b8b9e819c80ae89838f8782c08d8183" href="/cdn-cgi/l/email-protection">[email protected]</a></p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Responded</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011946-bbs2-0022" title="SageRJ , LopiccoloMC , LiuA , MahmoudBH , TierneyEP , KoubaDJ . Subcuticular incision versus naturally sourced porcine collagen filler for acne scars: a randomized split‐face comparison. Dermatologic Surgery2011;37(4):426‐31. [PUBMED: 21388487] ">Sage 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kouba DJ</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a class="__cf_email__" data-cfemail="6206090d17000353220a040a114c0d1005" href="/cdn-cgi/l/email-protection">[email protected]</a></p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Did not reply</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011946-bbs2-0023" title="TanziEL , AlsterTS . Comparison of a 1450‐nm diode laser and a 1320‐nm Nd:YAG laser in the treatment of atrophic facial scars: a prospective clinical and histologic study. Dermatologic Surgery2004;30(2 Pt 1):152‐7. [PUBMED: 14756642] ">Tanzi 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Alster TS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a class="__cf_email__" data-cfemail="d5a1b4b9a6a1b0a795a6bebcbbb9b4a6b0a7fbb6bab8" href="/cdn-cgi/l/email-protection">[email protected]</a></p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Did not reply</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011946-bbs2-0024" title="ZhangZ , FeiY , ChenX , LuW , ChenJ . Comparison of a fractional microplasma radio frequency technology and carbon dioxide fractional laser for the treatment of atrophic acne scars: a randomized split‐face clinical study. Dermatologic Surgery2013;39(4):559‐66. [PUBMED: 23379344] ">Zhang 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chen J</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a class="__cf_email__" data-cfemail="38405c5b505d5678555d5c55595154165b5755165b56" href="/cdn-cgi/l/email-protection">[email protected]</a></p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Did not reply</p> </td> </tr> </tbody> </table> </div> </section> <section id="CD011946-sec-0075"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed heterogeneity by considering clinical factors (type of scars, severity of scars, and skin phototype) and methodological factors (allocation concealment and attrition). </p> <p>We tested statistical heterogeneity using the Chi² test (significance level: 0.1) and I² statistic (0% to 40%: may not be important; 30% to 60%: may represent moderate heterogeneity; 50% to 90%: may represent substantial heterogeneity; 75% to 100%: represents considerable heterogeneity) (<a href="./references#CD011946-bbs2-0087" title="HigginsJPT , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327(7414):557‐60. ">Higgins 2003</a>; <a href="./references#CD011946-bbs2-0088" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). </p> <p>Where we observed high levels of heterogeneity among the trials (I² statistic ≥ 50% or P &lt; 0.1), we considered clinical factors (e.g. type of scars) and methodological factors (e.g. allocation concealment and attrition) of the included studies. We tried to explore the source of heterogeneity by subgroup analysis (described in <a href="#CD011946-sec-0078">Subgroup analysis and investigation of heterogeneity</a>) or by <a href="#CD011946-sec-0079">Sensitivity analysis</a>. </p> </section> <section id="CD011946-sec-0076"> <h4 class="title">Assessment of reporting biases</h4> <p>We planned to investigate reporting biases (such as publication bias) for primary outcomes using funnel plots if there were 10 or more studies in the meta‐analysis. We planned to assess funnel plot asymmetry visually. If a visual assessment suggested asymmetry, we planned to perform exploratory sensitivity analyses. </p> </section> <section id="CD011946-sec-0077"> <h4 class="title">Data synthesis</h4> <p>We carried out statistical analysis using Review Manager 5 software (<a href="./references#CD011946-bbs2-0102" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>). We used a fixed‐effect meta‐analysis for combining data from published studies where it was reasonable to assume that studies were estimating the same underlying treatment effect, i.e. where trials were examining the same intervention and we judged the trials' populations and methods as sufficiently similar. </p> <p>If there were clinical heterogeneity sufficient to expect that the underlying treatment effects differed between trials, or if we had detected a high level of heterogeneity among the trials (I² statistic ≥ 50% or P &lt; 0.1), we would have used a random‐effects meta‐analysis to produce an overall summary if we considered an average treatment effect across trials as clinically meaningful. We treated the random‐effects summary as the average of the range of possible treatment effects, and we discussed the clinical implications of treatment effects differing between trials. If the average treatment effect was not clinically meaningful, we did not combine trials. If we had used random‐effects analyses, we would have presented the results as the average treatment effects with 95% confidence intervals and the estimates of Tau² and I² statistic. If heterogeneity was considerable (I² statistic of 75% to 100%), we would not perform a meta‐analysis. Instead, we would have provided a narrative, qualitative summary. </p> <p>For individual studies with low numbers of outcomes (fewer than 10 in total) or where the total sample size was less than 30 participants and a risk ratio was used, we reported the proportion of outcomes in each treatment group together with a P value from a Fisher's exact test (<a href="./references#CD011946-bbs2-0088" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). </p> </section> <section id="CD011946-sec-0078"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We planned to carry out the following subgroup analyses for our primary outcomes:</p> <p> <ol id="CD011946-list-0011"> <li> <p>Type of scar: ice pick versus boxcar versus rolling versus hypertrophic;</p> </li> <li> <p>Scar severity: superficial to medium scars versus deep scars;</p> </li> <li> <p>Skin phototype: skin phototype I to III versus skin phototype IV to VI.</p> </li> </ol> </p> <p>There were not enough (at least 10) studies to conduct the planned subgroup analysis. In future updates, we plan to conduct the prespecified subgroup analyses classifying whole trials by interaction tests (<a href="./references#CD011946-bbs2-0088" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). </p> </section> <section id="CD011946-sec-0079"> <h4 class="title">Sensitivity analysis</h4> <p>We did not perform any sensitivity analysis, due to the paucity of studies for each comparison. In future updates, we plan to perform sensitivity analyses for assessing the quality of studies (by including studies judged to be at low risk of bias in allocation concealment and attrition domains). We also plan to carry out sensitivity analysis to explore the effects of fixed‐effect or random‐effects analyses for outcomes with statistical heterogeneity, and if we identify an asymmetrical funnel plot. </p> <section id="CD011946-sec-0080"> <h5 class="title">'Summary of findings' tables</h5> <p>We assessed the quality of the evidence using the GRADE approach (<a href="./references#CD011946-bbs2-0104" title="SchünemannH , BrożekJ , GuyattG , OxmanA , (editors) . GRADE handbook for grading quality of evidence and strength of recommendations. Updated October 2013. The GRADE Working Group, 2013. www.guidelinedevelopment.org/handbook (accessed 2 November 2015). ">Schünemann 2013</a>) related to the following main outcomes, which are important for decision‐making: </p> <p> <ol id="CD011946-list-0012"> <li> <p>Participant‐reported scar improvement (long‐term);</p> </li> <li> <p>Participant‐reported scar improvement (short‐term);</p> </li> <li> <p>Investigator‐assessed adverse events (short‐term);</p> </li> <li> <p>Participant‐assessed adverse events (short‐term);</p> </li> <li> <p>Participant satisfaction;</p> </li> <li> <p>Quality of life.</p> </li> </ol> </p> <p>We used the GRADEpro Guideline Development Tool (GRADEpro GDT) (<a href="./references#CD011946-bbs2-0083" title="McMaster University (developed by Evidence Prime, Inc.). GRADEpro GDT: GRADEpro Guideline Development Tool. Version 2015. McMaster University (developed by Evidence Prime, Inc.), 2015. ">GRADEpro GDT 2015</a>) to import data from Review Manager 5 (<a href="./references#CD011946-bbs2-0102" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>) in order to create 'Summary of findings' (SoF) tables. There were many comparisons and consequently several SoF tables. We created SoF tables for the most important comparisons<i>.</i> </p> <p>We produced a summary of the intervention effect and a measure of quality for each of the above outcomes, using the GRADE approach (<a href="./references#CD011946-bbs2-0104" title="SchünemannH , BrożekJ , GuyattG , OxmanA , (editors) . GRADE handbook for grading quality of evidence and strength of recommendations. Updated October 2013. The GRADE Working Group, 2013. www.guidelinedevelopment.org/handbook (accessed 2 November 2015). ">Schünemann 2013</a>). This uses five considerations: study limitations, consistency of effect, imprecision, indirectness, and publication bias, to assess the quality of the body of evidence for each outcome. The evidence can be downgraded from 'high quality' by one level for serious, or by two levels for very serious limitations, depending on assessments for risk of bias, indirectness of evidence, serious inconsistency, and imprecision of effect estimates or potential publication bias. </p> </section> <section id="CD011946-sec-0081"> <h5 class="title">Summary of research gaps</h5> <p>We summarised the research uncertainties by mapping the research gaps (<a href="#CD011946-tbl-0009">Table 2</a>) using a PICOT (population, intervention, comparison, outcome, time) framework (<a href="./references#CD011946-bbs2-0103" title="RobinsonKA , AkinyedeO , DuttaT , SawinVI , LiT , SpencerMR , et al. Framework for Determining Research Gaps During Systematic Review: Evaluation 2013. www.ncbi.nlm.nih.gov/books/NBK126708/ (accessed 2 November 2015). [PUBMED: 23487868] ">Robinson 2013</a>). </p> <div class="table" id="CD011946-tbl-0009"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Summary of research gaps</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Gap No.</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Reason(s) for Gap*</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> POPULATION</b> </p> <p><b> (P)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> INTERVENTION</b> </p> <p><b> (I)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> COMPARISON</b> </p> <p><b> (C)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> OUTCOMES</b> </p> <p><b> (O)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> SETTING</b> </p> <p><b> (S)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Free Text Gap</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>People with acne scars</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fractional Laser</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participant‐reported scar improvement (long‐term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospital‐based/outpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lack of a validated standardised improvement scale</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>2</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A1</p> <p>D4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>People with acne scars</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fractional Laser</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Non‐fractional non‐ablative laser</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participant‐reported scar improvement (long‐term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospital‐based/outpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lack of a validated standardised improvement scale</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>3</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A2</p> <p>A3</p> <p>A4</p> <p>B2</p> <p>C1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>People with acne scars</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fractional Laser</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Non‐fractional non‐ablative laser</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participant‐reported scar improvement (short‐term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospital‐based/outpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lack of a validated standardised improvement scale</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>4</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A1</p> <p>D4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>People with acne scars</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fractional Laser</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Radiofrequency</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participant‐reported scar improvement (long‐term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospital‐based/outpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lack of a validated standardised improvement scale</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>5</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A2</p> <p>A3</p> <p>B2</p> <p>C1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>People with acne scars</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fractional Laser</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Radiofrequency</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participant‐reported scar improvement (short‐term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospital‐based/outpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lack of a validated standardised improvement scale</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>6</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>People with acne scars</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fractional Laser</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chemical peeling</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participant‐reported scar improvement (short‐ and long‐term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospital‐based/outpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lack of a validated standardised improvement scale</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>7</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A2</p> <p>A3</p> <p>B2</p> <p>C1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>People with acne scars</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fractional Laser</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Combined chemical peeling plus needling</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participant‐reported scar improvement (long‐term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospital‐based/outpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lack of a validated standardised improvement scale</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>8</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>People with acne scars</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fractional Laser</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Combined chemical peeling plus needling</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participant‐reported scar improvement (short‐term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospital‐based/outpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lack of a validated standardised improvement scale</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>9</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>People with acne scars</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fractional Laser</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Microdermabrasion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participant‐reported scar improvement (short‐ and long‐term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospital‐based/outpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lack of a validated standardised improvement scale</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>10</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>People with acne scars</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fractional Laser</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Needling</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participant‐reported scar improvement (short‐ and long‐term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospital‐based/outpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lack of a validated standardised improvement scale</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>11</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>People with acne scars</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fractional Laser</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Injectible fillers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participant‐reported scar improvement (short‐ and long‐term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospital‐based/outpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lack of a validated standardised improvement scale</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>12</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A1</p> <p>D4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>People with acne scars</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chemical peeling</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo/no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participant‐reported scar improvement (long‐term and short‐term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospital‐based/outpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lack of a validated standardised improvement scale</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>13</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A2</p> <p>A3</p> <p>B2</p> <p>C1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>People with acne scars</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chemical peeling</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Combined chemical peeling with any active intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participant‐reported scar improvement (long‐term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospital‐based/outpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lack of a validated standardised improvement scale</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>14</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>People with acne scars</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chemical peeling</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Combined chemical peeling with any active intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participant‐reported scar improvement (short‐term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospital‐based/outpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lack of a validated standardised improvement scale</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>15</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A1</p> <p>D4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>People with acne scars</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chemical peeling</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Needling</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participant‐reported scar improvement (long‐term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospital‐based/outpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lack of a validated standardised improvement scale</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>16</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A2</p> <p>A3</p> <p>B2</p> <p>C1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>People with acne scars</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chemical peeling</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Needling</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participant‐reported scar improvement (short‐term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospital‐based/outpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lack of a validated standardised improvement scale</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>17</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A1</p> <p>D4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>People with acne scars</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Injectable fillers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo/no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participant‐reported scar improvement (long‐term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lack of a validated standardised improvement scale</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>18</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A2</p> <p>C1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>People with acne scars</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Injectable fillers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo/no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participant‐reported scar improvement (short‐term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>lack of a validated standardised improvement scale</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>19</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>People with acne scars</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Injectable fillers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Autologous bone marrow stem‐cell transplant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participant‐reported scar improvement (short‐ and long‐term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospital‐based</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lack of a validated standardised improvement scale</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>20</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>People with acne scars</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Microdermabrasion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participant‐reported scar improvement (short‐ and long‐term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lack of a validated standardised improvement scale</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>21</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>People with acne scars</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Microdermabrasion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Needling</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participant‐reported scar improvement (short‐ and long‐term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lack of a validated standardised improvement scale</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>22</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>People with acne scars</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Microdermabrasion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Subcision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participant‐reported scar improvement (short‐ and long‐term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lack of a validated standardised improvement scale</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>23</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>People with acne scars</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Needling</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participant‐reported scar improvement (short‐ and long‐term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lack of a validated standardised improvement scale</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>24</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>People with acne scars</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Needling</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Subcision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participant‐reported scar improvement (short‐ and long‐term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lack of a validated standardised improvement scale</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><b>* Reasons for Gap </b> </p> <p><b>Insufficient or imprecise information: A1</b> = No studies; <b>A2</b> = Limited number of studies; <b>A3</b> = Sample sizes too small; <b>A4</b> = Estimate of effect is imprecise<br/> <b>Information at 'Risk of bias': B1</b> = Inappropriate study design; <b>B2</b> = Major methodological limitations in studies<br/> <b>Inconsistency or unknown consistency: C1</b> = Consistency unknown (only 1 study); <b>C2</b> = Inconsistent results across studies<br/> <b>Not the right information: D1</b> = Results not applicable to population of interest; <b>D2</b> = Inadequate duration of interventions/comparisons; <b>D3</b> = Inadequate duration of follow‐up; <b>D4</b> = Optimal/most important outcomes not addressed; <b>D5</b> = Results not applicable to setting of interest </p> </div> </div> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD011946-sec-0082" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD011946-sec-0082"></div> <section id="CD011946-sec-0083"> <h3 class="title">Description of studies</h3> <p>See <a href="./references#CD011946-sec-0193" title="">Characteristics of included studies</a> and <a href="./references#CD011946-sec-0194" title="">Characteristics of excluded studies</a>. </p> <section id="CD011946-sec-0084"> <h4 class="title">Results of the search</h4> <p>As shown in <a href="#CD011946-fig-0001">Figure 1</a>, our search identified 288 citations. After removing duplicates, we assessed 216 citations. We excluded 158 citations because the title, abstract, or both did not meet our inclusion criteria. We sought the full text of the remaining 58 citations. We included 24 RCTs and excluded 23 studies. Nine studies are awaiting classification, and two are ongoing studies. </p> <div class="figure" id="CD011946-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD011946-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011946.pub2/media/CDSR/CD011946/image_n/nCD011946-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD011946-sec-0085"> <h4 class="title">Included studies</h4> <p>This review includes 24 RCTs (published in 27 reports) with a total of 789 participants. Two papers reported on <a href="./references#CD011946-bbs2-0001" title="AlamM , HanS , PongprutthipanM , DisphanuratW , KakarR , NodzenskiM , et al. Efficacy of a needling device for the treatment of acne scars: a randomized clinical trial. JAMA Dermatology2014;150(8):844‐9. [PUBMED: 24919799] PongprutthipanM , NodzenskiM , VeledarE , WestD , DubinaM , AlamM , et al. A randomized controlled trial to assess the efficacy of a needling device for the treatment of acne scars. Lasers in Surgery and Medicine2014;46:4. [EMBASE: 71594493] ">Alam 2014</a>; two papers reported on <a href="./references#CD011946-bbs2-0014" title="LehetaT , ElTawdyA , Abdel HayR , FaridS . Percutaneous collagen induction versus full‐concentration trichloroacetic acid in the treatment of atrophic acne scars. Dermatologic Surgery2011;37(2):207‐16. [PUBMED: 21269351] LehetaT , TawdyAE , HayRA , FaridS . Percutaneous collagen induction versus full concentration trichloroacetic acid in the treatment of atrophic acne scars. 21st Annual Meeting of the European Tissue Repair Society Amsterdam Netherlands. Conference Start: 20111005 Conference End: 20111007. Wound Repair and Regeneration2011;19(5):A70. [EMBASE: 70532581] ">Leheta 2011</a> ; and two papers reported on <a href="./references#CD011946-bbs2-0018" title="ManuskiattiW , IamphonratT , WanitphakdeedechaR , EimpunthS . Comparison of fractional Er:YAG and CO2 lasers in resurfacing of atrophic acne scars in Asians. 31st Annual Conference of the American Society for Laser Medicine and Surgery, ASLMS 2011 Grapevine, TX United States. Conference Start: 20110330 Conference End: 20110403. Lasers in Surgery and Medicine2011;43:938‐939. [EMBASE: 70640237] ManuskiattiW , IamphonratT , WanitphakdeedechaR , EimpunthS . Comparison of fractional erbium‐doped yttrium aluminum garnet and carbon dioxide lasers in resurfacing of atrophic acne scars in Asians. Dermatologic Surgery2013;39(1 Pt 1):111‐20. [EMBASE: 23205717] ">Manuskiatti 2013</a>. See <a href="./references#CD011946-sec-0193" title="">Characteristics of included studies</a> tables for detailed descriptions. </p> <section id="CD011946-sec-0086"> <h5 class="title">Design</h5> <p>We identified seven parallel RCTs (<a href="./references#CD011946-bbs2-0002" title="AsilianA , SalimiE , FaghihiG , DehghaniF , TajmirriahiN , HosseiniSM . Comparison of Q‐Switched 1064‐nm Nd: YAG laser and fractional CO2 laser efficacies on improvement of atrophic facial acne scar. Journal of Research in Medical Sciences2011;16(9):1189‐95. [EMBASE: 2011598154] ">Asilian 2011</a>; <a href="./references#CD011946-bbs2-0004" title="ChaeWS , SeongJY , JungHN , KongSH , KimMH , SuhHS , et al. Comparative study on efficacy and safety of 1550 nm Er: Glass fractional laser and fractional radiofrequency microneedle device for facial atrophic acne scar. Journal of Cosmetic Dermatology2015;14(2):100‐6. [EMBASE: 2015071568] ">Chae 2015</a>; <a href="./references#CD011946-bbs2-0006" title="ErbağciZ , AkçaliC . Biweekly serial glycolic acid peels vs. long‐term daily use of topical low‐strength glycolic acid in the treatment of atrophic acne scars. International Journal of Dermatology2000;39(10):789‐94. [EMBASE: 2000387524] ">Erbağci 2000</a>; <a href="./references#CD011946-bbs2-0010" title="KarnikJ , BaumannL , BruceS , CallenderV , CohenS , GrimesP , et al. A double‐blind, randomized, multicenter, controlled trial of suspended polymethylmethacrylate microspheres for the correction of atrophic facial acne scars. Journal of the American Academy of Dermatology2014;71(1):77‐83. [EMBASE: 2014426024] ">Karnik 2014</a>; <a href="./references#CD011946-bbs2-0014" title="LehetaT , ElTawdyA , Abdel HayR , FaridS . Percutaneous collagen induction versus full‐concentration trichloroacetic acid in the treatment of atrophic acne scars. Dermatologic Surgery2011;37(2):207‐16. [PUBMED: 21269351] LehetaT , TawdyAE , HayRA , FaridS . Percutaneous collagen induction versus full concentration trichloroacetic acid in the treatment of atrophic acne scars. 21st Annual Meeting of the European Tissue Repair Society Amsterdam Netherlands. Conference Start: 20111005 Conference End: 20111007. Wound Repair and Regeneration2011;19(5):A70. [EMBASE: 70532581] ">Leheta 2011</a>; <a href="./references#CD011946-bbs2-0015" title="LehetaTM , Abdel HayRM , GaremYF . Deep peeling using phenol versus percutaneous collagen induction combined with trichloroacetic acid 20% in atrophic post‐acne scars; a randomized controlled trial. Journal of Dermatological Treatment2014;25(2):130‐6. [PUBMED: 22397516 ] ">Leheta 2014a</a>; <a href="./references#CD011946-bbs2-0016" title="LehetaTM , Abdel HayRM , HegazyRA , ElGaremYF . Do combined alternating sessions of 1540 nm nonablative fractional laser and percutaneous collagen induction with trichloroacetic acid 20% show better results than each individual modality in the treatment of atrophic acne scars? A randomized controlled trial. Journal of Dermatological Treatment2014;25(2):137‐41. [PUBMED: 22640000] ">Leheta 2014b</a>) and 17 within‐individual (split‐face) RCTs. Seven studies (two parallel RCTs (<a href="./references#CD011946-bbs2-0006" title="ErbağciZ , AkçaliC . Biweekly serial glycolic acid peels vs. long‐term daily use of topical low‐strength glycolic acid in the treatment of atrophic acne scars. International Journal of Dermatology2000;39(10):789‐94. [EMBASE: 2000387524] ">Erbağci 2000</a>; <a href="./references#CD011946-bbs2-0010" title="KarnikJ , BaumannL , BruceS , CallenderV , CohenS , GrimesP , et al. A double‐blind, randomized, multicenter, controlled trial of suspended polymethylmethacrylate microspheres for the correction of atrophic facial acne scars. Journal of the American Academy of Dermatology2014;71(1):77‐83. [EMBASE: 2014426024] ">Karnik 2014</a>) and five split‐face RCTs (<a href="./references#CD011946-bbs2-0001" title="AlamM , HanS , PongprutthipanM , DisphanuratW , KakarR , NodzenskiM , et al. Efficacy of a needling device for the treatment of acne scars: a randomized clinical trial. JAMA Dermatology2014;150(8):844‐9. [PUBMED: 24919799] PongprutthipanM , NodzenskiM , VeledarE , WestD , DubinaM , AlamM , et al. A randomized controlled trial to assess the efficacy of a needling device for the treatment of acne scars. Lasers in Surgery and Medicine2014;46:4. [EMBASE: 71594493] ">Alam 2014</a>; <a href="./references#CD011946-bbs2-0003" title="BernsteinEF , FerreiraM , AndersonD . A pilot investigation to subjectively measure treatment effect and side‐effect profile of non‐ablative skin remodeling using a 532 nm, 2 ms pulse‐duration laser. Journal of Cosmetic &amp; Laser Therapy2001;3(3):137‐41. [EMBASE: 2002362049] ">Bernstein 2001</a>; <a href="./references#CD011946-bbs2-0008" title="HedelundL , MoreauKER , BeyerDM , NymannP , HaedersdalM . Fractional nonablative 1,540‐nm laser resurfacing of atrophic acne scars. A randomized controlled trial with blinded response evaluation. Lasers in Medical Science2010;25(5):749‐54. [EMBASE: 2010472544] ">Hedelund 2010</a>; <a href="./references#CD011946-bbs2-0009" title="HedelundL , HaakCS , Togsverd‐BoK , BoghMK , BjerringP , HaedersdalM . Fractional CO2 laser resurfacing for atrophic acne scars: A randomized controlled trial with blinded response evaluation. Lasers in Surgery and Medicine2012;44(6):447‐52. [EMBASE: 2012412028] ">Hedelund 2012</a>; <a href="./references#CD011946-bbs2-0020" title="MunavalliGS , SmithS , MaslowskiJM , WeissRA . Successful treatment of depressed, distensible acne scars using autologous fibroblasts: a multi‐site, prospective, double blind, placebo‐controlled clinical trial. Dermatologic Surgery2013;39(8):1226‐36. [PUBMED: 23566237] ">Munavalli 2013</a>)) compared an active intervention to a placebo or no treatments. The remaining 17 RCTs compared active interventions. </p> </section> <section id="CD011946-sec-0087"> <h5 class="title">Sample sizes</h5> <p>The number of participants in the included studies ranged from 6 to 147. Fifteen of the 24 included trials, (one parallel (<a href="./references#CD011946-bbs2-0015" title="LehetaTM , Abdel HayRM , GaremYF . Deep peeling using phenol versus percutaneous collagen induction combined with trichloroacetic acid 20% in atrophic post‐acne scars; a randomized controlled trial. Journal of Dermatological Treatment2014;25(2):130‐6. [PUBMED: 22397516 ] ">Leheta 2014a</a>) and 14 split‐face (<a href="./references#CD011946-bbs2-0001" title="AlamM , HanS , PongprutthipanM , DisphanuratW , KakarR , NodzenskiM , et al. Efficacy of a needling device for the treatment of acne scars: a randomized clinical trial. JAMA Dermatology2014;150(8):844‐9. [PUBMED: 24919799] PongprutthipanM , NodzenskiM , VeledarE , WestD , DubinaM , AlamM , et al. A randomized controlled trial to assess the efficacy of a needling device for the treatment of acne scars. Lasers in Surgery and Medicine2014;46:4. [EMBASE: 71594493] ">Alam 2014</a>; <a href="./references#CD011946-bbs2-0003" title="BernsteinEF , FerreiraM , AndersonD . A pilot investigation to subjectively measure treatment effect and side‐effect profile of non‐ablative skin remodeling using a 532 nm, 2 ms pulse‐duration laser. Journal of Cosmetic &amp; Laser Therapy2001;3(3):137‐41. [EMBASE: 2002362049] ">Bernstein 2001</a>; <a href="./references#CD011946-bbs2-0005" title="ChoSB , LeeSJ , ChoS , OhSH , ChungWS , KangJM , et al. Non‐ablative 1550‐nm erbium‐glass and ablative 10 600‐nm carbon dioxide fractional lasers for acne scars: a randomized split‐face study with blinded response evaluation. Journal of the European Academy of Dermatology and Venereology2010;24(8):921‐5. [EMBASE: 2010378178] ">Cho 2010</a>; <a href="./references#CD011946-bbs2-0008" title="HedelundL , MoreauKER , BeyerDM , NymannP , HaedersdalM . Fractional nonablative 1,540‐nm laser resurfacing of atrophic acne scars. A randomized controlled trial with blinded response evaluation. Lasers in Medical Science2010;25(5):749‐54. [EMBASE: 2010472544] ">Hedelund 2010</a>; <a href="./references#CD011946-bbs2-0009" title="HedelundL , HaakCS , Togsverd‐BoK , BoghMK , BjerringP , HaedersdalM . Fractional CO2 laser resurfacing for atrophic acne scars: A randomized controlled trial with blinded response evaluation. Lasers in Surgery and Medicine2012;44(6):447‐52. [EMBASE: 2012412028] ">Hedelund 2012</a>; <a href="./references#CD011946-bbs2-0011" title="KimHJ , KimTG , KwonYS , ParkJM , LeeJH . Comparison of a 1,550 nm Erbium: glass fractional laser and a chemical reconstruction of skin scars (CROSS) method in the treatment of acne scars: a simultaneous split‐face trial. Lasers in Surgery and Medicine2009;41(8):545‐9. [PUBMED: 19639620] ">Kim 2009</a>; <a href="./references#CD011946-bbs2-0012" title="LeeDH , ChoiYS , MinSU , YoonMY , SuhDH . Comparison of a 585‐nm pulsed dye laser and a 1064‐nm Nd:YAG laser for the treatment of acne scars: a randomized split‐face clinical study. Journal of the American Academy of Dermatology2009;60(5):801‐7. [PUBMED: 19217691] ">Lee 2009</a>; <a href="./references#CD011946-bbs2-0013" title="LeeJW , KimBJ , KimMN , MunSK . The efficacy of autologous platelet rich plasma combined with ablative carbon dioxide fractional resurfacing for acne scars: a simultaneous split‐face trial. Dermatologic Surgery2011;37(7):931‐8. [PUBMED: 21635618] ">Lee 2011</a>; <a href="./references#CD011946-bbs2-0017" title="LinknerRV , Jim OnS , HaddicanM , SingerG , Shim‐ChangH . Evaluating the efficacy of photodynamic therapy with 20% aminolevulinic acid and microdermabrasion as a combination treatment regimen for acne scarring: A split‐face, randomized, double‐blind pilot study. Journal of Clinical &amp; Aesthetic Dermatology2014;7(5):32‐5. [PUBMED: 24847407] ">Linkner 2014</a>; <a href="./references#CD011946-bbs2-0018" title="ManuskiattiW , IamphonratT , WanitphakdeedechaR , EimpunthS . Comparison of fractional Er:YAG and CO2 lasers in resurfacing of atrophic acne scars in Asians. 31st Annual Conference of the American Society for Laser Medicine and Surgery, ASLMS 2011 Grapevine, TX United States. Conference Start: 20110330 Conference End: 20110403. Lasers in Surgery and Medicine2011;43:938‐939. [EMBASE: 70640237] ManuskiattiW , IamphonratT , WanitphakdeedechaR , EimpunthS . Comparison of fractional erbium‐doped yttrium aluminum garnet and carbon dioxide lasers in resurfacing of atrophic acne scars in Asians. Dermatologic Surgery2013;39(1 Pt 1):111‐20. [EMBASE: 23205717] ">Manuskiatti 2013</a>; <a href="./references#CD011946-bbs2-0019" title="MinSU , ChoiYS , LeeDH , YoonMY , SuhDH . Comparison of a long‐pulse Nd:YAG laser and a combined 585/1,064‐nm laser for the treatment of acne scars: a randomized split‐face clinical study. Dermatologic Surgery2009;35(11):1720‐7. [PUBMED: 19250299] ">Min 2009</a>; <a href="./references#CD011946-bbs2-0021" title="RongsaardN , RummaneethornP . Comparison of a fractional bipolar radiofrequency device and a fractional erbium‐doped glass 1,550‐nm device for the treatment of atrophic acne scars: a randomized split‐face clinical study. Dermatologic Surgery2014;40(1):14‐21. [PUBMED: 24267397] ">Rongsaard 2014</a>; <a href="./references#CD011946-bbs2-0022" title="SageRJ , LopiccoloMC , LiuA , MahmoudBH , TierneyEP , KoubaDJ . Subcuticular incision versus naturally sourced porcine collagen filler for acne scars: a randomized split‐face comparison. Dermatologic Surgery2011;37(4):426‐31. [PUBMED: 21388487] ">Sage 2011</a>; <a href="./references#CD011946-bbs2-0023" title="TanziEL , AlsterTS . Comparison of a 1450‐nm diode laser and a 1320‐nm Nd:YAG laser in the treatment of atrophic facial scars: a prospective clinical and histologic study. Dermatologic Surgery2004;30(2 Pt 1):152‐7. [PUBMED: 14756642] ">Tanzi 2004</a>)), had a small sample sizes of fewer than 30 participants. </p> </section> <section id="CD011946-sec-0088"> <h5 class="title">Setting</h5> <p>Of the 24 included trials, 23 were single‐centre and one study (<a href="./references#CD011946-bbs2-0010" title="KarnikJ , BaumannL , BruceS , CallenderV , CohenS , GrimesP , et al. A double‐blind, randomized, multicenter, controlled trial of suspended polymethylmethacrylate microspheres for the correction of atrophic facial acne scars. Journal of the American Academy of Dermatology2014;71(1):77‐83. [EMBASE: 2014426024] ">Karnik 2014</a>) was multicentre. They were conducted in different countries (China 1, Denmark 2, Egypt 3, Iran 2, South Korea 6, Thailand 2, Turkey 1, and USA 7 studies). </p> </section> <section id="CD011946-sec-0089"> <h5 class="title">Participants</h5> <p>All of the included trials included adults aged 18 years or older. Twenty RCTs (706 participants) enrolled both men and women, three RCTs (75 participants) enrolled only women and one RCT (8 participants) enrolled only men. Nineteen RCTs enrolled 718 individuals with atrophic acne scars and five RCTs enrolled 71 individual with mixed atrophic and hypertrophic acne scars. We did not find any trials that included any information on acne scars on the back. </p> </section> <section id="CD011946-sec-0090"> <h5 class="title">Interventions</h5> <p>The included trials assessed the effects of interventions for treating facial acne scars including: </p> <p> <ol id="CD011946-list-0013"> <li> <p>Non‐fractional non‐ablative laser</p> </li> <li> <p>Fractional laser</p> </li> <li> <p>Fractional radiofrequency</p> </li> <li> <p>Chemical peeling</p> </li> <li> <p>Injectable filler</p> </li> <li> <p>Needling</p> </li> <li> <p>Subcision</p> </li> <li> <p>Combined interventions</p> <ol id="CD011946-list-0014"> <li> <p>Fractional laser plus intradermal platelet‐rich plasma (PRP)</p> </li> <li> <p>Fractional laser plus punch elevation</p> </li> <li> <p>Microdermabrasion plus photodynamic therapy with aminolevulinic acid (ALA‐PDT)</p> </li> <li> <p>Needling plus chemical peeling</p> </li> </ol> </li> </ol> </p> </section> <section id="CD011946-sec-0091"> <h5 class="title">Outcomes</h5> <p>Of the 24 included trials, 19 reported improvement of acne scars, 23 studies reported adverse effects and eight studies reported participant satisfaction. None of the included trials reported quality of life. </p> </section> <section id="CD011946-sec-0092"> <h5 class="title">Funding source</h5> <p>Of the 24 included trials, five were supported by industry, four by academic institutions; the other 15 trials did not report their funding source. </p> </section> <section id="CD011946-sec-0093"> <h5 class="title">Studies awaiting classification</h5> <p>We planned in the protocol not to include studies reported as abstracts‐only as we could not extract enough information for 'Risk of bias' assessment and completion of the <a href="./references#CD011946-sec-0193" title="">Characteristics of included studies</a> tables. Please see details of these nine studies under <a href="./references#CD011946-sec-0195" title="">Characteristics of studies awaiting classification</a>. </p> </section> <section id="CD011946-sec-0094"> <h5 class="title">Ongoing Studies</h5> <p>We identified two ongoing trials ( <a href="./references#CD011946-bbs2-0057" title="NCT02216864 . Effect of multiple subcisions on rolling a scars. clinicaltrials.gov/ct2/show/study/NCT02216864 (accessed 30 December 2015). ">NCT02216864</a>; <a href="./references#CD011946-bbs2-0058" title="NCT02643628 . A pilot study to evaluate the safety and effectiveness of microneedling and bellafill to treat facial acne scars. clinicaltrials.gov/ct2/show/study/NCT02643628 (accessed 30 December 2015). ">NCT02643628</a>). The first ongoing trial (<a href="./references#CD011946-bbs2-0057" title="NCT02216864 . Effect of multiple subcisions on rolling a scars. clinicaltrials.gov/ct2/show/study/NCT02216864 (accessed 30 December 2015). ">NCT02216864</a>) is a split‐face RCT of multiple subcision versus no treatment. The second ongoing trial (<a href="./references#CD011946-bbs2-0058" title="NCT02643628 . A pilot study to evaluate the safety and effectiveness of microneedling and bellafill to treat facial acne scars. clinicaltrials.gov/ct2/show/study/NCT02643628 (accessed 30 December 2015). ">NCT02643628</a>) is a parallel RCT of microneedling versus combined microneedling and injectable filler. We present the details of these trials in the '<a href="./references#CD011946-sec-0196" title="">Characteristics of ongoing studies</a>' tables. </p> </section> </section> <section id="CD011946-sec-0095"> <h4 class="title">Excluded studies</h4> <p>We excluded 23 studies. We list the reasons for exclusion in the <a href="./references#CD011946-sec-0194" title="">Characteristics of excluded studies</a> tables. In our criteria for included studies we did not plan to consider the same intervention with different settings such as different treatment levels (e.g. <a href="./references#CD011946-bbs2-0026" title="AlexisA , ColeyM , AlamM , LukeJ , ShahS , ArgobiY . A prospective randomized split‐face comparison study of non‐ablative fractional laser resurfacing in the treatment of acne scarring in fitzpatrick skin phototypes IV‐VI. 31st Annual Conference of the American Society for Laser Medicine and Surgery, ASLMS 2011 Grapevine, TX United States. Conference Start: 20110330 Conference End: 20110403. Lasers in Surgery and Medicine2011;43:939. [EMBASE: 70640238] ">Alexis 2011</a>), different treatment time intervals (<a href="./references#CD011946-bbs2-0030" title="BjørnM , Stausbøl‐GrønB , Braae OlesenA , HedelundL . Treatment of acne scars with fractional CO2 laser at 1‐month versus 3‐month intervals: An intra‐individual randomized controlled trial. Lasers in Surgery and Medicine2014;46(2):89‐93. [EMBASE: 2014128952] ">Bjørn 2014</a>), different wavelengths (<a href="./references#CD011946-bbs2-0046" title="YaghmaiD , GardenJM , BakusAD , MassaMC . Comparison of a 1,064 nm laser and a 1,320 nm laser for the nonablative treatment of acne scars. Dermatologic Surgery2005;31(8 Pt 1):903‐9. [PUBMED: 16042934] ">Yaghmai 2005</a>; <a href="./references#CD011946-bbs2-0047" title="YuanXH , ZhongSX , LiSS . Comparison study of fractional carbon dioxide laser resurfacing using different fluences and densities for acne scars in Asians: A randomized split‐face trial. Dermatologic Surgery2014;40(5):545‐52. [PUBMED: 24645970] ">Yuan 2014</a>), different fluences or power (<a href="./references#CD011946-bbs2-0035" title="JungJY , LeeJH , RyuDJ , LeeSJ , BangD , ChoSB . Lower‐fluence, higher‐density versus higher‐fluence, lower‐density treatment with a 10,600‐nm carbon dioxide fractional laser system: A split‐face, evaluator‐blinded study. Dermatologic Surgery2010;36(12):2022‐9. [EMBASE: 2010679252] ">Jung 2010</a>; <a href="./references#CD011946-bbs2-0038" title="LaubachH‐J , MansteinD , ZurakowskiD , BayerH , PeukertN , BeckeD , et al. Non‐ablative fractional photothermolysis of acne scars: Effects of energy distribution and penetration depth. 29th Annual Conference of the American Society for Laser Medicine and Surgery National Harbor, MD United States. Conference Start: 20090401 Conference End: 20090405. Lasers in Surgery and Medicine2009;41:31. [EMBASE: 70332706] ">Laubach 2009</a>; <a href="./references#CD011946-bbs2-0043" title="MahmoudBH , SrivastavaD , JanigaJJ , YangJJ , LimHW , OzogDM . Safety and efficacy of erbium‐doped yttrium aluminum garnet fractionated laser for treatment of acne scars in type IV to VI skin. Dermatologic Surgery2010;36(5):602‐9. [PUBMED: 20384757] SrivastavaD , MahmoudB , OzogD , LimH , JanigaJ . The safety and efficacy of fractional laser treatments for acne scars in Fitzpatrick skin types IV to VI. 67th Annual Meeting of the American Academy of Dermatology, AAD San Francisco, CA United States. Conference Start: 20090306 Conference End: 20090310. Journal of the American Academy of Dermatology2009;60(3 Suppl 1):AB197. [EMBASE: 70142499] ">Srivastava 2009</a>), or different depths of penetration (<a href="./references#CD011946-bbs2-0044" title="TanghettiE , TanghettiM . Is deeper better: a prospective study of deep vs superficial non‐ablative fractional laser treatment of acne scars and photo‐aging. 33rd Annual Conference of the American Society for Laser Medicine and Surgery, ASLMS 2013 Boston, MA United States. Conference Start: 20130403 Conference End: 20130407. Lasers in Surgery and Medicine2013;45:4. [EMBASE: 71033948] ">Tanghetti 2013</a>). </p> </section> </section> <section id="CD011946-sec-0096"> <h3 class="title">Risk of bias in included studies</h3> <p>We include a plot of the distribution of review authors' judgements across studies for each 'Risk of bias' domain in <a href="#CD011946-fig-0002">Figure 2</a> and a summary of review authors' judgements for each 'Risk of bias' domain for each study in <a href="#CD011946-fig-0003">Figure 3</a>. We present further details in the 'Risk of bias' tables in the <a href="./references#CD011946-sec-0193" title="">Characteristics of included studies</a> section. The risk of bias of the included trials varied from low to high. </p> <div class="figure" id="CD011946-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD011946-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011946.pub2/media/CDSR/CD011946/image_n/nCD011946-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD011946-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD011946-fig-0003" src="/cdsr/doi/10.1002/14651858.CD011946.pub2/media/CDSR/CD011946/image_n/nCD011946-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD011946-sec-0097"> <h4 class="title">Allocation</h4> <p>Eleven trials used an adequate method of randomisation (<a href="./references#CD011946-bbs2-0002" title="AsilianA , SalimiE , FaghihiG , DehghaniF , TajmirriahiN , HosseiniSM . Comparison of Q‐Switched 1064‐nm Nd: YAG laser and fractional CO2 laser efficacies on improvement of atrophic facial acne scar. Journal of Research in Medical Sciences2011;16(9):1189‐95. [EMBASE: 2011598154] ">Asilian 2011</a>; <a href="./references#CD011946-bbs2-0007" title="FaghihiG , NouraeiS , AsilianA , KeyvanS , Abtahi‐NaeiniB , RakhshanpourM , et al. Efficacy of punch elevation combined with fractional carbon dioxide laser resurfacing in facial atrophic acne scarring: a randomized split‐face clinical study. Indian Journal of Dermatology2015;60(5):473‐8. [EMBASE: 2015376448] ">Faghihi 2015</a>; <a href="./references#CD011946-bbs2-0008" title="HedelundL , MoreauKER , BeyerDM , NymannP , HaedersdalM . Fractional nonablative 1,540‐nm laser resurfacing of atrophic acne scars. A randomized controlled trial with blinded response evaluation. Lasers in Medical Science2010;25(5):749‐54. [EMBASE: 2010472544] ">Hedelund 2010</a>; <a href="./references#CD011946-bbs2-0009" title="HedelundL , HaakCS , Togsverd‐BoK , BoghMK , BjerringP , HaedersdalM . Fractional CO2 laser resurfacing for atrophic acne scars: A randomized controlled trial with blinded response evaluation. Lasers in Surgery and Medicine2012;44(6):447‐52. [EMBASE: 2012412028] ">Hedelund 2012</a>; <a href="./references#CD011946-bbs2-0010" title="KarnikJ , BaumannL , BruceS , CallenderV , CohenS , GrimesP , et al. A double‐blind, randomized, multicenter, controlled trial of suspended polymethylmethacrylate microspheres for the correction of atrophic facial acne scars. Journal of the American Academy of Dermatology2014;71(1):77‐83. [EMBASE: 2014426024] ">Karnik 2014</a>; <a href="./references#CD011946-bbs2-0014" title="LehetaT , ElTawdyA , Abdel HayR , FaridS . Percutaneous collagen induction versus full‐concentration trichloroacetic acid in the treatment of atrophic acne scars. Dermatologic Surgery2011;37(2):207‐16. [PUBMED: 21269351] LehetaT , TawdyAE , HayRA , FaridS . Percutaneous collagen induction versus full concentration trichloroacetic acid in the treatment of atrophic acne scars. 21st Annual Meeting of the European Tissue Repair Society Amsterdam Netherlands. Conference Start: 20111005 Conference End: 20111007. Wound Repair and Regeneration2011;19(5):A70. [EMBASE: 70532581] ">Leheta 2011</a>; <a href="./references#CD011946-bbs2-0015" title="LehetaTM , Abdel HayRM , GaremYF . Deep peeling using phenol versus percutaneous collagen induction combined with trichloroacetic acid 20% in atrophic post‐acne scars; a randomized controlled trial. Journal of Dermatological Treatment2014;25(2):130‐6. [PUBMED: 22397516 ] ">Leheta 2014a</a>; <a href="./references#CD011946-bbs2-0016" title="LehetaTM , Abdel HayRM , HegazyRA , ElGaremYF . Do combined alternating sessions of 1540 nm nonablative fractional laser and percutaneous collagen induction with trichloroacetic acid 20% show better results than each individual modality in the treatment of atrophic acne scars? A randomized controlled trial. Journal of Dermatological Treatment2014;25(2):137‐41. [PUBMED: 22640000] ">Leheta 2014b</a>; <a href="./references#CD011946-bbs2-0018" title="ManuskiattiW , IamphonratT , WanitphakdeedechaR , EimpunthS . Comparison of fractional Er:YAG and CO2 lasers in resurfacing of atrophic acne scars in Asians. 31st Annual Conference of the American Society for Laser Medicine and Surgery, ASLMS 2011 Grapevine, TX United States. Conference Start: 20110330 Conference End: 20110403. Lasers in Surgery and Medicine2011;43:938‐939. [EMBASE: 70640237] ManuskiattiW , IamphonratT , WanitphakdeedechaR , EimpunthS . Comparison of fractional erbium‐doped yttrium aluminum garnet and carbon dioxide lasers in resurfacing of atrophic acne scars in Asians. Dermatologic Surgery2013;39(1 Pt 1):111‐20. [EMBASE: 23205717] ">Manuskiatti 2013</a>; <a href="./references#CD011946-bbs2-0021" title="RongsaardN , RummaneethornP . Comparison of a fractional bipolar radiofrequency device and a fractional erbium‐doped glass 1,550‐nm device for the treatment of atrophic acne scars: a randomized split‐face clinical study. Dermatologic Surgery2014;40(1):14‐21. [PUBMED: 24267397] ">Rongsaard 2014</a>; <a href="./references#CD011946-bbs2-0022" title="SageRJ , LopiccoloMC , LiuA , MahmoudBH , TierneyEP , KoubaDJ . Subcuticular incision versus naturally sourced porcine collagen filler for acne scars: a randomized split‐face comparison. Dermatologic Surgery2011;37(4):426‐31. [PUBMED: 21388487] ">Sage 2011</a>), while the other 13 trials did not provide sufficient information about the sequence generation process to permit judgement. </p> <p>Allocation could not be foreseen in nine trials (<a href="./references#CD011946-bbs2-0001" title="AlamM , HanS , PongprutthipanM , DisphanuratW , KakarR , NodzenskiM , et al. Efficacy of a needling device for the treatment of acne scars: a randomized clinical trial. JAMA Dermatology2014;150(8):844‐9. [PUBMED: 24919799] PongprutthipanM , NodzenskiM , VeledarE , WestD , DubinaM , AlamM , et al. A randomized controlled trial to assess the efficacy of a needling device for the treatment of acne scars. Lasers in Surgery and Medicine2014;46:4. [EMBASE: 71594493] ">Alam 2014</a>; <a href="./references#CD011946-bbs2-0007" title="FaghihiG , NouraeiS , AsilianA , KeyvanS , Abtahi‐NaeiniB , RakhshanpourM , et al. Efficacy of punch elevation combined with fractional carbon dioxide laser resurfacing in facial atrophic acne scarring: a randomized split‐face clinical study. Indian Journal of Dermatology2015;60(5):473‐8. [EMBASE: 2015376448] ">Faghihi 2015</a>; <a href="./references#CD011946-bbs2-0008" title="HedelundL , MoreauKER , BeyerDM , NymannP , HaedersdalM . Fractional nonablative 1,540‐nm laser resurfacing of atrophic acne scars. A randomized controlled trial with blinded response evaluation. Lasers in Medical Science2010;25(5):749‐54. [EMBASE: 2010472544] ">Hedelund 2010</a>; <a href="./references#CD011946-bbs2-0009" title="HedelundL , HaakCS , Togsverd‐BoK , BoghMK , BjerringP , HaedersdalM . Fractional CO2 laser resurfacing for atrophic acne scars: A randomized controlled trial with blinded response evaluation. Lasers in Surgery and Medicine2012;44(6):447‐52. [EMBASE: 2012412028] ">Hedelund 2012</a>; <a href="./references#CD011946-bbs2-0014" title="LehetaT , ElTawdyA , Abdel HayR , FaridS . Percutaneous collagen induction versus full‐concentration trichloroacetic acid in the treatment of atrophic acne scars. Dermatologic Surgery2011;37(2):207‐16. [PUBMED: 21269351] LehetaT , TawdyAE , HayRA , FaridS . Percutaneous collagen induction versus full concentration trichloroacetic acid in the treatment of atrophic acne scars. 21st Annual Meeting of the European Tissue Repair Society Amsterdam Netherlands. Conference Start: 20111005 Conference End: 20111007. Wound Repair and Regeneration2011;19(5):A70. [EMBASE: 70532581] ">Leheta 2011</a>; <a href="./references#CD011946-bbs2-0015" title="LehetaTM , Abdel HayRM , GaremYF . Deep peeling using phenol versus percutaneous collagen induction combined with trichloroacetic acid 20% in atrophic post‐acne scars; a randomized controlled trial. Journal of Dermatological Treatment2014;25(2):130‐6. [PUBMED: 22397516 ] ">Leheta 2014a</a>; <a href="./references#CD011946-bbs2-0016" title="LehetaTM , Abdel HayRM , HegazyRA , ElGaremYF . Do combined alternating sessions of 1540 nm nonablative fractional laser and percutaneous collagen induction with trichloroacetic acid 20% show better results than each individual modality in the treatment of atrophic acne scars? A randomized controlled trial. Journal of Dermatological Treatment2014;25(2):137‐41. [PUBMED: 22640000] ">Leheta 2014b</a>; <a href="./references#CD011946-bbs2-0021" title="RongsaardN , RummaneethornP . Comparison of a fractional bipolar radiofrequency device and a fractional erbium‐doped glass 1,550‐nm device for the treatment of atrophic acne scars: a randomized split‐face clinical study. Dermatologic Surgery2014;40(1):14‐21. [PUBMED: 24267397] ">Rongsaard 2014</a>; <a href="./references#CD011946-bbs2-0022" title="SageRJ , LopiccoloMC , LiuA , MahmoudBH , TierneyEP , KoubaDJ . Subcuticular incision versus naturally sourced porcine collagen filler for acne scars: a randomized split‐face comparison. Dermatologic Surgery2011;37(4):426‐31. [PUBMED: 21388487] ">Sage 2011</a>), so we judged them to be at low risk of bias, while it was unclear if allocation was concealed in the other 15 trials. </p> </section> <section id="CD011946-sec-0098"> <h4 class="title">Blinding</h4> <p>Three trials reported blinding of investigators (<a href="./references#CD011946-bbs2-0010" title="KarnikJ , BaumannL , BruceS , CallenderV , CohenS , GrimesP , et al. A double‐blind, randomized, multicenter, controlled trial of suspended polymethylmethacrylate microspheres for the correction of atrophic facial acne scars. Journal of the American Academy of Dermatology2014;71(1):77‐83. [EMBASE: 2014426024] ">Karnik 2014</a>; <a href="./references#CD011946-bbs2-0017" title="LinknerRV , Jim OnS , HaddicanM , SingerG , Shim‐ChangH . Evaluating the efficacy of photodynamic therapy with 20% aminolevulinic acid and microdermabrasion as a combination treatment regimen for acne scarring: A split‐face, randomized, double‐blind pilot study. Journal of Clinical &amp; Aesthetic Dermatology2014;7(5):32‐5. [PUBMED: 24847407] ">Linkner 2014</a>; <a href="./references#CD011946-bbs2-0020" title="MunavalliGS , SmithS , MaslowskiJM , WeissRA . Successful treatment of depressed, distensible acne scars using autologous fibroblasts: a multi‐site, prospective, double blind, placebo‐controlled clinical trial. Dermatologic Surgery2013;39(8):1226‐36. [PUBMED: 23566237] ">Munavalli 2013</a>) and we judged these trials to be at a low risk of performance bias. There was insufficient information about the blinding of investigators in four trials (<a href="./references#CD011946-bbs2-0002" title="AsilianA , SalimiE , FaghihiG , DehghaniF , TajmirriahiN , HosseiniSM . Comparison of Q‐Switched 1064‐nm Nd: YAG laser and fractional CO2 laser efficacies on improvement of atrophic facial acne scar. Journal of Research in Medical Sciences2011;16(9):1189‐95. [EMBASE: 2011598154] ">Asilian 2011</a>; <a href="./references#CD011946-bbs2-0005" title="ChoSB , LeeSJ , ChoS , OhSH , ChungWS , KangJM , et al. Non‐ablative 1550‐nm erbium‐glass and ablative 10 600‐nm carbon dioxide fractional lasers for acne scars: a randomized split‐face study with blinded response evaluation. Journal of the European Academy of Dermatology and Venereology2010;24(8):921‐5. [EMBASE: 2010378178] ">Cho 2010</a>; <a href="./references#CD011946-bbs2-0013" title="LeeJW , KimBJ , KimMN , MunSK . The efficacy of autologous platelet rich plasma combined with ablative carbon dioxide fractional resurfacing for acne scars: a simultaneous split‐face trial. Dermatologic Surgery2011;37(7):931‐8. [PUBMED: 21635618] ">Lee 2011</a>; <a href="./references#CD011946-bbs2-0018" title="ManuskiattiW , IamphonratT , WanitphakdeedechaR , EimpunthS . Comparison of fractional Er:YAG and CO2 lasers in resurfacing of atrophic acne scars in Asians. 31st Annual Conference of the American Society for Laser Medicine and Surgery, ASLMS 2011 Grapevine, TX United States. Conference Start: 20110330 Conference End: 20110403. Lasers in Surgery and Medicine2011;43:938‐939. [EMBASE: 70640237] ManuskiattiW , IamphonratT , WanitphakdeedechaR , EimpunthS . Comparison of fractional erbium‐doped yttrium aluminum garnet and carbon dioxide lasers in resurfacing of atrophic acne scars in Asians. Dermatologic Surgery2013;39(1 Pt 1):111‐20. [EMBASE: 23205717] ">Manuskiatti 2013</a>) to permit judgement. The investigators were not blinded In 17 trials (<a href="./references#CD011946-bbs2-0001" title="AlamM , HanS , PongprutthipanM , DisphanuratW , KakarR , NodzenskiM , et al. Efficacy of a needling device for the treatment of acne scars: a randomized clinical trial. JAMA Dermatology2014;150(8):844‐9. [PUBMED: 24919799] PongprutthipanM , NodzenskiM , VeledarE , WestD , DubinaM , AlamM , et al. A randomized controlled trial to assess the efficacy of a needling device for the treatment of acne scars. Lasers in Surgery and Medicine2014;46:4. [EMBASE: 71594493] ">Alam 2014</a>; <a href="./references#CD011946-bbs2-0003" title="BernsteinEF , FerreiraM , AndersonD . A pilot investigation to subjectively measure treatment effect and side‐effect profile of non‐ablative skin remodeling using a 532 nm, 2 ms pulse‐duration laser. Journal of Cosmetic &amp; Laser Therapy2001;3(3):137‐41. [EMBASE: 2002362049] ">Bernstein 2001</a>; <a href="./references#CD011946-bbs2-0004" title="ChaeWS , SeongJY , JungHN , KongSH , KimMH , SuhHS , et al. Comparative study on efficacy and safety of 1550 nm Er: Glass fractional laser and fractional radiofrequency microneedle device for facial atrophic acne scar. Journal of Cosmetic Dermatology2015;14(2):100‐6. [EMBASE: 2015071568] ">Chae 2015</a>; <a href="./references#CD011946-bbs2-0006" title="ErbağciZ , AkçaliC . Biweekly serial glycolic acid peels vs. long‐term daily use of topical low‐strength glycolic acid in the treatment of atrophic acne scars. International Journal of Dermatology2000;39(10):789‐94. [EMBASE: 2000387524] ">Erbağci 2000</a>; <a href="./references#CD011946-bbs2-0007" title="FaghihiG , NouraeiS , AsilianA , KeyvanS , Abtahi‐NaeiniB , RakhshanpourM , et al. Efficacy of punch elevation combined with fractional carbon dioxide laser resurfacing in facial atrophic acne scarring: a randomized split‐face clinical study. Indian Journal of Dermatology2015;60(5):473‐8. [EMBASE: 2015376448] ">Faghihi 2015</a>; <a href="./references#CD011946-bbs2-0008" title="HedelundL , MoreauKER , BeyerDM , NymannP , HaedersdalM . Fractional nonablative 1,540‐nm laser resurfacing of atrophic acne scars. A randomized controlled trial with blinded response evaluation. Lasers in Medical Science2010;25(5):749‐54. [EMBASE: 2010472544] ">Hedelund 2010</a>; <a href="./references#CD011946-bbs2-0009" title="HedelundL , HaakCS , Togsverd‐BoK , BoghMK , BjerringP , HaedersdalM . Fractional CO2 laser resurfacing for atrophic acne scars: A randomized controlled trial with blinded response evaluation. Lasers in Surgery and Medicine2012;44(6):447‐52. [EMBASE: 2012412028] ">Hedelund 2012</a>; <a href="./references#CD011946-bbs2-0011" title="KimHJ , KimTG , KwonYS , ParkJM , LeeJH . Comparison of a 1,550 nm Erbium: glass fractional laser and a chemical reconstruction of skin scars (CROSS) method in the treatment of acne scars: a simultaneous split‐face trial. Lasers in Surgery and Medicine2009;41(8):545‐9. [PUBMED: 19639620] ">Kim 2009</a>; <a href="./references#CD011946-bbs2-0012" title="LeeDH , ChoiYS , MinSU , YoonMY , SuhDH . Comparison of a 585‐nm pulsed dye laser and a 1064‐nm Nd:YAG laser for the treatment of acne scars: a randomized split‐face clinical study. Journal of the American Academy of Dermatology2009;60(5):801‐7. [PUBMED: 19217691] ">Lee 2009</a>; <a href="./references#CD011946-bbs2-0014" title="LehetaT , ElTawdyA , Abdel HayR , FaridS . Percutaneous collagen induction versus full‐concentration trichloroacetic acid in the treatment of atrophic acne scars. Dermatologic Surgery2011;37(2):207‐16. [PUBMED: 21269351] LehetaT , TawdyAE , HayRA , FaridS . Percutaneous collagen induction versus full concentration trichloroacetic acid in the treatment of atrophic acne scars. 21st Annual Meeting of the European Tissue Repair Society Amsterdam Netherlands. Conference Start: 20111005 Conference End: 20111007. Wound Repair and Regeneration2011;19(5):A70. [EMBASE: 70532581] ">Leheta 2011</a>; <a href="./references#CD011946-bbs2-0015" title="LehetaTM , Abdel HayRM , GaremYF . Deep peeling using phenol versus percutaneous collagen induction combined with trichloroacetic acid 20% in atrophic post‐acne scars; a randomized controlled trial. Journal of Dermatological Treatment2014;25(2):130‐6. [PUBMED: 22397516 ] ">Leheta 2014a</a>; <a href="./references#CD011946-bbs2-0016" title="LehetaTM , Abdel HayRM , HegazyRA , ElGaremYF . Do combined alternating sessions of 1540 nm nonablative fractional laser and percutaneous collagen induction with trichloroacetic acid 20% show better results than each individual modality in the treatment of atrophic acne scars? A randomized controlled trial. Journal of Dermatological Treatment2014;25(2):137‐41. [PUBMED: 22640000] ">Leheta 2014b</a>; <a href="./references#CD011946-bbs2-0019" title="MinSU , ChoiYS , LeeDH , YoonMY , SuhDH . Comparison of a long‐pulse Nd:YAG laser and a combined 585/1,064‐nm laser for the treatment of acne scars: a randomized split‐face clinical study. Dermatologic Surgery2009;35(11):1720‐7. [PUBMED: 19250299] ">Min 2009</a>; <a href="./references#CD011946-bbs2-0021" title="RongsaardN , RummaneethornP . Comparison of a fractional bipolar radiofrequency device and a fractional erbium‐doped glass 1,550‐nm device for the treatment of atrophic acne scars: a randomized split‐face clinical study. Dermatologic Surgery2014;40(1):14‐21. [PUBMED: 24267397] ">Rongsaard 2014</a>; <a href="./references#CD011946-bbs2-0022" title="SageRJ , LopiccoloMC , LiuA , MahmoudBH , TierneyEP , KoubaDJ . Subcuticular incision versus naturally sourced porcine collagen filler for acne scars: a randomized split‐face comparison. Dermatologic Surgery2011;37(4):426‐31. [PUBMED: 21388487] ">Sage 2011</a>; <a href="./references#CD011946-bbs2-0023" title="TanziEL , AlsterTS . Comparison of a 1450‐nm diode laser and a 1320‐nm Nd:YAG laser in the treatment of atrophic facial scars: a prospective clinical and histologic study. Dermatologic Surgery2004;30(2 Pt 1):152‐7. [PUBMED: 14756642] ">Tanzi 2004</a>; <a href="./references#CD011946-bbs2-0024" title="ZhangZ , FeiY , ChenX , LuW , ChenJ . Comparison of a fractional microplasma radio frequency technology and carbon dioxide fractional laser for the treatment of atrophic acne scars: a randomized split‐face clinical study. Dermatologic Surgery2013;39(4):559‐66. [PUBMED: 23379344] ">Zhang 2013</a>) because the control arm was easily distinguishable from the treatment arm during treatment. We judged these 17 trials to be at high risk of performance bias. </p> <p>All 24 trials reported that a blinded investigator assessed the outcome. We judged the 24 trials to be at a low risk of detection bias for outcome assessment. </p> <p>Three trials reported blinding of participants (<a href="./references#CD011946-bbs2-0010" title="KarnikJ , BaumannL , BruceS , CallenderV , CohenS , GrimesP , et al. A double‐blind, randomized, multicenter, controlled trial of suspended polymethylmethacrylate microspheres for the correction of atrophic facial acne scars. Journal of the American Academy of Dermatology2014;71(1):77‐83. [EMBASE: 2014426024] ">Karnik 2014</a>; <a href="./references#CD011946-bbs2-0017" title="LinknerRV , Jim OnS , HaddicanM , SingerG , Shim‐ChangH . Evaluating the efficacy of photodynamic therapy with 20% aminolevulinic acid and microdermabrasion as a combination treatment regimen for acne scarring: A split‐face, randomized, double‐blind pilot study. Journal of Clinical &amp; Aesthetic Dermatology2014;7(5):32‐5. [PUBMED: 24847407] ">Linkner 2014</a>; <a href="./references#CD011946-bbs2-0020" title="MunavalliGS , SmithS , MaslowskiJM , WeissRA . Successful treatment of depressed, distensible acne scars using autologous fibroblasts: a multi‐site, prospective, double blind, placebo‐controlled clinical trial. Dermatologic Surgery2013;39(8):1226‐36. [PUBMED: 23566237] ">Munavalli 2013</a>). There was insufficient information about the blinding of participants in seven trials (<a href="./references#CD011946-bbs2-0002" title="AsilianA , SalimiE , FaghihiG , DehghaniF , TajmirriahiN , HosseiniSM . Comparison of Q‐Switched 1064‐nm Nd: YAG laser and fractional CO2 laser efficacies on improvement of atrophic facial acne scar. Journal of Research in Medical Sciences2011;16(9):1189‐95. [EMBASE: 2011598154] ">Asilian 2011</a>; <a href="./references#CD011946-bbs2-0005" title="ChoSB , LeeSJ , ChoS , OhSH , ChungWS , KangJM , et al. Non‐ablative 1550‐nm erbium‐glass and ablative 10 600‐nm carbon dioxide fractional lasers for acne scars: a randomized split‐face study with blinded response evaluation. Journal of the European Academy of Dermatology and Venereology2010;24(8):921‐5. [EMBASE: 2010378178] ">Cho 2010</a>; <a href="./references#CD011946-bbs2-0013" title="LeeJW , KimBJ , KimMN , MunSK . The efficacy of autologous platelet rich plasma combined with ablative carbon dioxide fractional resurfacing for acne scars: a simultaneous split‐face trial. Dermatologic Surgery2011;37(7):931‐8. [PUBMED: 21635618] ">Lee 2011</a>; <a href="./references#CD011946-bbs2-0018" title="ManuskiattiW , IamphonratT , WanitphakdeedechaR , EimpunthS . Comparison of fractional Er:YAG and CO2 lasers in resurfacing of atrophic acne scars in Asians. 31st Annual Conference of the American Society for Laser Medicine and Surgery, ASLMS 2011 Grapevine, TX United States. Conference Start: 20110330 Conference End: 20110403. Lasers in Surgery and Medicine2011;43:938‐939. [EMBASE: 70640237] ManuskiattiW , IamphonratT , WanitphakdeedechaR , EimpunthS . Comparison of fractional erbium‐doped yttrium aluminum garnet and carbon dioxide lasers in resurfacing of atrophic acne scars in Asians. Dermatologic Surgery2013;39(1 Pt 1):111‐20. [EMBASE: 23205717] ">Manuskiatti 2013</a>; <a href="./references#CD011946-bbs2-0021" title="RongsaardN , RummaneethornP . Comparison of a fractional bipolar radiofrequency device and a fractional erbium‐doped glass 1,550‐nm device for the treatment of atrophic acne scars: a randomized split‐face clinical study. Dermatologic Surgery2014;40(1):14‐21. [PUBMED: 24267397] ">Rongsaard 2014</a>; <a href="./references#CD011946-bbs2-0023" title="TanziEL , AlsterTS . Comparison of a 1450‐nm diode laser and a 1320‐nm Nd:YAG laser in the treatment of atrophic facial scars: a prospective clinical and histologic study. Dermatologic Surgery2004;30(2 Pt 1):152‐7. [PUBMED: 14756642] ">Tanzi 2004</a>; <a href="./references#CD011946-bbs2-0024" title="ZhangZ , FeiY , ChenX , LuW , ChenJ . Comparison of a fractional microplasma radio frequency technology and carbon dioxide fractional laser for the treatment of atrophic acne scars: a randomized split‐face clinical study. Dermatologic Surgery2013;39(4):559‐66. [PUBMED: 23379344] ">Zhang 2013</a>) to permit judgement. In 14 trials (<a href="./references#CD011946-bbs2-0001" title="AlamM , HanS , PongprutthipanM , DisphanuratW , KakarR , NodzenskiM , et al. Efficacy of a needling device for the treatment of acne scars: a randomized clinical trial. JAMA Dermatology2014;150(8):844‐9. [PUBMED: 24919799] PongprutthipanM , NodzenskiM , VeledarE , WestD , DubinaM , AlamM , et al. A randomized controlled trial to assess the efficacy of a needling device for the treatment of acne scars. Lasers in Surgery and Medicine2014;46:4. [EMBASE: 71594493] ">Alam 2014</a>; <a href="./references#CD011946-bbs2-0003" title="BernsteinEF , FerreiraM , AndersonD . A pilot investigation to subjectively measure treatment effect and side‐effect profile of non‐ablative skin remodeling using a 532 nm, 2 ms pulse‐duration laser. Journal of Cosmetic &amp; Laser Therapy2001;3(3):137‐41. [EMBASE: 2002362049] ">Bernstein 2001</a>; <a href="./references#CD011946-bbs2-0004" title="ChaeWS , SeongJY , JungHN , KongSH , KimMH , SuhHS , et al. Comparative study on efficacy and safety of 1550 nm Er: Glass fractional laser and fractional radiofrequency microneedle device for facial atrophic acne scar. Journal of Cosmetic Dermatology2015;14(2):100‐6. [EMBASE: 2015071568] ">Chae 2015</a>; <a href="./references#CD011946-bbs2-0006" title="ErbağciZ , AkçaliC . Biweekly serial glycolic acid peels vs. long‐term daily use of topical low‐strength glycolic acid in the treatment of atrophic acne scars. International Journal of Dermatology2000;39(10):789‐94. [EMBASE: 2000387524] ">Erbağci 2000</a>; <a href="./references#CD011946-bbs2-0007" title="FaghihiG , NouraeiS , AsilianA , KeyvanS , Abtahi‐NaeiniB , RakhshanpourM , et al. Efficacy of punch elevation combined with fractional carbon dioxide laser resurfacing in facial atrophic acne scarring: a randomized split‐face clinical study. Indian Journal of Dermatology2015;60(5):473‐8. [EMBASE: 2015376448] ">Faghihi 2015</a>; <a href="./references#CD011946-bbs2-0008" title="HedelundL , MoreauKER , BeyerDM , NymannP , HaedersdalM . Fractional nonablative 1,540‐nm laser resurfacing of atrophic acne scars. A randomized controlled trial with blinded response evaluation. Lasers in Medical Science2010;25(5):749‐54. [EMBASE: 2010472544] ">Hedelund 2010</a>; <a href="./references#CD011946-bbs2-0009" title="HedelundL , HaakCS , Togsverd‐BoK , BoghMK , BjerringP , HaedersdalM . Fractional CO2 laser resurfacing for atrophic acne scars: A randomized controlled trial with blinded response evaluation. Lasers in Surgery and Medicine2012;44(6):447‐52. [EMBASE: 2012412028] ">Hedelund 2012</a>; <a href="./references#CD011946-bbs2-0011" title="KimHJ , KimTG , KwonYS , ParkJM , LeeJH . Comparison of a 1,550 nm Erbium: glass fractional laser and a chemical reconstruction of skin scars (CROSS) method in the treatment of acne scars: a simultaneous split‐face trial. Lasers in Surgery and Medicine2009;41(8):545‐9. [PUBMED: 19639620] ">Kim 2009</a>; <a href="./references#CD011946-bbs2-0012" title="LeeDH , ChoiYS , MinSU , YoonMY , SuhDH . Comparison of a 585‐nm pulsed dye laser and a 1064‐nm Nd:YAG laser for the treatment of acne scars: a randomized split‐face clinical study. Journal of the American Academy of Dermatology2009;60(5):801‐7. [PUBMED: 19217691] ">Lee 2009</a>; <a href="./references#CD011946-bbs2-0014" title="LehetaT , ElTawdyA , Abdel HayR , FaridS . Percutaneous collagen induction versus full‐concentration trichloroacetic acid in the treatment of atrophic acne scars. Dermatologic Surgery2011;37(2):207‐16. [PUBMED: 21269351] LehetaT , TawdyAE , HayRA , FaridS . Percutaneous collagen induction versus full concentration trichloroacetic acid in the treatment of atrophic acne scars. 21st Annual Meeting of the European Tissue Repair Society Amsterdam Netherlands. Conference Start: 20111005 Conference End: 20111007. Wound Repair and Regeneration2011;19(5):A70. [EMBASE: 70532581] ">Leheta 2011</a>; <a href="./references#CD011946-bbs2-0015" title="LehetaTM , Abdel HayRM , GaremYF . Deep peeling using phenol versus percutaneous collagen induction combined with trichloroacetic acid 20% in atrophic post‐acne scars; a randomized controlled trial. Journal of Dermatological Treatment2014;25(2):130‐6. [PUBMED: 22397516 ] ">Leheta 2014a</a>; <a href="./references#CD011946-bbs2-0016" title="LehetaTM , Abdel HayRM , HegazyRA , ElGaremYF . Do combined alternating sessions of 1540 nm nonablative fractional laser and percutaneous collagen induction with trichloroacetic acid 20% show better results than each individual modality in the treatment of atrophic acne scars? A randomized controlled trial. Journal of Dermatological Treatment2014;25(2):137‐41. [PUBMED: 22640000] ">Leheta 2014b</a>; <a href="./references#CD011946-bbs2-0019" title="MinSU , ChoiYS , LeeDH , YoonMY , SuhDH . Comparison of a long‐pulse Nd:YAG laser and a combined 585/1,064‐nm laser for the treatment of acne scars: a randomized split‐face clinical study. Dermatologic Surgery2009;35(11):1720‐7. [PUBMED: 19250299] ">Min 2009</a>; <a href="./references#CD011946-bbs2-0022" title="SageRJ , LopiccoloMC , LiuA , MahmoudBH , TierneyEP , KoubaDJ . Subcuticular incision versus naturally sourced porcine collagen filler for acne scars: a randomized split‐face comparison. Dermatologic Surgery2011;37(4):426‐31. [PUBMED: 21388487] ">Sage 2011</a>) participants were not blinded because the control arm was easily distinguishable from the treatment arm. We judged these 14 trials to be at a high risk of detection bias because the outcome assessment was likely to be influenced by lack of blinding of participants. </p> </section> <section id="CD011946-sec-0099"> <h4 class="title">Incomplete outcome data</h4> <p>The risk of attrition bias was high in two trials (<a href="./references#CD011946-bbs2-0006" title="ErbağciZ , AkçaliC . Biweekly serial glycolic acid peels vs. long‐term daily use of topical low‐strength glycolic acid in the treatment of atrophic acne scars. International Journal of Dermatology2000;39(10):789‐94. [EMBASE: 2000387524] ">Erbağci 2000</a>; <a href="./references#CD011946-bbs2-0014" title="LehetaT , ElTawdyA , Abdel HayR , FaridS . Percutaneous collagen induction versus full‐concentration trichloroacetic acid in the treatment of atrophic acne scars. Dermatologic Surgery2011;37(2):207‐16. [PUBMED: 21269351] LehetaT , TawdyAE , HayRA , FaridS . Percutaneous collagen induction versus full concentration trichloroacetic acid in the treatment of atrophic acne scars. 21st Annual Meeting of the European Tissue Repair Society Amsterdam Netherlands. Conference Start: 20111005 Conference End: 20111007. Wound Repair and Regeneration2011;19(5):A70. [EMBASE: 70532581] ">Leheta 2011</a>) because of a high dropout rate. The risk of attrition bias was low in the remaining 22 trials because of a low or null dropout rate </p> </section> <section id="CD011946-sec-0100"> <h4 class="title">Selective reporting</h4> <p>All trials reported their prespecified outcomes that are of interest in the review in the prespecified way. We judged all 24 trials to be at a low risk of reporting bias. </p> </section> <section id="CD011946-sec-0101"> <h4 class="title">Other potential sources of bias</h4> <p>We judged the 24 trials to be at a low risk of other potential sources of bias, e.g. baseline imbalance and blocked randomisation in unblinded trials. </p> </section> </section> <section id="CD011946-sec-0102"> <h3 class="title" id="CD011946-sec-0102">Effects of interventions</h3> <p>See: <a href="./full#CD011946-tbl-0001"><b>Summary of findings for the main comparison</b> Fractional laser versus non‐fractional non‐ablative laser for acne scars</a>; <a href="./full#CD011946-tbl-0002"><b>Summary of findings 2</b> Fractional laser versus radiofrequency for acne scars</a>; <a href="./full#CD011946-tbl-0003"><b>Summary of findings 3</b> Fractional laser versus combined chemical peeling plus needling for acne scars</a>; <a href="./full#CD011946-tbl-0004"><b>Summary of findings 4</b> Chemical peeling versus placebo or no treatment for acne scars</a>; <a href="./full#CD011946-tbl-0005"><b>Summary of findings 5</b> Chemical peeling versus combined chemical peeling plus any active intervention for acne scars</a>; <a href="./full#CD011946-tbl-0006"><b>Summary of findings 6</b> Chemical peeling versus needling for acne scars</a>; <a href="./full#CD011946-tbl-0007"><b>Summary of findings 7</b> Injectable fillers versus placebo or no treatment for acne scars</a> </p> <p>We reported our prespecified outcomes under the following 14 pair‐wise comparisons:</p> <p> <ol id="CD011946-list-0015"> <li> <p>Non‐fractional non‐ablative laser versus placebo or no treatment</p> </li> <li> <p>Fractional laser versus non‐fractional non‐ablative laser</p> </li> <li> <p>Fractional laser versus placebo or no treatment</p> </li> <li> <p>Fractional laser versus radiofrequency</p> </li> <li> <p>Fractional laser versus combined fractional laser plus any active intervention</p> </li> <li> <p>Fractional laser versus chemical peeling</p> </li> <li> <p>Fractional laser versus combined chemical peeling plus needling</p> </li> <li> <p>Chemical peeling versus placebo or no treatment</p> </li> <li> <p>Chemical peeling versus combined chemical peeling plus any active intervention</p> </li> <li> <p>Chemical peeling versus needling</p> </li> <li> <p>Needling versus placebo or no treatment</p> </li> <li> <p>Injectable fillers versus placebo or no treatment</p> </li> <li> <p>Injectable fillers versus subcision</p> </li> <li> <p>Combined microdermabrasion plus ALA‐PDT versus combined microdermabrasion plus placebo‐PDT</p> </li> </ol> </p> <p>As we specified in our protocol, we assessed our primary outcome of scar improvement over a time frame of up to 24 weeks (short‐term) and more than 24 weeks (long‐term) and present these outcomes separately as 'Number of participants with &gt; 50% improvement'. We also used this timing for our secondary outcome 'Investigator‐assessed scar improvement' which we also present as 'Number of participants with &gt; 50% improvement'. Our secondary outcome 'Participant satisfaction' was expressed as 'Number of satisfied participants'. </p> <p>We assessed our adverse events outcomes in the short term up to four weeks after the procedure and in the long term more than four weeks after the procedure. </p> <p>We employed GRADE methodology to provide an assessment of the quality of the evidence for each of the primary and secondary outcomes. </p> <p>Nine studies provided no usable data on many outcomes and did not contribute further to the results of this review. For the other studies the main reasons why data could not be used were that our outcomes were not addressed, outcomes were only described and not reported numerically, or insufficient data were available to determine, e.g. standard deviations. </p> <section id="CD011946-sec-0103"> <h4 class="title">1. Non‐fractional non‐ablative laser versus placebo or no treatments</h4> <p>This analysis includes one within‐individual study (<a href="./references#CD011946-bbs2-0003" title="BernsteinEF , FerreiraM , AndersonD . A pilot investigation to subjectively measure treatment effect and side‐effect profile of non‐ablative skin remodeling using a 532 nm, 2 ms pulse‐duration laser. Journal of Cosmetic &amp; Laser Therapy2001;3(3):137‐41. [EMBASE: 2002362049] ">Bernstein 2001</a>; n = 11) in which one cheek was randomised to receive a frequency‐doubled 532 nm Nd:YAG laser for an average of three treatments and the other cheek was kept untreated. This study did not assess our second primary outcome or any of our secondary outcomes. See <a href="./references#CD011946-fig-0004" title="">Analysis 1.1</a> for a precis of our findings. </p> <section id="CD011946-sec-0104"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD011946-list-0016"> <li> <p>Participant‐reported scar improvement (short‐term): Acne scarring was rated as improved by an average of 53.6%, with a range from 10% to 90%. Eight of 11 participants showed more than 50% improvement in acne scars on the laser‐treated side; there were no data available for the untreated side. We judged this study to be at high risk of detection bias. </p> </li> </ul> </p> </section> </section> <section id="CD011946-sec-0105"> <h4 class="title">2. Fractional laser versus non‐fractional non‐ablative laser</h4> <p>This analysis includes one parallel‐group study (<a href="./references#CD011946-bbs2-0002" title="AsilianA , SalimiE , FaghihiG , DehghaniF , TajmirriahiN , HosseiniSM . Comparison of Q‐Switched 1064‐nm Nd: YAG laser and fractional CO2 laser efficacies on improvement of atrophic facial acne scar. Journal of Research in Medical Sciences2011;16(9):1189‐95. [EMBASE: 2011598154] ">Asilian 2011</a>) in which 64 participants with atrophic acne scars were randomised to receive four sessions of fractional CO₂ laser (four‐week intervals) or the comparator of four sessions of non‐fractional non‐ablative Q Switched 1064 nm Nd:YAG laser (four‐week intervals). This study only assessed three of our secondary outcomes. See <a href="./full#CD011946-tbl-0001">summary of findings Table for the main comparison</a> for our grading of the evidence. </p> <section id="CD011946-sec-0106"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD011946-list-0017"> <li> <p>Participant‐reported scar improvement (short‐term): At six months post‐treatment 12/32 participants reported more than 50% improvement in acne scarring in the fractional laser arm and 3/32 reported more than 50% improvement in acne scarring in the non‐fractional non‐ablative arm. There was a statistically significant difference in favour of fractional laser (RR 4.00, 95% CI 1.25 to 12.84; very low‐quality evidence; <a href="./references#CD011946-fig-0005" title="">Analysis 2.1</a>). We rated this study at unclear risk of detection bias. </p> </li> <li> <p>Participants with adverse effects serious or severe enough to have caused their withdrawal from the study: All participants (n = 64) completed the allocated treatments, indicating that no‐one experienced adverse effects severe enough to withdraw from the study. </p> </li> </ul> </p> </section> <section id="CD011946-sec-0107"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD011946-list-0018"> <li> <p>Investigator‐assessed scar improvement (short‐term): After treatment, 12/32 participants post‐fractional laser treatment versus 4/32 participants post‐non‐fractional treatment non‐ablative laser showed more than 50% improvement in acne scarring. There was a statistically significant difference in favour of fractional laser (RR 3.00, 95% CI 1.08 to 8.32; <a href="./references#CD011946-fig-0006" title="">Analysis 2.2</a>). </p> </li> <li> <p>Participant‐reported adverse events (short‐term): All participants in the non‐fractional non‐ablative group (n = 32) reported transient post‐treatment burning sensation but it was more severe in those treated with fractional CO₂ laser (n = 32). The burning sensation lasted for more than a few hours (RR 1.00, 95% CI 0.94 to 1.06; very low‐quality evidence; <a href="./references#CD011946-fig-0007" title="">Analysis 2.3</a>). </p> </li> <li> <p>Investigator‐assessed adverse events (short‐term): Post‐inflammatory hyperpigmentation lasting for two to three weeks was reported by 6/32 and 10/32 participants treated with non‐fractional non‐ablative laser and fractional CO₂ laser respectively (RR 0.60, 95% CI 0.25 to 1.45; low‐quality evidence <a href="./references#CD011946-fig-0008" title="">Analysis 2.4</a>). </p> </li> </ul> </p> </section> </section> <section id="CD011946-sec-0108"> <h4 class="title">3. Fractional laser versus placebo or no treatment</h4> <p>This analysis includes two within‐individual studies (<a href="./references#CD011946-bbs2-0008" title="HedelundL , MoreauKER , BeyerDM , NymannP , HaedersdalM . Fractional nonablative 1,540‐nm laser resurfacing of atrophic acne scars. A randomized controlled trial with blinded response evaluation. Lasers in Medical Science2010;25(5):749‐54. [EMBASE: 2010472544] ">Hedelund 2010</a>; <a href="./references#CD011946-bbs2-0009" title="HedelundL , HaakCS , Togsverd‐BoK , BoghMK , BjerringP , HaedersdalM . Fractional CO2 laser resurfacing for atrophic acne scars: A randomized controlled trial with blinded response evaluation. Lasers in Surgery and Medicine2012;44(6):447‐52. [EMBASE: 2012412028] ">Hedelund 2012</a>). See <a href="./references#CD011946-fig-0009" title="">Analysis 3.1</a> for a precis of our findings. </p> <p><a href="./references#CD011946-bbs2-0008" title="HedelundL , MoreauKER , BeyerDM , NymannP , HaedersdalM . Fractional nonablative 1,540‐nm laser resurfacing of atrophic acne scars. A randomized controlled trial with blinded response evaluation. Lasers in Medical Science2010;25(5):749‐54. [EMBASE: 2010472544] ">Hedelund 2010</a> was a within‐individual trial with 10 participants in which one area on the site (A) was randomised to receive fractional 1540‐nm Er:Glass laser treatment for three sessions at four‐week intervals and the area on the contralateral site (B) received no treatment. This study did not assess our secondary outcome ‘Quality of life’. </p> <section id="CD011946-sec-0109"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD011946-list-0019"> <li> <p>Participant‐reported scar improvement (short‐term): The overall acne scar appearance was evaluated by the participants after 12 weeks on a five‐point scale (worse, not improved, slightly improved, moderately improved, significantly improved) and revealed that 8/10 were improved on the laser‐treated side; there were no data available for the untreated side. We judged this study to be at high risk of detection bias. </p> </li> <li> <p>Participants with adverse effects serious or severe enough to have caused their withdrawal from the study: All 10 participants completed the allocated treatments, indicating that no‐one experienced adverse effects severe enough to withdraw from the study. </p> </li> </ul> </p> </section> <section id="CD011946-sec-0110"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD011946-list-0020"> <li> <p>Investigator‐assessed scar improvement (short‐term): After treatment, scar texture severity score remained constant in untreated areas but improved in treated areas, with an average improvement of 1.5 on the 0 – 10 scale (0 even skin texture without scarring, 5 moderate scarring, and 10 worst possible scarring). </p> </li> <li> <p>Participant satisfaction: Participants were satisfied with the treatment side with median satisfaction score of 5.5 (interquartile range (IQR) 1 – 7) at week 12 based on a patient satisfaction scale (from score 0, no satisfaction, to 10, best imaginable satisfaction); there were no data available for the untreated side. </p> </li> <li> <p>Participant‐reported adverse events (short‐term): 10/10 participants reported immediate pain and transient erythema post‐treatment; no adverse effects were seen in untreated control areas. </p> </li> <li> <p>Investigator‐assessed adverse events (long‐term): No significant differences were found in skin redness and pigmentation between treated and untreated areas (P value not reported). </p> </li> <li> <p>Post‐procedure down time (days): The skin reactions developed post‐procedure did not influence the participants’ daily activities. </p> </li> </ul> </p> <p><a href="./references#CD011946-bbs2-0009" title="HedelundL , HaakCS , Togsverd‐BoK , BoghMK , BjerringP , HaedersdalM . Fractional CO2 laser resurfacing for atrophic acne scars: A randomized controlled trial with blinded response evaluation. Lasers in Surgery and Medicine2012;44(6):447‐52. [EMBASE: 2012412028] ">Hedelund 2012</a> was a within‐individual trial with 13 participants in which one area on the site (A) was randomised to receive fractional CO₂ laser treatment for three sessions at four‐ to five‐week intervals and the area on the contralateral site (B) received no treatment. It did not assess our second primary outcome ‘Serious adverse effects’ or several of our secondary outcomes. One participant left the trial before the end assessment and was not included in the analysis 6 months postoperatively (<a href="./references#CD011946-bbs2-0009" title="HedelundL , HaakCS , Togsverd‐BoK , BoghMK , BjerringP , HaedersdalM . Fractional CO2 laser resurfacing for atrophic acne scars: A randomized controlled trial with blinded response evaluation. Lasers in Surgery and Medicine2012;44(6):447‐52. [EMBASE: 2012412028] ">Hedelund 2012</a>); no mention was made of the cause for withdrawal. </p> </section> <section id="CD011946-sec-0111"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD011946-list-0021"> <li> <p>Participant‐reported scar improvement (short‐term): Participants (n = 12) reported mild to moderate improvement in scar texture at six months postoperatively on the laser‐treated side, based on a numerical scale from 0 (even skin texture without scarring) to 10 (worst possible scarring); there were no data available for the untreated site. We judged this study to be at high risk of detection bias. </p> </li> </ul> </p> </section> <section id="CD011946-sec-0112"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD011946-list-0022"> <li> <p>Investigator‐assessed scar improvement (short‐term): Fractional CO₂ laser resurfacing was shown to significantly improve skin texture appearance and atrophy (depth of scars) in 12/12 participants with atrophic acne scars, from a mean of 6.15 (standard deviation (SD) 1.23) for skin texture and 5.72 (SD 1.45) for depth of scars before treatment to a mean of 3.89 (SD 1.74) for skin texture and 3.56 (SD 1.76) for depth of scars at six months (P &lt; 0.0001). These measurements were based on three physicians who were blinded to the assessments and who used a grading scale (0 = even skin texture without scarring or atrophy to 10 = worst possible scarring or atrophy) (P &lt; 0.0001). </p> </li> <li> <p>Participant satisfaction: All participants (n = 13) were satisfied with the treatment, with a median satisfaction score of 4.5 (IQR 2 – 7) at week 24 based on a numerical scale from 0 (unsatisfied) to 10 (maximal satisfaction); there were no data available for the untreated side. </p> </li> <li> <p>Participant‐reported adverse events (short‐term): Participants (n = 13) experienced mild to moderate pain on the treated side. No adverse effects were seen in untreated control areas. </p> </li> <li> <p>Investigator‐assessed adverse events (short‐term): 9/13 participants responded with mild to moderate erythema while all participants responded with mild to moderate wound formation two to three days post‐treatment. No significant differences were found in skin redness and pigmentation between treated and untreated areas. </p> </li> <li> <p>Post‐procedure down time (days): The skin reactions developed post‐procedure did not influence the participants’ daily activities. </p> </li> </ul> </p> </section> </section> <section id="CD011946-sec-0113"> <h4 class="title">4. Fractional laser versus radiofrequency</h4> <p>This analysis includes one parallel‐group study (<a href="./references#CD011946-bbs2-0004" title="ChaeWS , SeongJY , JungHN , KongSH , KimMH , SuhHS , et al. Comparative study on efficacy and safety of 1550 nm Er: Glass fractional laser and fractional radiofrequency microneedle device for facial atrophic acne scar. Journal of Cosmetic Dermatology2015;14(2):100‐6. [EMBASE: 2015071568] ">Chae 2015</a>) and two within‐individual studies (<a href="./references#CD011946-bbs2-0021" title="RongsaardN , RummaneethornP . Comparison of a fractional bipolar radiofrequency device and a fractional erbium‐doped glass 1,550‐nm device for the treatment of atrophic acne scars: a randomized split‐face clinical study. Dermatologic Surgery2014;40(1):14‐21. [PUBMED: 24267397] ">Rongsaard 2014</a>; <a href="./references#CD011946-bbs2-0024" title="ZhangZ , FeiY , ChenX , LuW , ChenJ . Comparison of a fractional microplasma radio frequency technology and carbon dioxide fractional laser for the treatment of atrophic acne scars: a randomized split‐face clinical study. Dermatologic Surgery2013;39(4):559‐66. [PUBMED: 23379344] ">Zhang 2013</a>). See <a href="./full#CD011946-tbl-0002">summary of findings Table 2</a> for our grading of the evidence. </p> <p><a href="./references#CD011946-bbs2-0004" title="ChaeWS , SeongJY , JungHN , KongSH , KimMH , SuhHS , et al. Comparative study on efficacy and safety of 1550 nm Er: Glass fractional laser and fractional radiofrequency microneedle device for facial atrophic acne scar. Journal of Cosmetic Dermatology2015;14(2):100‐6. [EMBASE: 2015071568] ">Chae 2015</a> was a parallel trial in which 40 participants were randomly divided into two equal groups to receive three sessions (four‐week intervals) of 1550 nm Er:Glass fractional laser or the comparator of three sessions (four‐week intervals) with the fractional radiofrequency device. This study did not assess several of our secondary outcomes. </p> <section id="CD011946-sec-0114"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD011946-list-0023"> <li> <p>Participant‐reported scar improvement (short‐term): 7/20 participants reported more than 50% improvement in the appearance of acne scars in the fractional laser arm, while in the radiofrequency microneedle arm 9/20 participants reported more than 50% acne scar improvement using participant’s self assessment of percentage of improvement. No statistically significant difference was reported (RR 0.78, 95% CI 0.36 to 1.68; very low‐quality evidence; <a href="./references#CD011946-fig-0010" title="">Analysis 4.1</a>). We rated this study at high risk of detection bias. </p> </li> <li> <p>Participants with adverse effects serious or severe enough to have caused their withdrawal from the study: No serious adverse effects were reported. All 40 participants completed the trial as planned. </p> </li> </ul> </p> </section> <section id="CD011946-sec-0115"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD011946-list-0024"> <li> <p>Investigator‐assessed scar improvement (short‐term): At eight weeks post‐treatment, two blinded physicians who were not involved in the trial assessed scar improvement in both arms using the physician’s global assessment scale. Eleven of 20 participants in the fractional laser group and 8/20 participants in the radiofrequency microneedle group showed more than 50% improvement following treatment, but there was no statistically significant difference between them (RR 1.38, 95% CI 0.71 to 2.68; <a href="./references#CD011946-fig-0011" title="">Analysis 4.2</a>). The mean Clinical Evaluation Scale for Acne Scarring (échelle d’évaluation clinique des cicatrices d’acné (ECCA)) grading scale of both groups decreased significantly over the 20‐week time period of the study. In the fractional laser group, the mean ECCA grading scale was reduced from 74.25 to 55.5 (P &lt; 0.001), with a 25.0% reduction from baseline scale. In the radiofrequency group, the mean ECCA grading scale decreased from 68.75 to 56.0 (P &lt; 0.01), with an 18.6% reduction. At the end of the study, in both groups, there were meaningful decreases from the baseline ECCA grade. However, the difference between both interventions was not statistically significant (P &gt; 0.05). </p> </li> <li> <p>Participant‐reported adverse events (short‐term): Overall, participants experienced more pain with the fractional laser than with the radiofrequency device, with a mean of 5.5 (SD 1.10) and 4.7 (SD 1.08) respectively on visual analogue scale (VAS) (P value not reported). </p> </li> <li> <p>Investigator‐assessed adverse events (short‐term): 5/12 and 3/12 participants experienced erythema for more than five days with the fractional laser and radiofrequency microneedle respectively. Oedema over more than five days was reported in 3/20 and 1/20 participants with the fractional laser and the radiofrequency microneedle respectively. Post‐inflammatory hyperpigmentation was reported in 2/20 participants with the fractional laser only, while none was found with the radiofrequency device (unclear whether they are participant‐ or investigator‐reported) (P value not reported). </p> </li> </ul> </p> <p>With regard to the two within‐individual studies see <a href="./references#CD011946-fig-0012" title="">Analysis 4.3</a> for a precis of our findings. </p> <p><a href="./references#CD011946-bbs2-0021" title="RongsaardN , RummaneethornP . Comparison of a fractional bipolar radiofrequency device and a fractional erbium‐doped glass 1,550‐nm device for the treatment of atrophic acne scars: a randomized split‐face clinical study. Dermatologic Surgery2014;40(1):14‐21. [PUBMED: 24267397] ">Rongsaard 2014</a> was a within‐individual trial in which one side of the face was randomised to be treated with the fractional 1550‐nm Er:Glass laser and the other side of the face treated using the fractional bipolar radiofrequency (RF) device for three treatment sessions at four‐week intervals. This study did not assess several of our secondary outcomes . </p> </section> <section id="CD011946-sec-0116"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD011946-list-0025"> <li> <p>Participant‐reported scar improvement (short‐term): Mean improvement grade in acne scars after treatment was 2.89 (SD 0.57) for the fractional laser Er:Glass (n = 19) and 2.74 (SD 0.73) for the fractional bipolar RF (n = 19) devices respectively, using the grading scale: 0 = no improvement; 1 = &lt; 25% (mild) improvement; 2 = 25% – 50% (moderate) improvement; 3 = 51% – 75% (good) improvement; 4 = &gt; 75% (excellent) improvement), with no significant difference between the treated sides (P value not reported). This study showed unclear risk of detection bias. </p> </li> <li> <p>Participants with adverse effects serious or severe enough to have caused their withdrawal from the study: 1/20 withdrew from the study because of prolonged dyspigmentation which negatively affected his quality of life. </p> </li> </ul> </p> </section> <section id="CD011946-sec-0117"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD011946-list-0026"> <li> <p>Investigator‐assessed scar improvement (short‐term): The mean improvement grade in acne scars after treatment was 2.86 (SD 0.42) and 2.70 (SD 0.37) for the fractional Er:Glass laser (n = 19) and the fractional bipolar RF (n = 19) devices respectively, with no significant difference between the treated sides (P value not mentioned). </p> </li> <li> <p>Participant satisfaction: All participants (n = 19) were satisfied with both treatments.</p> </li> <li> <p>Participant‐reported adverse events (short‐term): Pain, transitory facial erythema, facial dryness, and scab construction had been reported for both interventions. The pain score reported with the fractional laser was higher than with the fractional RF (mean difference = 1.85 (SD 1.30); P &lt; 0.001), while the length of scab‐shedding treatment was longer with the fractional RF than with the fractional laser (<a href="./references#CD011946-bbs2-0021" title="RongsaardN , RummaneethornP . Comparison of a fractional bipolar radiofrequency device and a fractional erbium‐doped glass 1,550‐nm device for the treatment of atrophic acne scars: a randomized split‐face clinical study. Dermatologic Surgery2014;40(1):14‐21. [PUBMED: 24267397] ">Rongsaard 2014</a>) (mean difference = 1.55 (SD 2.65) days; P = 0.01). There was no significant difference between the two devices regarding duration of facial erythema and dryness (P = 0.60 and 0.10 respectively). </p> </li> </ul> </p> <p><a href="./references#CD011946-bbs2-0024" title="ZhangZ , FeiY , ChenX , LuW , ChenJ . Comparison of a fractional microplasma radio frequency technology and carbon dioxide fractional laser for the treatment of atrophic acne scars: a randomized split‐face clinical study. Dermatologic Surgery2013;39(4):559‐66. [PUBMED: 23379344] ">Zhang 2013</a> was a within‐individual trial of 33 participants in which one facial half was randomised to receive treatment with a 10,600‐nm CO₂ fractional laser (FS) and the other half received treatment with a fractional microplasma radiofrequency device (RF) for three treatment sessions at six‐ to 12‐week (average eight‐week) intervals. This study did not assess our first primary outcome or several of our secondary outcomes . </p> </section> <section id="CD011946-sec-0118"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD011946-list-0027"> <li> <p>Participants with adverse effects serious or severe enough to have caused their withdrawal from the study: All participants completed the allocated treatments and none withdrew from the study. </p> </li> </ul> </p> </section> <section id="CD011946-sec-0119"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD011946-list-0028"> <li> <p>Investigator‐assessed scar improvement (short‐term): After treatment, acne scars improved in all participants (n = 33) by 59.2% and 56.4% following CO₂ FS and fractional RF treatments respectively using the ECCA score, with no significant difference (P = 0.93). </p> </li> <li> <p>Participant satisfaction: After treatment, 90.9% (30/33) and 93.9% (31/33) of participants were satisfied with the CO₂ FS and fractional RF treatments respectively (RR 1.5) with no significant difference (P = 0.16). </p> </li> <li> <p>Participant‐reported adverse events (short‐term): Post‐therapy erythema and scaling remained for longer on the CO₂ FS side than on the fractional RF side, with mean duration of 10.2 days and 5.7 days respectively (P &lt; 0.001). </p> </li> <li> <p>Investigator‐assessed adverse events (long‐term): 12/33 (36.4%) experienced post‐inflammatory hyperpigmentation with 45.8 days average duration on the CO₂ FS side; no post‐inflammatory hyperpigmentation was observed on the fractional RF sides (P &lt; 0.001). </p> </li> </ul> </p> </section> </section> <section id="CD011946-sec-0120"> <h4 class="title">5. Fractional laser versus combined fractional laser plus any active intervention</h4> <p>This comparison includes two within‐individual studies (<a href="./references#CD011946-bbs2-0007" title="FaghihiG , NouraeiS , AsilianA , KeyvanS , Abtahi‐NaeiniB , RakhshanpourM , et al. Efficacy of punch elevation combined with fractional carbon dioxide laser resurfacing in facial atrophic acne scarring: a randomized split‐face clinical study. Indian Journal of Dermatology2015;60(5):473‐8. [EMBASE: 2015376448] ">Faghihi 2015</a>; <a href="./references#CD011946-bbs2-0013" title="LeeJW , KimBJ , KimMN , MunSK . The efficacy of autologous platelet rich plasma combined with ablative carbon dioxide fractional resurfacing for acne scars: a simultaneous split‐face trial. Dermatologic Surgery2011;37(7):931‐8. [PUBMED: 21635618] ">Lee 2011</a>). See <a href="./references#CD011946-fig-0013" title="">Analysis 5.1</a>.for a precis of our findings. </p> <p><a href="./references#CD011946-bbs2-0007" title="FaghihiG , NouraeiS , AsilianA , KeyvanS , Abtahi‐NaeiniB , RakhshanpourM , et al. Efficacy of punch elevation combined with fractional carbon dioxide laser resurfacing in facial atrophic acne scarring: a randomized split‐face clinical study. Indian Journal of Dermatology2015;60(5):473‐8. [EMBASE: 2015376448] ">Faghihi 2015</a> was a within‐individual trial of 42 participants in which one side of the participant's face was randomised to be treated using the 10,600­nm fractional CO₂ laser alone for two sessions with a one‐month interval and the other side of the face was treated with the same fractional CO₂ laser plus one session of punch elevation before the laser sessions. This study did not assess our first primary outcome or several of our secondary outcomes. </p> <section id="CD011946-sec-0121"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD011946-list-0029"> <li> <p>Participants with adverse effects serious or severe enough to have caused their withdrawal from the study: All participants (n = 42) completed the allocated treatments and were included in the analyses. </p> </li> </ul> </p> </section> <section id="CD011946-sec-0122"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD011946-list-0030"> <li> <p>Investigator‐assessed scar improvement (short‐term): After treatment, 26/42 participants post‐treatment with the fractional laser alone versus 31/42 participants post‐treatment with the combined fractional laser and punch elevation, reported more than a 50% improvement in their acne scars (RR 1.45) using the following grading scale (1 ≤ 25% (minimal) improvement; 2 = 5% – 50% (moderate) improvement; 3 = 51% ‐ 75% (good) improvement; 4 ≥ 75% (excellent) improvement). Fractional CO₂ laser treatment combined with punch elevation produced better improvement in acne scars than fractional CO₂ laser treatment alone (P = 0.02). </p> </li> <li> <p>Participant satisfaction: Participants were more satisfied with the combined fractional laser with punch elevation treatment than with the fractional laser alone; mean acne scar improvement was 7.8 (SD 1.6) and 6.8 (SD 1.9) respectively using a VAS; 0 as no satisfaction, and 10 as the best possible satisfaction) (P = 0.009). </p> </li> <li> <p>Participant‐reported adverse events (short‐term): Transient erythema for three to four days and crusting lasting for about four to seven days were the most frequently testified adverse events. Transitory burning and redness after treatment were seen in all participants (n = 42) on both treatment sides which resolved without any treatment. </p> </li> <li> <p>Investigator‐assessed adverse events (long‐term): Mild post­inflammatory hyperpigmentation was observed in 9/42 (21.4%) of participants one month after treatment, lasting for less than six months. </p> </li> </ul> </p> <p><a href="./references#CD011946-bbs2-0013" title="LeeJW , KimBJ , KimMN , MunSK . The efficacy of autologous platelet rich plasma combined with ablative carbon dioxide fractional resurfacing for acne scars: a simultaneous split‐face trial. Dermatologic Surgery2011;37(7):931‐8. [PUBMED: 21635618] ">Lee 2011</a> was a within‐individual trial of 14 participants in which the entire face was treated with a fractional ablative CO₂ laser, and then one facial half was randomised to receive an intradermal injection with 0.3 ml normal saline and the other half received an intradermal treatment with 0.3 ml autologous platelet‐rich plasma (PRP). One month later, another similar treatment session was given to all participants. This study did not assess our first primary outcome or several of our secondary outcomes. </p> </section> <section id="CD011946-sec-0123"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD011946-list-0031"> <li> <p>Participants with adverse effects serious or severe enough to have caused their withdrawal from the study: All participants (n = 14) completed the allocated treatments and were included in the analysis. </p> </li> </ul> </p> </section> <section id="CD011946-sec-0124"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD011946-list-0032"> <li> <p>Investigator‐assessed scar improvement (short‐term): Four months after the final treatment, the mean overall degree of clinical improvement was 2.3 (SD 0.5) on the fractional laser‐only side and 2.7 (SD 0.7) on the combined fractional laser plus PRP side, with better results on the combined fractional laser plus PRP side (P = 0.03) using a quartile grading scale (0 = no improvement; 1 = &lt; 25% improvement; 2 = 25% – 50% improvement; 3 = 51% – 75% improvement; 4 = &gt; 75% improvement). </p> </li> <li> <p>Participant‐reported adverse events (short‐term): All participants (n = 14) reported some degree of post‐treatment crusting, which lasted longer on the fractional laser alone side for an average of 6.8 (SD 1.0) days compared to the combined fractional laser plus PRP side with an average of 5.9 (SD 1.1) days (P = 0.04). Oedema also lasted longer on the fractional laser alone side (n = 14) for an average of 7.1 (SD 1.5) days than on the combined fractional laser plus PRP side (n = 14) with an average of 6.1 (SD 1.1) days (P = 0.04). </p> </li> <li> <p>Investigator‐assessed adverse events (short‐term): The resurfacing‐associated erythema on the combined fractional laser plus PRP side was significantly less and improved faster than on the fractional laser alone side at post‐treatment day four (P = 0.047). Post‐treatment oedema on the combined fractional laser plus PRP side also improved faster than the fractional laser alone side, although the difference was not statistically significant (P value not mentioned). None of the other adverse events (petechiae, oozing, dyschromia, infection, scarring, or blistering) occurred in any participant. </p> </li> </ul> </p> </section> </section> <section id="CD011946-sec-0125"> <h4 class="title">6. Fractional laser versus chemical peeling</h4> <p>One within‐individual study (<a href="./references#CD011946-bbs2-0011" title="KimHJ , KimTG , KwonYS , ParkJM , LeeJH . Comparison of a 1,550 nm Erbium: glass fractional laser and a chemical reconstruction of skin scars (CROSS) method in the treatment of acne scars: a simultaneous split‐face trial. Lasers in Surgery and Medicine2009;41(8):545‐9. [PUBMED: 19639620] ">Kim 2009</a>) of 20 participants addressed this comparison, in which one side of the face was randomised to be treated with the 1550 nm Er:Glass fractional laser for three sessions (six‐week intervals) and the other side was treated with the chemical reconstruction of skin scars (CROSS) chemical peeling method twice every 12 weeks. This study did not assess our first primary outcome or several of our secondary outcomes. See <a href="./references#CD011946-fig-0014" title="">Analysis 6.1</a> for a precis of our findings. </p> <section id="CD011946-sec-0126"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD011946-list-0033"> <li> <p>Participants with adverse effects serious or severe enough to have caused their withdrawal from the study: 18/20 participants finished the trial and were included in the data. One participant left the trial because of minor discomfort with the treatment from pain and redness, and the other left the trial because of timetabling clashes (<a href="./references#CD011946-bbs2-0011" title="KimHJ , KimTG , KwonYS , ParkJM , LeeJH . Comparison of a 1,550 nm Erbium: glass fractional laser and a chemical reconstruction of skin scars (CROSS) method in the treatment of acne scars: a simultaneous split‐face trial. Lasers in Surgery and Medicine2009;41(8):545‐9. [PUBMED: 19639620] ">Kim 2009</a>). </p> </li> </ul> </p> </section> <section id="CD011946-sec-0127"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD011946-list-0034"> <li> <p>Investigator‐assessed scar improvement (short‐term): The overall average improvement grades were 2.51 in the fractional laser site (n = 18) and 2.44 in the chemical peeling site (n = 18) using a quartile scale (0 = no improvement; 1 = 1% – 25% improvement; 2 = 26% – 50% improvement; 3 = 51%– 75% improvement; 4 = &gt; 75% improvement). </p> </li> <li> <p>Participant‐reported adverse events (short‐term): The mean grade of pain was noted to be 4.49 on the laser‐treated sides and 3.33 on the chemical peeling‐treated sides using a 10‐point scale (0 – 9). Mean erythema lasting days were noted to be 3.30 days on the laser‐treated sides and 12.13 days on the chemical peeling‐treated sides (P value not assessed). </p> </li> <li> <p>Post‐procedure down time (days): Mean down times were noted to be 3.17 days on the laser‐treated sides (n = 18) and 9.72 days on the chemical peeling‐treated sides (n = 18) (P value not assessed). </p> </li> </ul> </p> </section> </section> <section id="CD011946-sec-0128"> <h4 class="title">7. Fractional laser versus combined chemical peeling plus needling</h4> <p>One parallel‐group study (<a href="./references#CD011946-bbs2-0016" title="LehetaTM , Abdel HayRM , HegazyRA , ElGaremYF . Do combined alternating sessions of 1540 nm nonablative fractional laser and percutaneous collagen induction with trichloroacetic acid 20% show better results than each individual modality in the treatment of atrophic acne scars? A randomized controlled trial. Journal of Dermatological Treatment2014;25(2):137‐41. [PUBMED: 22640000] ">Leheta 2014b</a>) addressed this comparison in which 39 participants with atrophic acne scarring were randomised into three equal groups, to include the group who received six sessions (four weeks apart) of fractional non‐ablative 1540 nm Er:Glass laser and the comparator who received six sessions (four weeks apart) of chemical peeling with trichloroacetic acid (TCA) 20% combined with skin needling, but we excluded the third arm of this trial. This study did not assess several of our secondary outcomes. See <a href="./full#CD011946-tbl-0003">summary of findings Table 3</a> for our grading of the evidence. </p> <section id="CD011946-sec-0129"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD011946-list-0035"> <li> <p>Participant‐reported scar improvement (long‐term): Twelve months after treatment, 9/13 participants in the fractional laser group reported more than 50% improvement in acne scars, and 9/13 participants in the combined chemical peeling plus needling group reported more than 50% improvement in acne scars, using a weighted scale and then a quartile grading scale (0 = minimal improvement &lt; 25%; 1 = mild improvement 25% – 50%; 2 = moderate improvement 51% – 75%; 3 = significant improvement &gt; 75%). No statistically significant difference was reported (RR 1.00, 95% CI 0.60 to 1.67; very low‐quality evidence; <a href="./references#CD011946-fig-0015" title="">Analysis 7.1</a>). We judged this study to be at high risk of detection bias. </p> </li> <li> <p>Participants with adverse effects serious or severe enough to have caused their withdrawal from the study: 1/13 in the combined chemical peeling plus needling group received one session and was then lost to follow‐up; we included this participant in the analyses on an intention‐to‐treat basis. All other participants completed the allocated treatments and were included in the analysis. </p> </li> </ul> </p> </section> <section id="CD011946-sec-0130"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD011946-list-0036"> <li> <p>Investigator‐assessed scar improvement (long‐term): Twelve months after treatment, acne scarring showed more than 50% improvement in 10/13 participants in the fractional laser group and in 10/13 participants in the combined chemical peeling plus needling group, using a weighted scale and then a quartile grading scale (0 = minimal improvement &lt; 25%; 1 = mild improvement 25% – 50%; 2 = moderate improvement 51% – 75%; 3 = significant improvement &gt; 75%). No statistically significant difference was reported (RR 1.00, 95% CI 0.66 to 1.52; <a href="./references#CD011946-fig-0016" title="">Analysis 7.2</a>). </p> </li> <li> <p>Participant‐reported adverse events (short‐term): All participants in both groups (n = 25) reported pain, transient oedema and erythema (RR 1.00, 95% CI 0.86 to 1.16; very low‐quality evidence; <a href="./references#CD011946-fig-0017" title="">Analysis 7.3</a>). </p> </li> </ul> </p> </section> </section> <section id="CD011946-sec-0131"> <h4 class="title">8. Chemical peeling versus placebo or no treatment</h4> <p>One parallel group study (<a href="./references#CD011946-bbs2-0006" title="ErbağciZ , AkçaliC . Biweekly serial glycolic acid peels vs. long‐term daily use of topical low‐strength glycolic acid in the treatment of atrophic acne scars. International Journal of Dermatology2000;39(10):789‐94. [EMBASE: 2000387524] ">Erbağci 2000</a>) addressed this comparison in which 58 women with atrophic acne scarring were randomised into three groups; one group (n = 23) received serial bi‐weekly applied glycolic acid peels with different concentrations in a gradually increasing manner (two‐week intervals), one group (n = 20) received 15% glycolic acid cream daily for 24 weeks, and the remaining group (n = 15) received a placebo cream daily. We combined the first two arms into a single‐arm group who received chemical peeling (n = 43) to be compared with the placebo group. This study did not assess our first primary outcome or several of our secondary outcomes. See <a href="./full#CD011946-tbl-0004">summary of findings Table 4</a> for our grading of the evidence. </p> <section id="CD011946-sec-0132"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD011946-list-0037"> <li> <p>Participants with adverse effects serious or severe enough to have caused their withdrawal from the study: 48/58 participants completed the study; in the chemical peeling group, nine participants did not complete the study: seven participants withdrew because they were unable to tolerate higher concentrations and longer contact times of the peeling agent, and two were lost to follow‐up. In the placebo group, one participant was lost to follow‐up and none were reported to have serious adverse events. No statistically significant difference was reported (RR 5.45, 95% CI 0.33 to 90.14; very low‐quality evidence; <a href="./references#CD011946-fig-0018" title="">Analysis 8.1</a>). We rated this study at high risk of attrition bias. </p> </li> </ul> </p> </section> <section id="CD011946-sec-0133"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD011946-list-0038"> <li> <p>Investigator‐assessed scar improvement (short‐term): Final assessment of the results revealed a good response (&gt; 60% grade change from the baseline) in 6/34, a partial response (30% ‐ 60% grade change from the baseline) in 22/34, and minor response (&lt; 30% grade change from the baseline) in 6/34 in the chemical peeling group, while a partial response in 5/14, a minor response in 6/14, and no response in 3/14 were detected in the placebo group, using a 10‐point scale for overall severity of the scars as follows: 0 = no scar; 1 = very mild; 2 ‐ 3 = mild; 4 ‐ 7 = moderate; 8 ‐ 9 = severe; 10 = very severe scar, with a significantly better response in the chemical peeling group (n = 34) (P &lt; 0.05). The reported values of the improvement were the average of the two readings taken (participant and investigator) and could not be used in the analysis. </p> </li> <li> <p>Participant‐reported adverse events (short‐term): Burning sensation and deep erythema were reported following frosting in 4/34 participants in the chemical peeling group. There were mo reported adverse events in the control group. </p> </li> <li> <p>Investigator‐assessed adverse events (long‐term): Frosting and whitening were reported in 4/34 participants that were confined to the scar areas. Persistent post‐inflammatory hyperpigmentation lasted for two to three months and prolonged erythema lasting several days were reported in 7/34 participants in the chemical peeling group. There were no reported adverse events in the control group. </p> </li> </ul> </p> </section> </section> <section id="CD011946-sec-0134"> <h4 class="title">9. Chemical peeling versus combined chemical peeling plus any active intervention</h4> <p>One parallel‐group study (<a href="./references#CD011946-bbs2-0015" title="LehetaTM , Abdel HayRM , GaremYF . Deep peeling using phenol versus percutaneous collagen induction combined with trichloroacetic acid 20% in atrophic post‐acne scars; a randomized controlled trial. Journal of Dermatological Treatment2014;25(2):130‐6. [PUBMED: 22397516 ] ">Leheta 2014a</a>) addressed this comparison in which 24 participants with atrophic acne scarring were randomised to receive one session of deep peeling using a non‐hydro‐alcoholic solution of oil phenol in 60% concentration formula or the comparator of four sessions (six‐week intervals) of chemical peeling with TCA 20% combined with skin needling. Twenty participants (10 in each group) completed the study and were included in the analyses. This study did not assess several of our secondary outcomes. See <a href="./full#CD011946-tbl-0005">summary of findings Table 5</a> for our grading of the evidence. </p> <section id="CD011946-sec-0135"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD011946-list-0039"> <li> <p>Participant‐reported scar improvement (long‐term): Eight months after treatment, all participants (10/10) in the chemical peeling group reported more than a 50% improvement in acne scars, while 80% (8/10) of participants in the chemical peeling plus needling group reported more than a 50% improvement in acne scars, using a weighted scale and then a quartile grading scale (0 = minimal improvement &lt; 25%; 1 = mild improvement 25% – 50%; 2 = moderate improvement 51% – 75%; 3 = significant improvement &gt; 75%). No statistically significant difference was reported (RR 1.24, 95% CI 0.87 to 1.75; very low‐quality evidence; <a href="./references#CD011946-fig-0019" title="">Analysis 9.1</a>). We judged this study to be at high risk of detection bias. </p> </li> <li> <p>Participants with adverse effects serious or severe enough to have caused their withdrawal from the study: 2/12 participants in each group did not receive the allocated treatment after enrolment in the study and were not included in the analyses. Otherwise, all participants (n = 10 in each group) completed the allocated treatments and did not withdraw due to serious adverse effects. </p> </li> </ul> </p> </section> <section id="CD011946-sec-0136"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD011946-list-0040"> <li> <p>Investigator‐assessed scar improvement (long‐term): Eight months after treatment, acne scarring showed more than 50% improvement in all participants (10/10) in the chemical peeling group and in 80% (8/10) of participants in the chemical peeling plus needling group, using a weighted scale then a quartile grading scale (0 = minimal improvement &lt; 25%; 1 = mild improvement 25% – 50%; 2 = moderate improvement 51% – 75%; 3 = significant improvement &gt; 75%). No statistically significant difference was reported (RR 1.24, 95% CI 0.87 to 1.75; <a href="./references#CD011946-fig-0020" title="">Analysis 9.2</a>). </p> </li> <li> <p>Participant‐reported adverse events (short‐term): All participants in both groups (n = 20) reported pain either during the session despite the use of topical anaesthetic cream (in the chemical peeling plus needling group) or after recovery from the general anaesthesia (in the chemical peeling group). All participants in both groups (n = 20) reported transient erythema which lasted for more than one month in the chemical peeling group and for only two to three days in the chemical peeling plus needling group. No statistically significant difference was reported (RR 1.00, 95% CI 0.83 to 1.20; very low‐quality evidence; <a href="./references#CD011946-fig-0021" title="">Analysis 9.3</a>). </p> </li> <li> <p>Investigator‐assessed adverse events (long‐term): All participants (10/10) in the chemical peeling group showed erythema for three to four months and pigmentation for six months. Two of 10 participants (20%) in this group had persistent erythema for six months. None of the participants in the chemical peeling plus needling group showed any adverse events one month after the procedure. There was a statistically significant difference (P &lt; 0.001, Fisher's exact test) in favour of chemical peeling plus needling (RR 21.00, 95% CI 1.40 to 315.98; <a href="./references#CD011946-fig-0022" title="">Analysis 9.4</a>). </p> </li> </ul> </p> </section> </section> <section id="CD011946-sec-0137"> <h4 class="title">10. Chemical peeling versus needling</h4> <p>One parallel‐group study (<a href="./references#CD011946-bbs2-0014" title="LehetaT , ElTawdyA , Abdel HayR , FaridS . Percutaneous collagen induction versus full‐concentration trichloroacetic acid in the treatment of atrophic acne scars. Dermatologic Surgery2011;37(2):207‐16. [PUBMED: 21269351] LehetaT , TawdyAE , HayRA , FaridS . Percutaneous collagen induction versus full concentration trichloroacetic acid in the treatment of atrophic acne scars. 21st Annual Meeting of the European Tissue Repair Society Amsterdam Netherlands. Conference Start: 20111005 Conference End: 20111007. Wound Repair and Regeneration2011;19(5):A70. [EMBASE: 70532581] ">Leheta 2011</a>) addressed this comparison in which 30 participants with atrophic acne scarring were randomised to receive four sessions (four‐week intervals) of chemical peeling using full‐strength trichloroacetic acid (100% TCA) CROSS or the comparator of four sessions (four‐week intervals) of skin needling using a dermaroller. Three out of 15 participants in the peeling group received one treatment session and were then lost to follow‐up so were not included in the analyses. This study did not assess several of our secondary outcomes. See <a href="./full#CD011946-tbl-0006">summary of findings Table 6</a> for our grading of the evidence. </p> <section id="CD011946-sec-0138"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD011946-list-0041"> <li> <p>Participant‐reported scar improvement (short‐term): One month after the last treatment session, 9/12 participants in the chemical peeling group reported more than a 50% improvement in acne scars, while 10/15 of participants in the needling group reported more than a 50% improvement in acne scars, using a weighted scale and then a quartile grading scale (0 = minimal improvement &lt; 25%; 1 = mild improvement 25% – 50%; 2 = moderate improvement 51% – 75%; 3 = significant improvement &gt; 75%). No statistically significant difference was reported between the interventions (RR 1.13, 95% CI 0.69 to 1.83; very low‐quality evidence; <a href="./references#CD011946-fig-0023" title="">Analysis 10.1</a>). We rated this study at high risk of detection bias. </p> </li> <li> <p>Participants with adverse effects serious or severe enough to have caused their withdrawal from the study: Apart from the three out of 15 participants in the peeling group who received one treatment session and were then lost to follow‐up, all other participants (n = 27) completed the allocated treatments and did not withdraw due to serious adverse events. We rated this study at high risk of attrition bias. </p> </li> </ul> </p> </section> <section id="CD011946-sec-0139"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD011946-list-0042"> <li> <p>Investigator‐assessed scar improvement (short‐term): One month after the last treatment session, 11/12 participants in the chemical peeling group reported more than a 50% improvement in acne scars, while 12/15 participants in the needling group reported more than a 50% improvement in acne scars, using a weighted scale and then a quartile grading scale (0 = minimal improvement &lt; 25%; 1 = mild improvement 25% – 50%; 2 = moderate improvement 51% – 75%; 3 = significant improvement &gt; 75%). No statistically significant difference was reported between the interventions (RR 1.15, 95% CI 0.84 to 1.55; <a href="./references#CD011946-fig-0024" title="">Analysis 10.2</a>). </p> </li> <li> <p>Participant satisfaction: One month after the last treatment, 9/12 participants in the chemical peeling group and 10/15 participants in the needling group were satisfied with the treatment. No statistically significant difference (P = 0.696, Fisher's exact test) was reported between the interventions (RR 1.13, 95% CI 0.69 to 1.83; very low‐quality evidence; <a href="./references#CD011946-fig-0025" title="">Analysis 10.3</a>). </p> </li> <li> <p>Participant‐reported adverse events (short‐term): All participants in both groups (n = 27) experienced pain which showed a higher mean of 5.4 (SD 1.9) in the needling group than the mean of 3.8 (SD 1.6) detected in the peeling group. All participants in both groups (n = 27) also developed transient erythema which lasted for a mean of 15.9 (SD 4.3) days in the chemical peeling group and for a mean of 3 (SD 0.8) days in the needling group. No statistically significant difference was reported between the interventions (RR 1.00, 95% CI 0.87 to 1.15; very low‐quality evidence; <a href="./references#CD011946-fig-0026" title="">Analysis 10.4</a>). </p> </li> <li> <p>Investigator‐assessed adverse events (short‐term): Transient post‐inflammatory hyperpigmentation lasting for one month occurred in 50% of participants (6/12) in the peeling group. None of the participants in the needling group showed any side effect one month after the treatment session (P = 0.003, Fisher's exact test) in favour of needling (RR 16.00, 95% CI 0.99 to 258.36; low‐quality evidence; <a href="./references#CD011946-fig-0027" title="">Analysis 10.5</a>). </p> </li> <li> <p>Post‐procedure down time (days): The overall mean post‐procedure down time was 9.6 (SD 3.1) days in the peeling group (n = 12) and was 3.7 (SD 1) days in the needling group (n = 15). There was a statistically significant difference in favour of needling (MD 5.90, 95% CI 4.07 to 7.73; <a href="./references#CD011946-fig-0028" title="">Analysis 10.6</a>). </p> </li> </ul> </p> </section> </section> <section id="CD011946-sec-0140"> <h4 class="title">11. Needling versus placebo or no treatment</h4> <p>One within‐individual study (<a href="./references#CD011946-bbs2-0001" title="AlamM , HanS , PongprutthipanM , DisphanuratW , KakarR , NodzenskiM , et al. Efficacy of a needling device for the treatment of acne scars: a randomized clinical trial. JAMA Dermatology2014;150(8):844‐9. [PUBMED: 24919799] PongprutthipanM , NodzenskiM , VeledarE , WestD , DubinaM , AlamM , et al. A randomized controlled trial to assess the efficacy of a needling device for the treatment of acne scars. Lasers in Surgery and Medicine2014;46:4. [EMBASE: 71594493] ">Alam 2014</a>) with 20 participants (of which 15 were analysed) compared needling which was randomly performed on one side (study area) for three sessions (two‐week intervals) while on the other side topical anaesthetic cream only was massaged onto the control area through three treatment visits. This study did not assess several of our secondary outcomes. See <a href="./references#CD011946-fig-0029" title="">Analysis 11.1</a> for a precis of our findings. </p> <section id="CD011946-sec-0141"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD011946-list-0043"> <li> <p>Participant‐reported scar improvement (short‐term): Participants (n = 15) reported a 41% mean improvement in acne scars on the treated side. </p> </li> <li> <p>Participants with adverse effects serious or severe enough to have caused their withdrawal from the study: No adverse events were reported during the whole study. </p> </li> </ul> </p> </section> <section id="CD011946-sec-0142"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD011946-list-0044"> <li> <p>Investigator‐assessed scar improvement (short‐term): In the needling group (n = 15), scar scores were significantly lower at six months compared with baseline (mean difference (MD) 3.4, 95% CI 0.2 to 6.5; P = 0.03). In the untreated control group (n = 15), mean scar scores did not vary significantly from baseline at six months (MD 0.4, 95% CI −2.80 to 3.50; P &gt; 0.99) using the Goodman and Baron global scarring grading system (<a href="./references#CD011946-bbs2-0079" title="GoodmanGJ , BaronJA . Postacne scarring: a qualitative global scarring grading system. Dermatologic Surgery2006;32(12):1458‐66. [MEDLINE: 17199653] ">Goodman 2006a</a>). </p> </li> <li> <p>Participant satisfaction: "Most participants" (no number reported) were very satisfied with their procedure. </p> </li> <li> <p>Participant‐reported adverse events (short‐term): The mean pain rating was 1.08 of 10 using a VAS. Mild transient erythema and oedema, which were not classified as adverse events and hence not formally tracked, were routinely reported by participants after treatments. </p> </li> <li> <p>Investigator‐assessed adverse events (short‐term): Mild transient erythema and oedema were seen in all participants (n = 15); these were not classified as adverse events and hence not formally tracked, but were routinely observed by the investigator after treatments. </p> </li> </ul> </p> </section> </section> <section id="CD011946-sec-0143"> <h4 class="title">12. Injectable fillers versus placebo or no treatment</h4> <p>One parallel‐group study (<a href="./references#CD011946-bbs2-0010" title="KarnikJ , BaumannL , BruceS , CallenderV , CohenS , GrimesP , et al. A double‐blind, randomized, multicenter, controlled trial of suspended polymethylmethacrylate microspheres for the correction of atrophic facial acne scars. Journal of the American Academy of Dermatology2014;71(1):77‐83. [EMBASE: 2014426024] ">Karnik 2014</a>) and one within‐individual study (<a href="./references#CD011946-bbs2-0020" title="MunavalliGS , SmithS , MaslowskiJM , WeissRA . Successful treatment of depressed, distensible acne scars using autologous fibroblasts: a multi‐site, prospective, double blind, placebo‐controlled clinical trial. Dermatologic Surgery2013;39(8):1226‐36. [PUBMED: 23566237] ">Munavalli 2013</a>) made these comparisons. See <a href="./full#CD011946-tbl-0007">summary of findings Table 7</a> for our grading of the evidence. </p> <p><a href="./references#CD011946-bbs2-0010" title="KarnikJ , BaumannL , BruceS , CallenderV , CohenS , GrimesP , et al. A double‐blind, randomized, multicenter, controlled trial of suspended polymethylmethacrylate microspheres for the correction of atrophic facial acne scars. Journal of the American Academy of Dermatology2014;71(1):77‐83. [EMBASE: 2014426024] ">Karnik 2014</a> randomised 157 participants with atrophic acne scars. Participants received injections with polymethylmethacrylate (PMMA) suspended in bovine collagen, or the comparator which was saline injections administered in a similar manner. One hundred and forty‐seven participants (97 in the injectable filler group and 50 in the placebo group) received at least one injection and were included in the analyses. This study did not assess several of our secondary outcomes. </p> <section id="CD011946-sec-0144"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD011946-list-0045"> <li> <p>Participant‐reported scar improvement (short‐term): The Subject Global Aesthetic Improvement Scale score demonstrated a greater response with 77% (75/97) of participants in the injectable filler group rated as improved compared with 42% (21/50) in the placebo group (P &lt; 0.05). There was a statistically significant difference in favour of injectable filler (RR 1.84, 95% CI 1.31 to 2.59; moderate‐quality evidence; <a href="./references#CD011946-fig-0030" title="">Analysis 12.1</a>). We rated this study at low risk of detection bias. </p> </li> <li> <p>Participants with adverse effects serious or severe enough to have caused their withdrawal from the study: No serious adverse events were reported during the whole study. </p> </li> </ul> </p> </section> <section id="CD011946-sec-0145"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD011946-list-0046"> <li> <p>Investigator‐assessed scar improvement (short‐term): The Physician Global Aesthetic Improvement Scale score demonstrated a greater response with 84% (82/97) in favour of injectable filler compared with 54% (27/50) in the placebo group (RR 1.57, 95% CI 1.20 to 2.05; <a href="./references#CD011946-fig-0031" title="">Analysis 12.2</a>). </p> </li> <li> <p>Participant satisfaction: Participants showed an elevated level of satisfaction through their scores on the Subject Assessment of Scar Correction. A total of 84% (82/97) of participants in the injectable filler group were satisfied or better, compared with 52% (26/50) in the placebo group (<a href="./references#CD011946-bbs2-0010" title="KarnikJ , BaumannL , BruceS , CallenderV , CohenS , GrimesP , et al. A double‐blind, randomized, multicenter, controlled trial of suspended polymethylmethacrylate microspheres for the correction of atrophic facial acne scars. Journal of the American Academy of Dermatology2014;71(1):77‐83. [EMBASE: 2014426024] ">Karnik 2014</a>). There was a statistically significant difference in favour of injectable filler (RR 1.63, 95% CI 1.23 to 2.15; moderate‐quality evidence; <a href="./references#CD011946-fig-0032" title="">Analysis 12.3</a>). </p> </li> <li> <p>Participant‐reported adverse events (short‐term): A list of reactions were noted with the injectable filler injections in 2.1% (2/97) of participants compared with 2% (1/50) in the placebo group, including erythema, swelling, bruising, pain, itching, lumps or bumps, and discolouration. Almost all reports were mild or moderate in severity with an average duration of from two days for pain and itching up to a maximum of six days for discolouration. No significant difference in the adverse events was noted between the groups (RR 1.03, 95% CI 0.10 to 11.10; low‐quality evidence; <a href="./references#CD011946-fig-0033" title="">Analysis 12.4</a>). </p> </li> <li> <p>Investigator‐assessed adverse events (short‐term): Adverse events were reported in 17/97 participants in the injectable filler group and in 13/50 participants in the control group. The most commonly reported adverse events included injection‐site pain, injection‐site tenderness, and swelling. No significant difference in adverse events was noted between the groups (RR 0.67, 95% CI 0.36 to 1.27; low‐quality evidence; <a href="./references#CD011946-fig-0034" title="">Analysis 12.5</a>). </p> </li> <li> <p>Investigator‐assessed adverse events (long‐term): Hyperpigmentation, hypopigmentation, hypertrophic scarring, and granuloma formation were not reported during the study. No significant difference in adverse events was noted between the groups. </p> </li> </ul> </p> <p><a href="./references#CD011946-bbs2-0020" title="MunavalliGS , SmithS , MaslowskiJM , WeissRA . Successful treatment of depressed, distensible acne scars using autologous fibroblasts: a multi‐site, prospective, double blind, placebo‐controlled clinical trial. Dermatologic Surgery2013;39(8):1226‐36. [PUBMED: 23566237] ">Munavalli 2013</a> was a within‐individual trial in which one cheek was randomised to receive autologous fibroblasts injected into the dermis at a maximum dose of 2 ml per treatment for three treatments (14 days apart), while the other cheek received vehicle control (dye‐free, protein‐free cell culture medium) injected into the dermis at a maximum dose of 2 ml per treatment for three treatments (14 days apart). Seven out of 109 treated participants did not continue the treatment plan: one person declared reasons unrelated to adverse events, and six were lost to follow‐up. No data were available for three participants, so 99 participants completed and were analysed. This study did not assess several of our secondary outcomes. See <a href="./references#CD011946-fig-0035" title="">Analysis 12.6</a> for a precis of our findings. </p> </section> <section id="CD011946-sec-0146"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD011946-list-0047"> <li> <p>Participant‐reported scar improvement (short‐term): Participants reported that 43% (n = 43) of the injectable filler‐treated sides showed a two‐point or greater improvement compared with 18% (n = 18) of the vehicle control‐treated sides using a five‐point scale for the acne scar assessment (‐2 = very dissatisfied; ‐1 = dissatisfied; 0 = somewhat satisfied; +1 = satisfied; +2 = very satisfied), co‐primary endpoint P &lt; 0.001. We judged this study to be at low risk of detection bias. </p> </li> <li> <p>Participants with adverse effects serious or severe enough to have caused their withdrawal from the study: There were no reported adverse effects severe enough to cause participants to withdraw from the study. </p> </li> </ul> </p> </section> <section id="CD011946-sec-0147"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD011946-list-0048"> <li> <p>Investigator‐assessed scar improvement (short‐term): 59% of the injectable filler–treated sides (n = 58) showed one‐point or greater improvement on the used scale compared with 42% of the vehicle control‐treated sides (n = 42), using a five‐point evaluator live acne scar assessment scale (0 = clear; 1 = very mild; 2 = mild; 3 = moderate; 4 = severe), co‐primary endpoint P = 0.01. Based on the three independent photographic reviewers' (IPRs) scores, each of the three reviewers repeatedly classified the cheeks injected with dermal filler as statistically significantly more improved than the cheeks treated with the placebo control, using a five‐point scale (–2 = much worse; –1 = worse; 0 = no change; +1 = improved; +2 = much improved). </p> </li> <li> <p>Investigator‐assessed adverse events (short‐term): The reported adverse events showed comparable incidence between both interventions. The most reported adverse effects were erythema in 11.1% of participants (n = 11) and swelling in 10.1% (n = 10). All treatment area‐related adverse effects showed mild or moderate severity. </p> </li> <li> <p>Investigator‐assessed adverse events (long‐term): No clinically meaningful changes were observed in skin pigmentation or evidence of hypertrophic scarring in either treated area. </p> </li> </ul> </p> </section> </section> <section id="CD011946-sec-0148"> <h4 class="title">13. Injectable fillers versus subcision</h4> <p>One within‐individual study (<a href="./references#CD011946-bbs2-0022" title="SageRJ , LopiccoloMC , LiuA , MahmoudBH , TierneyEP , KoubaDJ . Subcuticular incision versus naturally sourced porcine collagen filler for acne scars: a randomized split‐face comparison. Dermatologic Surgery2011;37(4):426‐31. [PUBMED: 21388487] ">Sage 2011</a>) with 10 participants made this comparison, in which one half of the face was injected with the injectable filler using a natural‐source porcine collagen (NSPC) filler for a single session, while the other half was treated with subcision using an 18‐gauge Nokor subcision needle for a single session. This study did not assess several of our secondary outcomes. See <a href="./references#CD011946-fig-0036" title="">Analysis 13.1</a> for a precis of our findings. </p> <section id="CD011946-sec-0149"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD011946-list-0049"> <li> <p>Participant‐reported scar improvement (short‐term): Six months after treatment, participants (n = 10) reported a higher global improvement rate with subcision (3.9) than NSPC injectable filler (3.5), with no significant difference between either intervention (P = 0.12), using a scale for the overall aesthetic improvement from 1 to 5 "(1 = worse than before treatment; 2 = no change; 3 = minimal disappearance; 4 = moderate disappearance; 5 = complete disappearance)" (<a href="./references#CD011946-bbs2-0022" title="SageRJ , LopiccoloMC , LiuA , MahmoudBH , TierneyEP , KoubaDJ . Subcuticular incision versus naturally sourced porcine collagen filler for acne scars: a randomized split‐face comparison. Dermatologic Surgery2011;37(4):426‐31. [PUBMED: 21388487] ">Sage 2011</a>). We rated this study at high risk of detection bias. </p> </li> <li> <p>Participants with adverse effects serious or severe enough to have caused their withdrawal from the study: All 10 participants completed the six‐month follow‐up visit. </p> </li> </ul> </p> </section> <section id="CD011946-sec-0150"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD011946-list-0050"> <li> <p>Investigator‐assessed scar improvement (short‐term): Physician assessment of the overall aesthetic improvement revealed that NSPC injectable filler has a higher global improvement mean score (3.05; n = 10) than subcision (2.95; n = 10), with no significant difference between the interventions (P = 0.69) using a scale from 1 to 5 (1 = worse than before treatment; 2 = no change; 3 = minimal disappearance; 4 = moderate disappearance; 5 = complete disappearance). </p> </li> <li> <p>Participant‐reported adverse events (short‐term): Participants graded adverse events of pain, erythema, swelling, discolouration, bruising, and lumpiness on a tolerability scale from 0 to 3. Participants rated bruising from subcision (mean severity 2.2) as significantly worse than from NSPC injection (mean severity 0.7; P = 0.007). Participants reported that lumpiness from subcision (mean 3.4) was significantly better than from NSPC injectable filler (mean 2.9; P = 0.15) using a scale from 1 to 5 (1 = worse than before treatment; 2 = no change; 3 = minimal disappearance; 4 = moderate disappearance; 5 = complete disappearance). Discolouration was equally reported for both treatments (mean 3.4, P &gt; 0.99). </p> </li> <li> <p>Investigator‐assessed adverse events (short‐term): A higher mean severity of bruising was reported with subcision (1.7) than with NSPC injection (1.1) with no significant difference between the interventions (P = 0.09) using a scale from 0 to 3 (0 = no symptoms; 1 = mild symptoms; 2 = moderate symptoms; 3 = severe symptoms). Severe adverse events were not stated for either treatment. </p> </li> </ul> </p> </section> </section> <section id="CD011946-sec-0151"> <h4 class="title">14. Combined microdermabrasion plus ALA‐PDT versus combined microdermabrasion plus placebo‐PDT </h4> <p>One within‐individual study (<a href="./references#CD011946-bbs2-0017" title="LinknerRV , Jim OnS , HaddicanM , SingerG , Shim‐ChangH . Evaluating the efficacy of photodynamic therapy with 20% aminolevulinic acid and microdermabrasion as a combination treatment regimen for acne scarring: A split‐face, randomized, double‐blind pilot study. Journal of Clinical &amp; Aesthetic Dermatology2014;7(5):32‐5. [PUBMED: 24847407] ">Linkner 2014</a>) with five participants made this comparison in which one cheek was randomised to receive a solution of 20% δ‐aminolevulinic acid (ALA) while the other cheek received a vehicle solution alone applied topically to the face. All the lesions were illuminated with 417 nm blue light (Blu‐U Blue Light Photodynamic Therapy Illuminator) after full‐face treatment with microdermabrasion for five sessions (four‐week interval). Six participants were enrolled, of whom five completed the study. This study did not assess any of our primary outcomes or several of our secondary outcomes. See <a href="./references#CD011946-fig-0037" title="">Analysis 14.1</a> for a precis of our findings. </p> <section id="CD011946-sec-0152"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD011946-list-0051"> <li> <p>Investigator‐assessed scar improvement (short‐term): At the end of the study, 80% of the participants (4/5) showed more improvement in scarring on the combined microdermabrasion plus ALA‐PDT split‐face versus the combined microdermabrasion plus vehicle‐PDT split‐face using Physician’s Global Assessment of Acne Scarring scale (P value not assessed). </p> </li> <li> <p>Participant satisfaction: At the end of the study, 80% of participants (4/5) appreciated an improvement in the acne scarring. </p> </li> <li> <p>Participant‐reported adverse events (short‐term): <a href="./references#CD011946-bbs2-0017" title="LinknerRV , Jim OnS , HaddicanM , SingerG , Shim‐ChangH . Evaluating the efficacy of photodynamic therapy with 20% aminolevulinic acid and microdermabrasion as a combination treatment regimen for acne scarring: A split‐face, randomized, double‐blind pilot study. Journal of Clinical &amp; Aesthetic Dermatology2014;7(5):32‐5. [PUBMED: 24847407] ">Linkner 2014</a> mentioned that the study would assess adverse effects, including pain, phototoxic parameters and pigmentary changes using a 10‐point scale (0 = none; 1 – 3 = mild; 4 – 6 = moderate; 7 – 9 = severe) during and immediately after each treatment, but no side effects were reported. </p> </li> <li> <p>Investigator‐assessed adverse events (short‐term): <a href="./references#CD011946-bbs2-0017" title="LinknerRV , Jim OnS , HaddicanM , SingerG , Shim‐ChangH . Evaluating the efficacy of photodynamic therapy with 20% aminolevulinic acid and microdermabrasion as a combination treatment regimen for acne scarring: A split‐face, randomized, double‐blind pilot study. Journal of Clinical &amp; Aesthetic Dermatology2014;7(5):32‐5. [PUBMED: 24847407] ">Linkner 2014</a> mentioned that the study would assess adverse effects, including pain, phototoxic parameters and pigmentary changes using a 10‐point scale (0 = none; 1 – 3 = mild; 4 – 6 = moderate; 7 – 9 = severe) during and immediately after each treatment, but no side effects were reported. </p> </li> </ul> </p> </section> <section id="CD011946-sec-0153"> <h5 class="title">Five split‐face studies</h5> <p>In this section there are five more split‐face studies (<a href="./references#CD011946-bbs2-0005" title="ChoSB , LeeSJ , ChoS , OhSH , ChungWS , KangJM , et al. Non‐ablative 1550‐nm erbium‐glass and ablative 10 600‐nm carbon dioxide fractional lasers for acne scars: a randomized split‐face study with blinded response evaluation. Journal of the European Academy of Dermatology and Venereology2010;24(8):921‐5. [EMBASE: 2010378178] ">Cho 2010</a>; <a href="./references#CD011946-bbs2-0012" title="LeeDH , ChoiYS , MinSU , YoonMY , SuhDH . Comparison of a 585‐nm pulsed dye laser and a 1064‐nm Nd:YAG laser for the treatment of acne scars: a randomized split‐face clinical study. Journal of the American Academy of Dermatology2009;60(5):801‐7. [PUBMED: 19217691] ">Lee 2009</a>; <a href="./references#CD011946-bbs2-0018" title="ManuskiattiW , IamphonratT , WanitphakdeedechaR , EimpunthS . Comparison of fractional Er:YAG and CO2 lasers in resurfacing of atrophic acne scars in Asians. 31st Annual Conference of the American Society for Laser Medicine and Surgery, ASLMS 2011 Grapevine, TX United States. Conference Start: 20110330 Conference End: 20110403. Lasers in Surgery and Medicine2011;43:938‐939. [EMBASE: 70640237] ManuskiattiW , IamphonratT , WanitphakdeedechaR , EimpunthS . Comparison of fractional erbium‐doped yttrium aluminum garnet and carbon dioxide lasers in resurfacing of atrophic acne scars in Asians. Dermatologic Surgery2013;39(1 Pt 1):111‐20. [EMBASE: 23205717] ">Manuskiatti 2013</a>; <a href="./references#CD011946-bbs2-0019" title="MinSU , ChoiYS , LeeDH , YoonMY , SuhDH . Comparison of a long‐pulse Nd:YAG laser and a combined 585/1,064‐nm laser for the treatment of acne scars: a randomized split‐face clinical study. Dermatologic Surgery2009;35(11):1720‐7. [PUBMED: 19250299] ">Min 2009</a>; <a href="./references#CD011946-bbs2-0023" title="TanziEL , AlsterTS . Comparison of a 1450‐nm diode laser and a 1320‐nm Nd:YAG laser in the treatment of atrophic facial scars: a prospective clinical and histologic study. Dermatologic Surgery2004;30(2 Pt 1):152‐7. [PUBMED: 14756642] ">Tanzi 2004</a>) comparing two interventions for acne scarring but which could not be incorporated in our comparisons, so are described narratively. </p> <p><a href="./references#CD011946-bbs2-0018" title="ManuskiattiW , IamphonratT , WanitphakdeedechaR , EimpunthS . Comparison of fractional Er:YAG and CO2 lasers in resurfacing of atrophic acne scars in Asians. 31st Annual Conference of the American Society for Laser Medicine and Surgery, ASLMS 2011 Grapevine, TX United States. Conference Start: 20110330 Conference End: 20110403. Lasers in Surgery and Medicine2011;43:938‐939. [EMBASE: 70640237] ManuskiattiW , IamphonratT , WanitphakdeedechaR , EimpunthS . Comparison of fractional erbium‐doped yttrium aluminum garnet and carbon dioxide lasers in resurfacing of atrophic acne scars in Asians. Dermatologic Surgery2013;39(1 Pt 1):111‐20. [EMBASE: 23205717] ">Manuskiatti 2013</a> compared fractional ablative Er:YAG laser to fractional ablative CO₂ laser. Both comparators are in the same category as fractional ablative laser. <a href="./references#CD011946-bbs2-0018" title="ManuskiattiW , IamphonratT , WanitphakdeedechaR , EimpunthS . Comparison of fractional Er:YAG and CO2 lasers in resurfacing of atrophic acne scars in Asians. 31st Annual Conference of the American Society for Laser Medicine and Surgery, ASLMS 2011 Grapevine, TX United States. Conference Start: 20110330 Conference End: 20110403. Lasers in Surgery and Medicine2011;43:938‐939. [EMBASE: 70640237] ManuskiattiW , IamphonratT , WanitphakdeedechaR , EimpunthS . Comparison of fractional erbium‐doped yttrium aluminum garnet and carbon dioxide lasers in resurfacing of atrophic acne scars in Asians. Dermatologic Surgery2013;39(1 Pt 1):111‐20. [EMBASE: 23205717] ">Manuskiatti 2013</a> was a within‐individual trial (24 enrolled and 20 completed the study), in which one facial half received fractional Er:YAG laser treatment and the other facial half received fractional CO₂ laser treatment, each group receiving two sessions at two‐month intervals. Participants were followed up for six months after the final session. This study did not assess several of our secondary outcomes. </p> </section> <section id="CD011946-sec-0154"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD011946-list-0052"> <li> <p>Participant‐reported scar improvement (short‐term; six months): Participants graded their global improvement of acne scars on a quartile scale (slightly better = &lt; 25%; fair = 25% ‐ 50%; good = 51% ‐ 75%; excellent = &gt; 76%). Accordingly, 70% (14/20) and 60% (12/20) of Er:YAG and CO₂ laser sites respectively were rated by participants as showing more than a 50% improvement, with no statistically significant difference between interventions (P = 0.47). We judged this study to be at unclear risk of detection bias. </p> </li> <li> <p>Participants with adverse effects serious or severe enough to have caused their withdrawal from the study: None of the three of 24 enrolled participants who were withdrawn from the study due to scheduling conflicts was affected by serious adverse events. However, it remains questionable why the fourth participant was withdrawn, as he could not be contacted during follow‐up. </p> </li> </ul> </p> </section> <section id="CD011946-sec-0155"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD011946-list-0053"> <li> <p>Investigator‐assessed scar improvement (short‐term; six months): A quartile grading scale (0 = &lt; 25%; 1 = 25% ‐ 50%; 2 = 51% ‐ 75%; 3 = &gt; 75% improvement) was used by a blinded dermatologist to evaluate the global acne scars improvement. Six months after treatment, 55% (11/20) and 65% (13/20) of Er:YAG and CO₂ laser sites respectively were rated as having more than a 50% improvement, with no statistically significant difference between the interventions (P = 0.87). </p> </li> <li> <p>Participant‐reported adverse events (short‐term: less than four weeks): Pain was largely well tolerated by all participants, but they reported a significantly higher pain score on the CO₂ laser than on the Er:YAG laser site (P = 0.001). Average pain scores described by the participants were 3.2 (SD 1.4) and 5.8 (SD 2.0) on the site treated with Er:YAG and CO₂ laser respectively, using a 10‐point pain scale (0 = no pain to 10 = severe pain). Pain lasted for an average of three hours. </p> </li> <li> <p>Investigator‐assessed adverse events: Adverse effects included moderate to marked erythema, mild to moderate oedema on both treated sites, followed by superficial crusting. Post‐inflammatory hyperpigmentation occurred in 7/20 and 10/20 of participants at the Er:YAG and CO₂ laser sites respectively (P = 0.52). </p> </li> <li> <p>Post‐procedure down time: Erythema and oedema persisted for 24 hours on both treated sites. Superficial crusting subsequently occurred and completely sloughed off in an average of 3.6 and 3.3 days with no statistically significant difference on both Er:YAG and CO₂ laser‐treated sides respectively (P = 0.80). </p> </li> </ul> </p> <p><a href="./references#CD011946-bbs2-0005" title="ChoSB , LeeSJ , ChoS , OhSH , ChungWS , KangJM , et al. Non‐ablative 1550‐nm erbium‐glass and ablative 10 600‐nm carbon dioxide fractional lasers for acne scars: a randomized split‐face study with blinded response evaluation. Journal of the European Academy of Dermatology and Venereology2010;24(8):921‐5. [EMBASE: 2010378178] ">Cho 2010</a> was a within‐individual trial of eight participants in which one side of the face was randomised to receive one session of non‐ablative 1550‐nm erbium‐doped fractional photothermolysis system (FPS) and the other side of the face was treated with 10,600‐nm CO₂ fractional laser system (CO₂ FS). This study did not assess our first primary outcome or several of our secondary outcomes. </p> </section> <section id="CD011946-sec-0156"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD011946-list-0054"> <li> <p>Participants with adverse effects serious or severe enough to have caused their withdrawal from the study: The eight treated participants completed the study follow‐up period. </p> </li> </ul> </p> </section> <section id="CD011946-sec-0157"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD011946-list-0055"> <li> <p>Investigator‐assessed scar improvement (short‐term; three months): A quartile grading scale was used by blinded investigators to assess global improvement of acne scars as follows: grade 1, &lt; 25% = minimal to no improvement; grade 2, 26% to 50% = moderate improvement; grade 3, 51% to 75% = marked improvement; grade 4, &gt; 75% = near‐total improvement. Three months after treatment, the mean grade of improvement was 2.0 ± 0.5 for FPS and 2.5 ± 0.8 for CO₂ FS. One of eight participant showed more than a 50% improvement after a single session of FPS, versus three of eight participant after a single session of CO₂ FS with no statistically significant difference (P = 0.158). </p> </li> <li> <p>Participant satisfaction: Participants evaluated their overall levels of satisfaction with treatment results using the following scale: very satisfied, satisfied, slightly satisfied and unsatisfied) with separate evaluations of each side of the face. The overall satisfaction levels were not significantly different (P = 0.105). Two of eight participants were satisfied and none of eight very satisfied after FPS treatment, versus four of eight satisfied and two of eight very satisfied after CO₂ FS treatment. </p> </li> <li> <p>Participant‐reported adverse events (short‐term: less than four weeks): Side effects included pain during the laser treatment, crusting or scaling after treatment, redness after therapy, fluid retention, hyperpigmentation after therapy, bleeding and oozing from the treated sites, and worsening of inflammatory acne lesions (<a href="./references#CD011946-bbs2-0005" title="ChoSB , LeeSJ , ChoS , OhSH , ChungWS , KangJM , et al. Non‐ablative 1550‐nm erbium‐glass and ablative 10 600‐nm carbon dioxide fractional lasers for acne scars: a randomized split‐face study with blinded response evaluation. Journal of the European Academy of Dermatology and Venereology2010;24(8):921‐5. [EMBASE: 2010378178] ">Cho 2010</a>). Relative pain scores were evaluated using 10‐cm VAS, with 0 being ‘no pain’ and 10 being ‘extremely painful’. The mean VAS pain score was significantly lower (3.9 ± 2.0) with the FPS than with the CO₂ FS treatment (7.0 ± 2.0; P = 0.012). </p> </li> <li> <p>Post‐procedure down time: On the area of the face treated by fractional non‐ablative laser, the mean period of crusting and scaling after treatment was 2.3 ± 2.9 days and that of erythema after treatment was 7.5 ± 5.7 days. On the area of the face treated by CO₂ FS, the mean duration of crusting and scaling after treatment was 7.4 ± 2.4 days and that of erythema after treatment was 11.5 ± 5.2 days. This variation in the time period of crusting or scaling after treatment was statistically significant (P = 0.006), but the variation in the length of erythema after treatment (P = 0.145) was not (<a href="./references#CD011946-bbs2-0005" title="ChoSB , LeeSJ , ChoS , OhSH , ChungWS , KangJM , et al. Non‐ablative 1550‐nm erbium‐glass and ablative 10 600‐nm carbon dioxide fractional lasers for acne scars: a randomized split‐face study with blinded response evaluation. Journal of the European Academy of Dermatology and Venereology2010;24(8):921‐5. [EMBASE: 2010378178] ">Cho 2010</a>). </p> </li> </ul> </p> <p><a href="./references#CD011946-bbs2-0012" title="LeeDH , ChoiYS , MinSU , YoonMY , SuhDH . Comparison of a 585‐nm pulsed dye laser and a 1064‐nm Nd:YAG laser for the treatment of acne scars: a randomized split‐face clinical study. Journal of the American Academy of Dermatology2009;60(5):801‐7. [PUBMED: 19217691] ">Lee 2009</a> was a within‐individual trial of 18 participants in which one facial half received non‐fractional non‐ablative pulsed dye laser (PDL) treatment and the other facial half received 1064‐nm long pulsed neodymium;yttrium‐aluminium‐garnet (NdYAG) laser treatment, four sessions at two‐week intervals. Participants were followed up for eight weeks after the final session (a total 14 weeks). This study did not assess our first primary outcome or several of our secondary outcomes. </p> </section> <section id="CD011946-sec-0158"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD011946-list-0056"> <li> <p>Participants with adverse effects serious or severe enough to have caused their withdrawal from the study: All participants completed the allocated treatments and were included in the analyses. </p> </li> </ul> </p> </section> <section id="CD011946-sec-0159"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD011946-list-0057"> <li> <p>Investigator‐assessed scar improvement (short‐term; eight weeks): The progress of acne scars was measured by evaluating the degrees of improvement according to the sort of scar and the ECCA scores (<a href="./references#CD011946-bbs2-0012" title="LeeDH , ChoiYS , MinSU , YoonMY , SuhDH . Comparison of a 585‐nm pulsed dye laser and a 1064‐nm Nd:YAG laser for the treatment of acne scars: a randomized split‐face clinical study. Journal of the American Academy of Dermatology2009;60(5):801‐7. [PUBMED: 19217691] ">Lee 2009</a>). ECCA scores significantly reduced following PDL (18.3% improvement) and Nd:YAG (18.7% improvement) treatments (P = 0.005 and P = 0.011 respectively), but these improvements were not statistically significantly different between both interventions (P value not mentioned). </p> </li> <li> <p>Participant satisfaction: Participant subjective satisfaction scores were established at every appointment by use of a 0 (neutral) to 10 (highly satisfied) scale (<a href="./references#CD011946-bbs2-0012" title="LeeDH , ChoiYS , MinSU , YoonMY , SuhDH . Comparison of a 585‐nm pulsed dye laser and a 1064‐nm Nd:YAG laser for the treatment of acne scars: a randomized split‐face clinical study. Journal of the American Academy of Dermatology2009;60(5):801‐7. [PUBMED: 19217691] ">Lee 2009</a>). Satisfaction scores increased throughout the therapy sessions with no statistically significant difference between the two groups (P value not mentioned). </p> </li> <li> <p>Participant‐reported adverse events (less than four weeks): Reported adverse events included transient pain, erythema, and oedema in the treated areas. </p> </li> </ul> </p> <p><a href="./references#CD011946-bbs2-0023" title="TanziEL , AlsterTS . Comparison of a 1450‐nm diode laser and a 1320‐nm Nd:YAG laser in the treatment of atrophic facial scars: a prospective clinical and histologic study. Dermatologic Surgery2004;30(2 Pt 1):152‐7. [PUBMED: 14756642] ">Tanzi 2004</a> was a within‐individual trial of 20 participants in which one facial half received non‐fractional non‐ablative 1320‐nm long pulsed NdYAG laser treatment and the other facial half received non‐fractional non‐ablative 1450‐nm diode laser treatment, each arm receiving three sessions at four‐week intervals. Participants were followed up for 12 months after the final session. This study did not assess any of our primary outcomes or several of our secondary outcomes. </p> </section> <section id="CD011946-sec-0160"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD011946-list-0058"> <li> <p>Investigator‐assessed scar improvement (long‐term; 12 months): The degree of improvement in the quality of skin texture was evaluated on clinical photographs using a quartile grading scale (1: less than 25% = minimal to no improvement; 2: 25% ‐ 50% = moderate improvement; 3: 51% ‐ 75% = marked improvement; 4: &gt; 75% = near total improvement). Higher average clinical scores were seen on the 1450‐nm diode laser‐treated facial halves at each visit in comparison to NdYAG laser‐treated half (at six months: 1.81 versus 1.67, and at 12 months: 1.34 versus 1.13 respectively) (P value not reported). </p> </li> <li> <p>Participant satisfaction: The participants recorded how satisfied they were on a scale of one (lowest) to 10 (highest) for each treated half (<a href="./references#CD011946-bbs2-0023" title="TanziEL , AlsterTS . Comparison of a 1450‐nm diode laser and a 1320‐nm Nd:YAG laser in the treatment of atrophic facial scars: a prospective clinical and histologic study. Dermatologic Surgery2004;30(2 Pt 1):152‐7. [PUBMED: 14756642] ">Tanzi 2004</a>). The mean satisfaction score was higher in the 1450‐nm diode than the Nd:YAG arm (5.7 versus 4.6 respectively) (P value not reported). </p> </li> <li> <p>Participant‐reported adverse events (short‐term; less than four weeks): Discomfort during treatment was reported by participants who were less satisfied with the 1450‐nm diode laser treatment. </p> </li> <li> <p>Investigator‐assessed adverse events: Post‐treatment erythema was seen in all participants studied, and post‐inflammatory hyperpigmentation was observed in 4/20 versus 2/20 participants treated with 1450‐nm diode and 1320‐nm Nd:YAG lasers respectively (P value not reported). </p> </li> <li> <p>Post‐procedure down time: Erythema lasted for 24 hours versus six hours after treatment with 1450‐nm diode and 1320‐nm Nd:YAG lasers respectively (P value not reported). </p> </li> </ul> </p> <p><a href="./references#CD011946-bbs2-0019" title="MinSU , ChoiYS , LeeDH , YoonMY , SuhDH . Comparison of a long‐pulse Nd:YAG laser and a combined 585/1,064‐nm laser for the treatment of acne scars: a randomized split‐face clinical study. Dermatologic Surgery2009;35(11):1720‐7. [PUBMED: 19250299] ">Min 2009</a> was a within‐individual trial of 19 participants in which one facial half received long pulsed Nd:YAG laser treatment and the other facial half received a combined 585/1064‐nm laser treatment, each half receiving four sessions at two‐week intervals. Participants were followed up for eight weeks after the final session (total 14 weeks). This study did not assess our first primary outcome or several of our secondary outcomes. </p> </section> <section id="CD011946-sec-0161"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD011946-list-0059"> <li> <p>Participants with adverse effects serious or severe enough to have caused their withdrawal from the study: All participants completed the allocated treatments and were included in the analyses. </p> </li> </ul> </p> </section> <section id="CD011946-sec-0162"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD011946-list-0060"> <li> <p>Investigator‐assessed scar improvement (short‐term; eight weeks): Acne scar improvements were quantified by assessing the degrees of improvement according to scar types and the ECCA scores. ECCA scores significantly reduced following the Nd:YAG (27% improvement) and the combined 585/1064‐nm (32.3% improvement) treatments (P = 0.001 for both). These improvements were not statistically significantly different between the interventions (P value not reported). </p> </li> <li> <p>Participant satisfaction: Participant subjective satisfaction scores were determined at each visit by use of a 0 (neutral) to 10 (highly satisfied) scale. For Nd:YAGlasertreatment, participant satisfaction scores increased from 0 (baseline) to 4.9 at eight weeks after final treatment. For combined 585/1064‐nm laser treatment, participant satisfaction scores increased from 0 (baseline) to 5.3 at eight weeks after final treatment. There was no statistically significant difference between the two treatment methods (P value not reported). </p> </li> <li> <p>Participant‐reported adverse events (less than four weeks): Adverse events were only transient pain, erythema, and oedema in both treated areas. </p> </li> </ul> </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD011946-sec-0163" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD011946-sec-0163"></div> <section id="CD011946-sec-0164"> <h3 class="title" id="CD011946-sec-0164">Summary of main results</h3> <p>Our searches identified 216 references for potential inclusion, of which 24 trials met our inclusion criteria, with a total of 789 participants. We included trials from each of our eight intervention groups, and in all cases the effects of an intervention were assessed by a single RCT, so meta‐analyses were not possible. </p> <p>Only 14 trials included our primary efficacy outcome measure 'Participant‐reported scar improvement'. Twenty trials included our primary outcome 'Participants with adverse effects serious or severe enough to have caused their withdrawal from the study'. Eight trials included our secondary outcome 'Participant satisfaction'; however, none of our included studies looked at quality of life. All the studies except one included some information about our secondary outcomes 'Participant‐reported short‐term adverse events' and 'Investigator‐assessed short‐term adverse events'. Of the 24 included trials, 21 included only atrophic acne scars, two studies (<a href="./references#CD011946-bbs2-0003" title="BernsteinEF , FerreiraM , AndersonD . A pilot investigation to subjectively measure treatment effect and side‐effect profile of non‐ablative skin remodeling using a 532 nm, 2 ms pulse‐duration laser. Journal of Cosmetic &amp; Laser Therapy2001;3(3):137‐41. [EMBASE: 2002362049] ">Bernstein 2001</a>; <a href="./references#CD011946-bbs2-0013" title="LeeJW , KimBJ , KimMN , MunSK . The efficacy of autologous platelet rich plasma combined with ablative carbon dioxide fractional resurfacing for acne scars: a simultaneous split‐face trial. Dermatologic Surgery2011;37(7):931‐8. [PUBMED: 21635618] ">Lee 2011</a>) did not specify the types of acne scars, and only one study (<a href="./references#CD011946-bbs2-0001" title="AlamM , HanS , PongprutthipanM , DisphanuratW , KakarR , NodzenskiM , et al. Efficacy of a needling device for the treatment of acne scars: a randomized clinical trial. JAMA Dermatology2014;150(8):844‐9. [PUBMED: 24919799] PongprutthipanM , NodzenskiM , VeledarE , WestD , DubinaM , AlamM , et al. A randomized controlled trial to assess the efficacy of a needling device for the treatment of acne scars. Lasers in Surgery and Medicine2014;46:4. [EMBASE: 71594493] ">Alam 2014</a>) included both atrophic and hypertrophic acne scars. We did not find any trials that included information about acne scars on the back. </p> <p>Evidence from one study of 64 people showed that fractional laser given for four monthly sessions improves acne scars more than non‐fractional non‐ablative laser at week 24. For the secondary outcome, 'Investigator‐assessed adverse effects' post‐inflammatory hyperpigmentation lasting for two to three weeks was reported by 6/32 and 10/32 participants treated with fractional laser and non‐fractional non‐ablative laser respectively. </p> <p>One study in 40 people showed that both fractional laser and fractional radiofrequency given for three monthly sessions improves acne scars by week eight. </p> <p>A study in 26 people showed that both fractional laser and chemical peeling combined with skin needling given for six monthly sessions improves acne scars by week 48. For the secondary outcomes, all participants in both groups reported pain, transient oedema and erythema for less than four weeks. </p> <p>A study in 58 people comparing chemical peeling to placebo showed that chemical peeling given for 24 weeks had no severe adverse events that caused participants to withdraw from the study; however, seven participants withdrew because they were unable to tolerate the peeling agent. </p> <p>One study in 20 people showed that both chemical peeling given for one session and chemical peeling combined with skin needling given for four sessions improve acne scars by week 32. For the secondary outcomes, all participants in both groups reported transient erythema which lasted for four weeks in the chemical peeling group and only for two to three days in the chemical peeling plus needling group, with no significant difference related to short‐term adverse events. </p> <p>One study in 27 people showed that both chemical peeling and skin needling given for four monthly sessions improves acne scars by week four. For the secondary outcomes, short‐term adverse events showed no significant difference between the interventions. For our outcome ‘Participant satisfaction’ participants were satisfied with both chemical peeling and skin needling. </p> <p>A study in 147 people showed that injectable filler given for one session improves atrophic acne scars by week 24. The Global Aesthetic Improvement Scale reported a significant difference in favour of injectable filler with 77% of participants responding as being improved compared to 42% for the placebo group. For the secondary outcomes, no significant difference in the adverse events was noted between the groups. For our outcome ‘Participant satisfaction’ participants were more satisfied with injectable filler. </p> <p>We do not have sufficient evidence to determine the effects or the safety of other included interventions such as subcision, combined fractional laser with PRP, combined fractional laser with punch elevation, and combined microdermabrasion plus ALA‐PDT in acne scars. </p> </section> <section id="CD011946-sec-0165"> <h3 class="title" id="CD011946-sec-0165">Overall completeness and applicability of evidence</h3> <p>All the included studies found for this review lack some information about trial methodology and detailed data for some of the reported outcomes. Several did not compare the outcome data between the two treatment groups, so that the clinical significance of the results was unclear. </p> </section> <section id="CD011946-sec-0166"> <h3 class="title" id="CD011946-sec-0166">Quality of the evidence</h3> <p>We judged many studies included in this review as having an unclear or high risk of bias for allocation concealment and blinding of participants. We therefore recommend caution in the interpretation of the results and in the extrapolation of the effects of the interventions. Most of the included studies were underpowered for their primary outcomes as well as for uncommon adverse events. </p> <p>Although acne scarring is a common condition, the total number of all participants enrolled was only 789 people in 24 trials. The evidence for our main outcomes ‘Participant‐reported scar improvement', 'Participant‐reported adverse events' and 'Participantnt satisfaction’ is drawn from studies at high risk of bias due to lack of blinding of participants. There were 14 comparisons of seven interventions and four combinations of interventions, whether compared to each other, to placebo or to no treatment. This clearly means that each intervention was not compared in enough trials and among enough individuals. Collectively, these factors point to a low quality of evidence. We downgraded the quality of evidence to 'very low' for the main outcomes, due mainly to unknown consistency or imprecision because the OIS was not met, low occurrence of events, or 95% CIs around the estimate of effect which included both no effect and appreciable benefit or harm. </p> <p>There were not enough studies to conduct the planned subgroup analyses. In future updates, we plan to conduct subgroup analyses classifying whole trials by interaction tests and to carry out sensitivity analysis to explore the effects of fixed‐effect or random‐effects analyses for outcomes with statistical heterogeneity between studies. </p> </section> <section id="CD011946-sec-0167"> <h3 class="title" id="CD011946-sec-0167">Potential biases in the review process</h3> <p>We have taken care to try and eliminate bias; however, it is always possible, although unlikely, that one or more trials have been missed, in journals not covered by the databases that we searched, or in a journal's correspondence section. With so few data in the review at present, any missing trials may have a greater potential to change the review conclusions. The fact that nine studies have not yet been incorporated may be a source of potential bias. </p> </section> <section id="CD011946-sec-0168"> <h3 class="title" id="CD011946-sec-0168">Agreements and disagreements with other studies or reviews</h3> <p>There have been no systematic reviews of acne scarring treatment apart from <a href="./references#CD011946-bbs2-0110" title="JordanR , CumminsCCL , BurlsA , SeukeranDDC . Laser resurfacing for facial acne scars. Cochrane Database of Systematic Reviews2000, Issue 3. [DOI: 10.1002/14651858.CD001866] ">Jordan 2000</a>, who conducted a systematic review to assess the effects of laser resurfacing for treating facial acne scars, but which found no RCTs where laser intervention was compared to either placebo or to a different type of laser. Most of the studies found were poor‐quality case series with small numbers of participants. <a href="./references#CD011946-bbs2-0110" title="JordanR , CumminsCCL , BurlsA , SeukeranDDC . Laser resurfacing for facial acne scars. Cochrane Database of Systematic Reviews2000, Issue 3. [DOI: 10.1002/14651858.CD001866] ">Jordan 2000</a> could not assess the effectiveness of lasers for treating atrophic acne scars. This conclusion is in agreement with our review, which failed to find sufficient evidence from RCTs to support laser therapy for acne scars. </p> <p><a href="./references#CD011946-bbs2-0107" title="Sánchez VieraM . Management of acne scars: fulfilling our duty of care for patients. British Journal of Dermatology2015;172(Suppl 1):47‐51. [PUBMED: 25597636] ">Sánchez Viera 2015</a> performed a comprehensive review focusing on procedural treatments for acne scars. This review mentioned that there have been a number of procedures for improving acne scars and the choice for each participant is determined mainly by the type of scars present. A combination of procedures is usually required to achieve the best result. The authors stated that fractional laser resurfacing has become a powerful tool in the treatment of acne scars, especially when combined with other treatment methods such as subcision, the chemical reconstruction of skin scars (CROSS) chemical peeling technique with TCA, punch excision or fillers. This conclusion is in disagreement with our review, which failed to find sufficient evidence from RCTs to support fractional laser therapy either alone or combined with punch elevation or PRP for acne scars. </p> <p><a href="./references#CD011946-bbs2-0105" title="SobankoJF , AlsterTS . Management of acne scarring, part I: a comparative review of laser surgical approaches. American Journal of Clinical Dermatology2012;13(5):319‐30. [PUBMED: 22612738] ">Sobanko 2012</a> produced a comparative review of laser surgical approaches in the management of acne scarring. They stated that atrophic scars have been best treated with ablative and fractionally ablative and non‐ablative laser systems, depending on individual patient circumstances. These lasers have a role in remodeling the scar contour through neocollagenesis. Non‐ablative laser systems, being less clinically efficacious, may be used in patients asking for a treatment with minimal to no postoperative down time. In recent years, fractional laser scar revision has spanned ablative and non‐ablative laser technologies. It is difficult to provide strong recommendations from our review because the RCT data on fractional laser for acne scars are often limited in terms of number of studies, study size and quality. </p> <p><a href="./references#CD011946-bbs2-0095" title="LevyLL , ZeichnerJA . Management of acne scarring, part II: a comparative review of non‐laser‐based, minimally invasive approaches. American Journal of Clinical Dermatology2012;13(5):331‐40. [MEDLINE: 22849351] ">Levy 2012</a> presented a comparative review focusing on the various non‐laser‐based minimally invasive approaches for the treatment of acne scarring. They mentioned superficial chemical peels as a powerful tool in treating atrophic scars with few adverse effects. The efficacy of various treatment methods such as dermabrasion, tissue augmentation, and punch excision has been highlighted focusing on choosing the correct modalities for individual scar types. This conclusion is in agreement with our review, which found moderate‐quality RCT evidence to support injectable fillers in treating atrophic acne scars. </p> <p><a href="./references#CD011946-bbs2-0099" title="OngMW , BashirSJ . Fractional laser resurfacing for acne scars: a review. British Journal of Dermatology2012;166(6):1160‐9. [PUBMED: 22296284] ">Ong 2012</a> conducted a review to investigate the effectiveness of ablative and non‐ablative fractional photothermolysis (FP) lasers for treating facial acne scars, and stated that FP technology seemed to improve acne scarring. They concluded that FP technology might be helpful in daily practice for the treatment of acne scars, but found significant limitations comparing published articles on the subject, and no meta‐analyses were possible. Like our review, <a href="./references#CD011946-bbs2-0099" title="OngMW , BashirSJ . Fractional laser resurfacing for acne scars: a review. British Journal of Dermatology2012;166(6):1160‐9. [PUBMED: 22296284] ">Ong 2012</a> was faced by the variability in study parameters, the different subjective improvement rating scales used across the studies, the short‐term reporting of acne scar improvement that could be unreliable, and by the lack of RCTs. <a href="./references#CD011946-bbs2-0099" title="OngMW , BashirSJ . Fractional laser resurfacing for acne scars: a review. British Journal of Dermatology2012;166(6):1160‐9. [PUBMED: 22296284] ">Ong 2012</a> just described an improvement range of 26% to 83% and of 26% to 50% following ablative and non‐ablative FP respectively. <a href="./references#CD011946-bbs2-0099" title="OngMW , BashirSJ . Fractional laser resurfacing for acne scars: a review. British Journal of Dermatology2012;166(6):1160‐9. [PUBMED: 22296284] ">Ong 2012</a> also reported the adverse events associated with FP technology such as it being an uncomfortable procedure and with long‐lasting erythema. Also post‐inflammatory hyperpigmentation is at higher incidence in ablative FP laser compared to non‐ablative FP lasers. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD011946-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/media/CDSR/CD011946/urn:x-wiley:14651858:media:CD011946:CD011946-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/media/CDSR/CD011946/image_t/tCD011946-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD011946-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011946.pub2/media/CDSR/CD011946/image_n/nCD011946-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/full#CD011946-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/media/CDSR/CD011946/image_n/nCD011946-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011946-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/media/CDSR/CD011946/urn:x-wiley:14651858:media:CD011946:CD011946-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/media/CDSR/CD011946/image_t/tCD011946-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD011946-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011946.pub2/media/CDSR/CD011946/image_n/nCD011946-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/full#CD011946-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/media/CDSR/CD011946/image_n/nCD011946-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011946-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/media/CDSR/CD011946/urn:x-wiley:14651858:media:CD011946:CD011946-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/media/CDSR/CD011946/image_t/tCD011946-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD011946-fig-0003" src="/cdsr/doi/10.1002/14651858.CD011946.pub2/media/CDSR/CD011946/image_n/nCD011946-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/full#CD011946-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/media/CDSR/CD011946/image_n/nCD011946-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011946-fig-0004"> <p> <div class="table" id="CD011946-tblf-0001"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Interventions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Summary Outcomes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comment</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bernstein 2001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>One side: Non‐fractional non‐ablative laser (Nd:YAG)</p> <p>Other side: untreated control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Participant‐reported scar improvement (short‐term):</p> <p>In the treatment arm: average 53.6% (range 10% ‐ 90%)</p> <p>Participant‐reported adverse events (short‐term):</p> <p>No side effects were noted.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011946-bbs2-0003" title="BernsteinEF , FerreiraM , AndersonD . A pilot investigation to subjectively measure treatment effect and side‐effect profile of non‐ablative skin remodeling using a 532 nm, 2 ms pulse‐duration laser. Journal of Cosmetic &amp; Laser Therapy2001;3(3):137‐41. [EMBASE: 2002362049] ">Bernstein 2001</a> did not assess the primary outcome ‘Serious adverse effects’ and the secondary outcomes ‘Investigator‐assessed scar improvement’, ‘Participant satisfaction’, ‘Quality of life’, ‘Investigator‐assessed adverse events’ and ‘Post‐procedure down time’ </p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Non‐fractional non‐ablative laser versus placebo or no treatment, Outcome 1 Within‐individual studies. </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/references#CD011946-fig-0004">Navigate to figure in review</a></div> </div> <div class="figure" id="CD011946-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/media/CDSR/CD011946/urn:x-wiley:14651858:media:CD011946:CD011946-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/media/CDSR/CD011946/image_t/tCD011946-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Fractional laser versus non‐fractional non‐ablative laser, Outcome 1 Participant‐reported scar improvement (short‐term)." data-id="CD011946-fig-0005" src="/cdsr/doi/10.1002/14651858.CD011946.pub2/media/CDSR/CD011946/image_n/nCD011946-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Fractional laser versus non‐fractional non‐ablative laser, Outcome 1 Participant‐reported scar improvement (short‐term). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/references#CD011946-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/media/CDSR/CD011946/image_n/nCD011946-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011946-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/media/CDSR/CD011946/urn:x-wiley:14651858:media:CD011946:CD011946-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/media/CDSR/CD011946/image_t/tCD011946-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Fractional laser versus non‐fractional non‐ablative laser, Outcome 2 Investigator‐assessed scar improvement (short‐term)." data-id="CD011946-fig-0006" src="/cdsr/doi/10.1002/14651858.CD011946.pub2/media/CDSR/CD011946/image_n/nCD011946-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Fractional laser versus non‐fractional non‐ablative laser, Outcome 2 Investigator‐assessed scar improvement (short‐term). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/references#CD011946-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/media/CDSR/CD011946/image_n/nCD011946-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011946-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/media/CDSR/CD011946/urn:x-wiley:14651858:media:CD011946:CD011946-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/media/CDSR/CD011946/image_t/tCD011946-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Fractional laser versus non‐fractional non‐ablative laser, Outcome 3 Participant‐reported adverse events (short‐term)." data-id="CD011946-fig-0007" src="/cdsr/doi/10.1002/14651858.CD011946.pub2/media/CDSR/CD011946/image_n/nCD011946-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Fractional laser versus non‐fractional non‐ablative laser, Outcome 3 Participant‐reported adverse events (short‐term). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/references#CD011946-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/media/CDSR/CD011946/image_n/nCD011946-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011946-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/media/CDSR/CD011946/urn:x-wiley:14651858:media:CD011946:CD011946-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/media/CDSR/CD011946/image_t/tCD011946-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Fractional laser versus non‐fractional non‐ablative laser, Outcome 4 Investigator‐assessed adverse events (short‐term)." data-id="CD011946-fig-0008" src="/cdsr/doi/10.1002/14651858.CD011946.pub2/media/CDSR/CD011946/image_n/nCD011946-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Fractional laser versus non‐fractional non‐ablative laser, Outcome 4 Investigator‐assessed adverse events (short‐term). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/references#CD011946-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/media/CDSR/CD011946/image_n/nCD011946-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011946-fig-0009"> <p> <div class="table" id="CD011946-tblf-0002"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Interventions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Summary Outcomes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comment</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hedelund 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>One side: Fractional non‐ablative 1,540‐nm laser</p> <p>Other side: untreated control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1. Investigator‐assessed improvement in scar texture (short‐term): median (IQR). In the treated arm: 4.5 (2.5 – 6.5); In the untreated arm: 6.0 (4.5 – 8.0) </p> <p>(P = 0.032)</p> <p>2. Participant satisfaction: Satisfaction scores</p> <p>In the treated arm: median 5.5, IQR 1 – 7 (P = 0.1875)</p> <p>3. Participant‐reported overall acne scar appearance (short‐term):</p> <p>In the treated arm: number of participants evaluated significantly (1/10), moderately (4/10) or slightly (3/10) improved. 2 participants evaluated the appearance of their scars as no improvement after treatment. </p> <p>4. Participant‐reported adverse events (short‐term):</p> <p>In the treated arm: Participants experienced moderate pain (median 4.5, IQR 3 – 6.5, P = 0.8302), transient erythema (10/10 participants, P = 0.6013), oedema (7/10 participants, P = 0.3675), superficial crusts (3/10 participants, P = 0.6013) and minor bullae (1/10 participants, P = 1). </p> <p>In the untreated arm: No adverse effects were seen in untreated control areas.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011946-bbs2-0008" title="HedelundL , MoreauKER , BeyerDM , NymannP , HaedersdalM . Fractional nonablative 1,540‐nm laser resurfacing of atrophic acne scars. A randomized controlled trial with blinded response evaluation. Lasers in Medical Science2010;25(5):749‐54. [EMBASE: 2010472544] ">Hedelund 2010</a> did not assess the secondary outcome ‘Quality of life’ </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hedelund 2012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>One side: Fractional ablative CO₂ laser</p> <p>Other side: untreated control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1. Investigator‐assessed improvement of scar texture and atrophy (short‐term): Mean values of the 3 evaluators assessment scores: </p> <p>In the treated arm: 3.89 ± 1.74</p> <p>In the untreated arm: 5.22 ± 2.06, (P &lt; 0.0001)</p> <p>Scar atrophy:<br/> In the treated arm: 3.56 ± 1.76<br/> In the untreated arm: 4.89 ± 1.94, (P &lt; 0.0001) </p> <p>2. Participant satisfaction: Satisfaction scores:</p> <p>In the treated arm: median 4.5, IQR 2 – 7, (P = 0.117)</p> <p>3. Participant self‐assessments of scar texture improvement (short‐term): median (IQR) In the treated arm: 3 (2 – 6) (P = 0.629) </p> <p>4. Participant‐reported adverse events (short‐term):</p> <p>In the treated arm: Participants experienced mild to moderate pain (median (IQR); 2 (2 – 4), P = 0.086). Participants responded with erythema (no erythma: 4/8, mild: 8/13; moderate 1/13) and wounds (mild 12/13; moderate 1/13) 2 – 3 days. </p> <p>In the untreated arm: No adverse effects were seen in untreated control areas.</p> <p>5. Investigator‐assessed adverse events (short‐term):<br/> 9/13 participants responded with mild to moderate erythema while all<br/> participants responded with mild to moderate wound formation 2 ‐ 3 days<br/> post‐treatment. No significant differences were found in skin redness<br/> and pigmentation between treated and untreated areas. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011946-bbs2-0009" title="HedelundL , HaakCS , Togsverd‐BoK , BoghMK , BjerringP , HaedersdalM . Fractional CO2 laser resurfacing for atrophic acne scars: A randomized controlled trial with blinded response evaluation. Lasers in Surgery and Medicine2012;44(6):447‐52. [EMBASE: 2012412028] ">Hedelund 2012</a> did not assess the primary outcome ‘Serious adverse effects’ and the secondary outcomes ‘Quality of life’. </p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Fractional laser versus placebo or no treatment, Outcome 1 Within‐individual studies. </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/references#CD011946-fig-0009">Navigate to figure in review</a></div> </div> <div class="figure" id="CD011946-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/media/CDSR/CD011946/urn:x-wiley:14651858:media:CD011946:CD011946-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/media/CDSR/CD011946/image_t/tCD011946-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Fractional laser versus radiofrequency, Outcome 1 Participant‐reported scar improvement (short‐term)." data-id="CD011946-fig-0010" src="/cdsr/doi/10.1002/14651858.CD011946.pub2/media/CDSR/CD011946/image_n/nCD011946-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 Fractional laser versus radiofrequency, Outcome 1 Participant‐reported scar improvement (short‐term). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/references#CD011946-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/media/CDSR/CD011946/image_n/nCD011946-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011946-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/media/CDSR/CD011946/urn:x-wiley:14651858:media:CD011946:CD011946-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/media/CDSR/CD011946/image_t/tCD011946-CMP-004-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Fractional laser versus radiofrequency, Outcome 2 Investigator‐assessed scar improvement (short‐term)." data-id="CD011946-fig-0011" src="/cdsr/doi/10.1002/14651858.CD011946.pub2/media/CDSR/CD011946/image_n/nCD011946-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 Fractional laser versus radiofrequency, Outcome 2 Investigator‐assessed scar improvement (short‐term). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/references#CD011946-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/media/CDSR/CD011946/image_n/nCD011946-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011946-fig-0012"> <p> <div class="table" id="CD011946-tblf-0003"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Interventions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Summary Outcomes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comment</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rongsaard 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>One side: Fractional non‐ablative 1,550‐nm Er:Glass laser</p> <p>Other side: Fractional radiofrequency device</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1. Participant‐reported scar improvement (short‐term): Mean improvement grade of participants was 2.74 ± 0.73 for the fractional RF device and 2.89 ± 0.57 for the fractional laser. </p> <p>2. Investigator‐assessed scar improvement (short‐term): Mean improvement grade in acne scars was 2.70 ± 0.37 for the fractional RF device and 2.86 ± 0.42 for the fractional laser. </p> <p>3. Improvement in facial texture: There were statistically significant (P &lt; .001) reductions in texture scores after treatment with the fractional RF (2.71 ± 1.92) and the fractional laser (2.94 ± 1.84) </p> <p>4. Participant satisfaction:</p> <p>In fractional RF arm: 6 participants (31.6%) rated themselves as moderately satisfied, 10 (52.6%) rated as very satisfied, and three (15.8%) rated as most satisfied.<br/> In fractional laser arm: 5 participants (26.3%) rated themselves as moderately satisfied, 13 (68.4%) rated as very satisfied, and one (5.3%) rated as most satisfied. </p> <p>5. Patient‐reported adverse events (short‐term):</p> <p>In fractional RF arm: Mean pain scores were 5.90 ± 1.21, duration of facial erythema was 3.10 ± 1.17 days, duration of scab shedding was 5.00 ± 2.60 days, duration of facial dryness was 3.85 ± 3.15 days<br/> In fractional laser arm: Mean pain scores were 7.75 ± 1.37, duration of facial erythema was 2.90 ± 1.65 days, duration of scab shedding was 3.45 ± 2.95 days, duration of facial dryness was 3.25 ± 2.71 days. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011946-bbs2-0021" title="RongsaardN , RummaneethornP . Comparison of a fractional bipolar radiofrequency device and a fractional erbium‐doped glass 1,550‐nm device for the treatment of atrophic acne scars: a randomized split‐face clinical study. Dermatologic Surgery2014;40(1):14‐21. [PUBMED: 24267397] ">Rongsaard 2014</a> did not assess the secondary outcomes ‘Quality of life’ </p> <p>‘Investigator‐reported adverse events’ and ‘Post‐procedure down time’.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Zhang 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>One side: Fractional ablative CO₂ (FS) laser</p> <p>Other side: fractional radiofrequency device (RF)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1. Investigator‐assessed scar improvement (short‐term):</p> <p>In fractional RF arm: ECCA scores fell from 51.1 ± 14.2 to 22.3 ± 8.6, with 56.4% improvement. </p> <p>In CO₂ FS arm: ECCA scores fell from 48.8 ± 15.1 to 19.9 ± 7.9, with 59.2% improvement.</p> <p>2. Participant satisfaction:</p> <p>In fractional RF arm: 22 (66.7%) were very satisfied or satisfied, 9 (27.3%) were slightly satisfied, and 2 (6.0%) were unsatisfied. </p> <p>In CO₂ FS arm: 20 (60.6%) were very satisfied or satisfied, 10 (30.3%) were slightly satisfied, and 3 (9.1%) were unsatisfied. </p> <p>3. Participant‐reported adverse events (short‐term):</p> <p>In fractional RF arm: Mean duration of post‐therapy erythema and scaling was 5.7 days, no PIH was observed in this arm. </p> <p>In CO₂ FS arm: Mean duration of post‐therapy erythema and scaling was 10.2 days, 12 participants (36.4%) experienced post‐inflammatory hyperpigmentation (PIH) after 30 of 99 treatment sessions (30.3%). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011946-bbs2-0024" title="ZhangZ , FeiY , ChenX , LuW , ChenJ . Comparison of a fractional microplasma radio frequency technology and carbon dioxide fractional laser for the treatment of atrophic acne scars: a randomized split‐face clinical study. Dermatologic Surgery2013;39(4):559‐66. [PUBMED: 23379344] ">Zhang 2013</a> did not assess the primary outcome ‘Participant‐reported scar improvement’ and the secondary outcomes ‘Quality of life’ ‘Investigator‐reported adverse events’ and ‘Post‐procedure down time’. </p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4 Fractional laser versus radiofrequency, Outcome 3 Within‐individual studies.</p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/references#CD011946-fig-0012">Navigate to figure in review</a></div> </div> <div class="figure" id="CD011946-fig-0013"> <p> <div class="table" id="CD011946-tblf-0004"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Interventions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Summary Outcomes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comment</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Faghihi 2015</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>One side: Fractional ablative CO₂ laser</p> <p>Other side: Fractional CO₂ laser plus punch elevation .</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious adverse effects: All participants completed the allocated treatments and were included in the analyses. </p> <p>Investigator‐assessed scar improvement (short‐term: 4 months): 26/42 participants post‐fractional laser alone versus 31/42 participants post‐combined fractional laser and punch elevation reported &gt; 50% improvement. </p> <p>Participant satisfaction: Participants were more satisfied with the combined fractional laser with punch elevation treatment than with the fractional laser alone. </p> <p>Participant‐reported adverse events (&lt; 4 weeks): The most commonly reported adverse effect was transient erythema and crusting lasting for an average of 3 – 4 and 4 – 7 days, respectively. </p> <p>Investigator‐assessed adverse events (long‐term) (&gt; 4 weeks): <br/> Mild post­inflammatory hyperpigmentation was observed in 21.4% of participants which lasted &lt; 6 months. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011946-bbs2-0007" title="FaghihiG , NouraeiS , AsilianA , KeyvanS , Abtahi‐NaeiniB , RakhshanpourM , et al. Efficacy of punch elevation combined with fractional carbon dioxide laser resurfacing in facial atrophic acne scarring: a randomized split‐face clinical study. Indian Journal of Dermatology2015;60(5):473‐8. [EMBASE: 2015376448] ">Faghihi 2015</a> did not assess the primary outcome ‘Participant‐reported scar improvement’ and the secondary outcomes ‘Quality of life’ and ‘Post‐procedure down time’. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lee 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>One side: Fractional ablative CO₂ laser + intradermal injection with normal saline</p> <p>Other side: Fractional ablative CO₂ laser + intradermal treatment with autologous PRP. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious adverse effects: All participants completed the allocated treatments and were included in the analysis. </p> <p>Investigator‐assessed scar improvement (4 months): the mean overall degree of clinical improvement was 2.3 (SD 0.5) on the fractional laser alone side and 2.7 (SD 0.7) on the combined fractional laser plus PRP side (P = 0.03). </p> <p>Participant‐reported adverse events (&lt; 4 weeks): All participants were observed to experience some degree of post‐treatment crusting. Oedema lasted an average of 7.1 (SD 1.5) days on the control side and 6.1 (SD 1.1) days on the experimental side (P = 0.04). </p> <p>Investigator‐assessed adverse events (3 months): erythema on the combined fractional laser + PRP side was significantly less and improved faster than on the fractional laser alone side. Post‐treatment oedema on the combined fractional laser + PRP side also improved faster than the fractional laser alone side. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011946-bbs2-0013" title="LeeJW , KimBJ , KimMN , MunSK . The efficacy of autologous platelet rich plasma combined with ablative carbon dioxide fractional resurfacing for acne scars: a simultaneous split‐face trial. Dermatologic Surgery2011;37(7):931‐8. [PUBMED: 21635618] ">Lee 2011</a> did not assess the primary outcomes ‘Participant‐reported failure of treatment’, ‘Participant‐reported scar improvement’ nor the </p> <p>secondary outcomes ‘Investigator‐reported failure of treatment’ ‘Participant satisfaction',</p> <p>‘Quality of life’ and ‘Post‐procedure down time’.</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5 Fractional laser versus combined fractional laser plus any active intervention, Outcome 1 Within‐individual studies. </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/references#CD011946-fig-0013">Navigate to figure in review</a></div> </div> <div class="figure" id="CD011946-fig-0014"> <p> <div class="table" id="CD011946-tblf-0005"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Interventions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Summary Outcomes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comment</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kim 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>One side: Fractional non‐ablative 1,550 nm Er:Glass laser</p> <p>Other side: Chemical peeling</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Serious adverse effects:</p> <p>18/20 participants completed the trial and were included in the data. 1 participant dropped out because of slight discomfort of the treatment such as pain and erythema, and the other participant dropped out because of scheduling conflicts. </p> <p>Investigator‐assessed scar improvement (12 weeks): The overall average improvement grades by dermatologists were 2.51 in the fractional laser site and 2.44 in the chemical peeling site. </p> <p>Participant‐reported adverse events: Pain was noted 4.49 in the laser sides and 3.33 in the chemical peeling sides. Mean erythema lasting days were noted as 3.30 days in the laser sides and 12.13 days in the chemical peeling sides. </p> <p>Post‐procedure down time: Mean downtimes were noted as 3.17 days in the laser sides and 9.72 days in the chemical peeling sides. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011946-bbs2-0011" title="KimHJ , KimTG , KwonYS , ParkJM , LeeJH . Comparison of a 1,550 nm Erbium: glass fractional laser and a chemical reconstruction of skin scars (CROSS) method in the treatment of acne scars: a simultaneous split‐face trial. Lasers in Surgery and Medicine2009;41(8):545‐9. [PUBMED: 19639620] ">Kim 2009</a> did not assess the primary outcomes 'Participant‐reported failure of treatment’, ‘Participant‐reported scar improvement’ and the secondary outcomes ‘Investigator‐reported failure of treatment’, ‘Participant satisfaction’, ‘Quality of life’ and ‘Investigator‐assessed adverse events’. </p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6 Fractional laser versus chemical peeling, Outcome 1 Within‐individual studies. </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/references#CD011946-fig-0014">Navigate to figure in review</a></div> </div> <div class="figure" id="CD011946-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/media/CDSR/CD011946/urn:x-wiley:14651858:media:CD011946:CD011946-CMP-007-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/media/CDSR/CD011946/image_t/tCD011946-CMP-007-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Fractional laser versus combined chemical peeling plus needling, Outcome 1 Participant‐reported scar improvement (12 months)." data-id="CD011946-fig-0015" src="/cdsr/doi/10.1002/14651858.CD011946.pub2/media/CDSR/CD011946/image_n/nCD011946-CMP-007-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7 Fractional laser versus combined chemical peeling plus needling, Outcome 1 Participant‐reported scar improvement (12 months). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/references#CD011946-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/media/CDSR/CD011946/image_n/nCD011946-CMP-007-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011946-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/media/CDSR/CD011946/urn:x-wiley:14651858:media:CD011946:CD011946-CMP-007-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/media/CDSR/CD011946/image_t/tCD011946-CMP-007-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Fractional laser versus combined chemical peeling plus needling, Outcome 2 Investigator‐assessed scar improvement (12 months)." data-id="CD011946-fig-0016" src="/cdsr/doi/10.1002/14651858.CD011946.pub2/media/CDSR/CD011946/image_n/nCD011946-CMP-007-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.2</div> <div class="figure-caption"> <p>Comparison 7 Fractional laser versus combined chemical peeling plus needling, Outcome 2 Investigator‐assessed scar improvement (12 months). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/references#CD011946-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/media/CDSR/CD011946/image_n/nCD011946-CMP-007-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011946-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/media/CDSR/CD011946/urn:x-wiley:14651858:media:CD011946:CD011946-CMP-007-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/media/CDSR/CD011946/image_t/tCD011946-CMP-007-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Fractional laser versus combined chemical peeling plus needling, Outcome 3 Participant‐reported adverse events (&lt; 4 weeks)." data-id="CD011946-fig-0017" src="/cdsr/doi/10.1002/14651858.CD011946.pub2/media/CDSR/CD011946/image_n/nCD011946-CMP-007-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.3</div> <div class="figure-caption"> <p>Comparison 7 Fractional laser versus combined chemical peeling plus needling, Outcome 3 Participant‐reported adverse events (&lt; 4 weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/references#CD011946-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/media/CDSR/CD011946/image_n/nCD011946-CMP-007-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011946-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/media/CDSR/CD011946/urn:x-wiley:14651858:media:CD011946:CD011946-CMP-008-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/media/CDSR/CD011946/image_t/tCD011946-CMP-008-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Chemical peeling versus placebo or no treatment, Outcome 1 Serious or severe adverse events." data-id="CD011946-fig-0018" src="/cdsr/doi/10.1002/14651858.CD011946.pub2/media/CDSR/CD011946/image_n/nCD011946-CMP-008-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.1</div> <div class="figure-caption"> <p>Comparison 8 Chemical peeling versus placebo or no treatment, Outcome 1 Serious or severe adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/references#CD011946-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/media/CDSR/CD011946/image_n/nCD011946-CMP-008-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011946-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/media/CDSR/CD011946/urn:x-wiley:14651858:media:CD011946:CD011946-CMP-009-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/media/CDSR/CD011946/image_t/tCD011946-CMP-009-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Chemical peeling versus combined chemical peeling plus any active intervention, Outcome 1 Participant‐reported scar improvement (8 months)." data-id="CD011946-fig-0019" src="/cdsr/doi/10.1002/14651858.CD011946.pub2/media/CDSR/CD011946/image_n/nCD011946-CMP-009-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.1</div> <div class="figure-caption"> <p>Comparison 9 Chemical peeling versus combined chemical peeling plus any active intervention, Outcome 1 Participant‐reported scar improvement (8 months). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/references#CD011946-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/media/CDSR/CD011946/image_n/nCD011946-CMP-009-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011946-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/media/CDSR/CD011946/urn:x-wiley:14651858:media:CD011946:CD011946-CMP-009-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/media/CDSR/CD011946/image_t/tCD011946-CMP-009-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Chemical peeling versus combined chemical peeling plus any active intervention, Outcome 2 Investigator‐assessed scar improvement (8 months)." data-id="CD011946-fig-0020" src="/cdsr/doi/10.1002/14651858.CD011946.pub2/media/CDSR/CD011946/image_n/nCD011946-CMP-009-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.2</div> <div class="figure-caption"> <p>Comparison 9 Chemical peeling versus combined chemical peeling plus any active intervention, Outcome 2 Investigator‐assessed scar improvement (8 months). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/references#CD011946-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/media/CDSR/CD011946/image_n/nCD011946-CMP-009-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011946-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/media/CDSR/CD011946/urn:x-wiley:14651858:media:CD011946:CD011946-CMP-009-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/media/CDSR/CD011946/image_t/tCD011946-CMP-009-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Chemical peeling versus combined chemical peeling plus any active intervention, Outcome 3 Participant‐reported adverse events (&lt; 4 weeks)." data-id="CD011946-fig-0021" src="/cdsr/doi/10.1002/14651858.CD011946.pub2/media/CDSR/CD011946/image_n/nCD011946-CMP-009-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.3</div> <div class="figure-caption"> <p>Comparison 9 Chemical peeling versus combined chemical peeling plus any active intervention, Outcome 3 Participant‐reported adverse events (&lt; 4 weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/references#CD011946-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/media/CDSR/CD011946/image_n/nCD011946-CMP-009-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011946-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/media/CDSR/CD011946/urn:x-wiley:14651858:media:CD011946:CD011946-CMP-009-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/media/CDSR/CD011946/image_t/tCD011946-CMP-009-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Chemical peeling versus combined chemical peeling plus any active intervention, Outcome 4 Investigator‐assessed adverse events (8 months)." data-id="CD011946-fig-0022" src="/cdsr/doi/10.1002/14651858.CD011946.pub2/media/CDSR/CD011946/image_n/nCD011946-CMP-009-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.4</div> <div class="figure-caption"> <p>Comparison 9 Chemical peeling versus combined chemical peeling plus any active intervention, Outcome 4 Investigator‐assessed adverse events (8 months). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/references#CD011946-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/media/CDSR/CD011946/image_n/nCD011946-CMP-009-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011946-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/media/CDSR/CD011946/urn:x-wiley:14651858:media:CD011946:CD011946-CMP-010-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/media/CDSR/CD011946/image_t/tCD011946-CMP-010-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 Chemical peeling versus needling, Outcome 1 Participant‐reported scar improvement (1 month)." data-id="CD011946-fig-0023" src="/cdsr/doi/10.1002/14651858.CD011946.pub2/media/CDSR/CD011946/image_n/nCD011946-CMP-010-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.1</div> <div class="figure-caption"> <p>Comparison 10 Chemical peeling versus needling, Outcome 1 Participant‐reported scar improvement (1 month). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/references#CD011946-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/media/CDSR/CD011946/image_n/nCD011946-CMP-010-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011946-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/media/CDSR/CD011946/urn:x-wiley:14651858:media:CD011946:CD011946-CMP-010-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/media/CDSR/CD011946/image_t/tCD011946-CMP-010-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 Chemical peeling versus needling, Outcome 2 Investigator‐assessed scar improvement (1 month)." data-id="CD011946-fig-0024" src="/cdsr/doi/10.1002/14651858.CD011946.pub2/media/CDSR/CD011946/image_n/nCD011946-CMP-010-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.2</div> <div class="figure-caption"> <p>Comparison 10 Chemical peeling versus needling, Outcome 2 Investigator‐assessed scar improvement (1 month). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/references#CD011946-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/media/CDSR/CD011946/image_n/nCD011946-CMP-010-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011946-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/media/CDSR/CD011946/urn:x-wiley:14651858:media:CD011946:CD011946-CMP-010-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/media/CDSR/CD011946/image_t/tCD011946-CMP-010-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 Chemical peeling versus needling, Outcome 3 Patient satisfaction." data-id="CD011946-fig-0025" src="/cdsr/doi/10.1002/14651858.CD011946.pub2/media/CDSR/CD011946/image_n/nCD011946-CMP-010-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.3</div> <div class="figure-caption"> <p>Comparison 10 Chemical peeling versus needling, Outcome 3 Patient satisfaction.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/references#CD011946-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/media/CDSR/CD011946/image_n/nCD011946-CMP-010-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011946-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/media/CDSR/CD011946/urn:x-wiley:14651858:media:CD011946:CD011946-CMP-010-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/media/CDSR/CD011946/image_t/tCD011946-CMP-010-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 Chemical peeling versus needling, Outcome 4 Participant‐reported adverse events (&lt; 4 weeks)." data-id="CD011946-fig-0026" src="/cdsr/doi/10.1002/14651858.CD011946.pub2/media/CDSR/CD011946/image_n/nCD011946-CMP-010-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.4</div> <div class="figure-caption"> <p>Comparison 10 Chemical peeling versus needling, Outcome 4 Participant‐reported adverse events (&lt; 4 weeks). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/references#CD011946-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/media/CDSR/CD011946/image_n/nCD011946-CMP-010-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011946-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/media/CDSR/CD011946/urn:x-wiley:14651858:media:CD011946:CD011946-CMP-010-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/media/CDSR/CD011946/image_t/tCD011946-CMP-010-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 Chemical peeling versus needling, Outcome 5 Investigator‐assessed adverse events (1 month)." data-id="CD011946-fig-0027" src="/cdsr/doi/10.1002/14651858.CD011946.pub2/media/CDSR/CD011946/image_n/nCD011946-CMP-010-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.5</div> <div class="figure-caption"> <p>Comparison 10 Chemical peeling versus needling, Outcome 5 Investigator‐assessed adverse events (1 month). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/references#CD011946-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/media/CDSR/CD011946/image_n/nCD011946-CMP-010-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011946-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/media/CDSR/CD011946/urn:x-wiley:14651858:media:CD011946:CD011946-CMP-010-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/media/CDSR/CD011946/image_t/tCD011946-CMP-010-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 Chemical peeling versus needling, Outcome 6 Post‐procedure down time." data-id="CD011946-fig-0028" src="/cdsr/doi/10.1002/14651858.CD011946.pub2/media/CDSR/CD011946/image_n/nCD011946-CMP-010-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.6</div> <div class="figure-caption"> <p>Comparison 10 Chemical peeling versus needling, Outcome 6 Post‐procedure down time.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/references#CD011946-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/media/CDSR/CD011946/image_n/nCD011946-CMP-010-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011946-fig-0029"> <p> <div class="table" id="CD011946-tblf-0006"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Interventions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Summary Outcomes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comment</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Alam 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>One side: Needling Other side: untreated control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Improvement of acne scars (6 months):</p> <p>Participants perceived a 41% mean improvement in overall scar appearance on the treated side. </p> <p>In the needling group, scar scores were significantly lower at 6 months compared with baseline (MD 3.4, 95% CI 0.2 to 6.5; P = 0.03). In the untreated control group, mean scar scores did not vary significantly from baseline at 6 months (MD 0.4, 95% CI −2.8 to 3.5; P &gt; 0.99). </p> <p>Participant satisfaction:</p> <p>Most participants were very satisfied with their procedure.</p> <p>Any adverse events:</p> <p>No adverse events were reported. The mean pain rating was 1.08.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011946-bbs2-0001" title="AlamM , HanS , PongprutthipanM , DisphanuratW , KakarR , NodzenskiM , et al. Efficacy of a needling device for the treatment of acne scars: a randomized clinical trial. JAMA Dermatology2014;150(8):844‐9. [PUBMED: 24919799] PongprutthipanM , NodzenskiM , VeledarE , WestD , DubinaM , AlamM , et al. A randomized controlled trial to assess the efficacy of a needling device for the treatment of acne scars. Lasers in Surgery and Medicine2014;46:4. [EMBASE: 71594493] ">Alam 2014</a> did not assess the primary outcome ‘Participant‐reported failure of treatment’ nor the secondary outcomes ‘Investigator‐reported failure of treatment’, ‘Quality of life’ and ‘Post‐procedure down time’. </p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.1</div> <div class="figure-caption"> <p>Comparison 11 Needling versus placebo or no treatment, Outcome 1 Within‐individual studies. </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/references#CD011946-fig-0029">Navigate to figure in review</a></div> </div> <div class="figure" id="CD011946-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/media/CDSR/CD011946/urn:x-wiley:14651858:media:CD011946:CD011946-CMP-012-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/media/CDSR/CD011946/image_t/tCD011946-CMP-012-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 12 Injectable fillers versus placebo or no treatment, Outcome 1 Participant‐reported scar improvement (short‐term)." data-id="CD011946-fig-0030" src="/cdsr/doi/10.1002/14651858.CD011946.pub2/media/CDSR/CD011946/image_n/nCD011946-CMP-012-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.1</div> <div class="figure-caption"> <p>Comparison 12 Injectable fillers versus placebo or no treatment, Outcome 1 Participant‐reported scar improvement (short‐term). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/references#CD011946-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/media/CDSR/CD011946/image_n/nCD011946-CMP-012-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011946-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/media/CDSR/CD011946/urn:x-wiley:14651858:media:CD011946:CD011946-CMP-012-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/media/CDSR/CD011946/image_t/tCD011946-CMP-012-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 12 Injectable fillers versus placebo or no treatment, Outcome 2 Investigator‐assessed scar improvement (short‐term)." data-id="CD011946-fig-0031" src="/cdsr/doi/10.1002/14651858.CD011946.pub2/media/CDSR/CD011946/image_n/nCD011946-CMP-012-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.2</div> <div class="figure-caption"> <p>Comparison 12 Injectable fillers versus placebo or no treatment, Outcome 2 Investigator‐assessed scar improvement (short‐term). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/references#CD011946-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/media/CDSR/CD011946/image_n/nCD011946-CMP-012-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011946-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/media/CDSR/CD011946/urn:x-wiley:14651858:media:CD011946:CD011946-CMP-012-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/media/CDSR/CD011946/image_t/tCD011946-CMP-012-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 12 Injectable fillers versus placebo or no treatment, Outcome 3 Participant satisfaction." data-id="CD011946-fig-0032" src="/cdsr/doi/10.1002/14651858.CD011946.pub2/media/CDSR/CD011946/image_n/nCD011946-CMP-012-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.3</div> <div class="figure-caption"> <p>Comparison 12 Injectable fillers versus placebo or no treatment, Outcome 3 Participant satisfaction. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/references#CD011946-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/media/CDSR/CD011946/image_n/nCD011946-CMP-012-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011946-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/media/CDSR/CD011946/urn:x-wiley:14651858:media:CD011946:CD011946-CMP-012-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/media/CDSR/CD011946/image_t/tCD011946-CMP-012-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 12 Injectable fillers versus placebo or no treatment, Outcome 4 Participant‐reported adverse events (short‐term)." data-id="CD011946-fig-0033" src="/cdsr/doi/10.1002/14651858.CD011946.pub2/media/CDSR/CD011946/image_n/nCD011946-CMP-012-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.4</div> <div class="figure-caption"> <p>Comparison 12 Injectable fillers versus placebo or no treatment, Outcome 4 Participant‐reported adverse events (short‐term). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/references#CD011946-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/media/CDSR/CD011946/image_n/nCD011946-CMP-012-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011946-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/media/CDSR/CD011946/urn:x-wiley:14651858:media:CD011946:CD011946-CMP-012-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/media/CDSR/CD011946/image_t/tCD011946-CMP-012-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 12 Injectable fillers versus placebo or no treatment, Outcome 5 Investigator‐assessed adverse events (short‐term)." data-id="CD011946-fig-0034" src="/cdsr/doi/10.1002/14651858.CD011946.pub2/media/CDSR/CD011946/image_n/nCD011946-CMP-012-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.5</div> <div class="figure-caption"> <p>Comparison 12 Injectable fillers versus placebo or no treatment, Outcome 5 Investigator‐assessed adverse events (short‐term). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/references#CD011946-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/media/CDSR/CD011946/image_n/nCD011946-CMP-012-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011946-fig-0035"> <p> <div class="table" id="CD011946-tblf-0007"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Interventions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Summary Outcomes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comment</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Munavalli 2013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>One side: Injectable filler using autologous fibroblasts injected into the dermis</p> <p>Other side: vehicle control (dye‐free, protein‐free cell culture medium) injected into the dermis </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Improvement of acne scars: More than twice as many participants rated the injectable filler treated area with a 2‐point or greater improvement than the area receiving vehicle control (43% vs 18%). Evaluators rated 59% of the injectable filler–treated sides with a 1‐point or greater improvement on the evaluator scale compared with 42% of the sides receiving vehicle control. </p> <p>Side effects: No participants experienced serious adverse events, discontinued treatment, or withdrew from the study as a result of a treatment‐emergent adverse event. The most common adverse events were treatment area erythema (occurring in 11.1% of participants) and swelling (occurring in 10.1% of participants). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011946-bbs2-0020" title="MunavalliGS , SmithS , MaslowskiJM , WeissRA . Successful treatment of depressed, distensible acne scars using autologous fibroblasts: a multi‐site, prospective, double blind, placebo‐controlled clinical trial. Dermatologic Surgery2013;39(8):1226‐36. [PUBMED: 23566237] ">Munavalli 2013</a> did not report the secondary outcomes ‘Participant satisfaction’, ‘Quality of life’, ‘Participant‐reported adverse events’ and ‘Post‐procedure down time’. </p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.6</div> <div class="figure-caption"> <p>Comparison 12 Injectable fillers versus placebo or no treatment, Outcome 6 Within‐individual studies. </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/references#CD011946-fig-0035">Navigate to figure in review</a></div> </div> <div class="figure" id="CD011946-fig-0036"> <p> <div class="table" id="CD011946-tblf-0008"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Interventions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Summary Outcomes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comment</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sage 2011</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>One side: Injectable filler using a natural source porcine collagen (NSPC) filler</p> <p>Other side: Subcision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Participant‐reported scar improvement (6 months):</p> <p>Participants rated subcision (3.9) higher than NSPC injectable filler (3.5) for global improvement (P = 0.12). </p> <p>Physician assessment of the overall aesthetic improvement revealed a higher mean score for global improvement with NSPC injectable filler (3.05) than with subcision (2.95) (P = 0.69). </p> <p>Participant‐reported adverse events (1 week):</p> <p>The most significant adverse effect reported was bruising in participants treated with subcision. Subcision had a higher incidence and mean severity of bruising (2.2) than NSPC injection (0.7) (P = 0.007) </p> <p>Participant‐reported adverse events (6 months):</p> <p>Participants rated lumpiness from subcision (mean 3.4) as better than NSPC injectable filler (mean 2.9) (P = 0.15). </p> <p>Investigator‐assessed adverse events (1 week):</p> <p>A higher mean severity of bruising with subcision (1.7) than with NSPC injection (1.1) (P = 0.09). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011946-bbs2-0022" title="SageRJ , LopiccoloMC , LiuA , MahmoudBH , TierneyEP , KoubaDJ . Subcuticular incision versus naturally sourced porcine collagen filler for acne scars: a randomized split‐face comparison. Dermatologic Surgery2011;37(4):426‐31. [PUBMED: 21388487] ">Sage 2011</a> did not assess the secondary outcomes ‘Participant satisfaction’, ‘Quality of life’ or ‘Post‐procedure down time'. </p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.1</div> <div class="figure-caption"> <p>Comparison 13 Injectable fillers versus subcision, Outcome 1 Within‐individual studies.</p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/references#CD011946-fig-0036">Navigate to figure in review</a></div> </div> <div class="figure" id="CD011946-fig-0037"> <p> <div class="table" id="CD011946-tblf-0009"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Interventions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Summary Outcomes</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comment</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Linkner 2014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>One side: microdermabrasion plus 20% δ‐aminolevulinic acid with PDT (ALA‐PDT)</p> <p>Other side: microdermabrasion plus vehicle solution with PDT (vehicle‐PDT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Improvement of acne scars (5 months)</p> <p>80% of the participants displayed more improvement in scarring on the ALA split face versus the vehicle split face. </p> <p>Participant satisfaction (5 months):</p> <p>80% of participants appreciated an improvement in the acne scarring.</p> <p>Side effects (5 months):</p> <p>No side effects were noted.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011946-bbs2-0017" title="LinknerRV , Jim OnS , HaddicanM , SingerG , Shim‐ChangH . Evaluating the efficacy of photodynamic therapy with 20% aminolevulinic acid and microdermabrasion as a combination treatment regimen for acne scarring: A split‐face, randomized, double‐blind pilot study. Journal of Clinical &amp; Aesthetic Dermatology2014;7(5):32‐5. [PUBMED: 24847407] ">Linkner 2014</a> did not assess the primary outcomes ‘Participant‐reported scar improvement’, ‘Serious adverse effects’, nor the secondary outcomes ‘Quality of life’ </p> <p>and ‘Post‐procedure down time’.</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.1</div> <div class="figure-caption"> <p>Comparison 14 Combined microdermabrasion plus ALA‐PDT versus combined microdermabrasion plus placebo‐PDT, Outcome 1 Within‐individual studies. </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/references#CD011946-fig-0037">Navigate to figure in review</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD011946-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Fractional laser versus non‐fractional non‐ablative laser for acne scars</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Fractional laser versus non‐fractional non‐ablative laser for acne scars</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with acne scars<br/> <b>Settings:</b> hospital‐based<br/> <b>Intervention:</b> fractional laser versus non‐fractional non‐ablative laser </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Fractional laser versus non‐fractional non‐ablative laser</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participant‐reported scar improvement (long‐term)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not measured</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participant‐reported scar improvement (short‐term)</b> <br/> N of participants with &gt; 50% improvement in acne scars<br/> Follow‐up: mean 6 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>94 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>375 per 1000</b> <br/> (117 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 4</b> <br/> (1.25 to 12.84) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Investigator‐assessed adverse events (short‐term) Hyperpigmentation</b> <br/> N of participants with adverse events<br/> Follow‐up: mean 4 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>312 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>188 per 1000</b> <br/> (78 to 453) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.6</b> <br/> (0.25 to 1.45) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participant‐assessed adverse events (short‐term) Burning</b> <br/> N of participants with adverse events<br/> Follow‐up: mean 4 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>1000 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>1000 per 1000</b> <br/> (940 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1</b> <br/> (0.94 to 1.06) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participant satisfaction</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not measured</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not measured</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded by one level because of unclear allocation concealment and blinding of participant and personnel.<br/> <sup>2</sup>Downgraded two levels for very serious imprecision because the optimal information size (OIS) is not met (should be 5600) and the CI is extremely wide.<br/> <sup>3</sup>Downgraded two levels for very serious imprecision because the optimal information size (OIS) is not met (should be around 1200), very small sample size, and the 95% CI around the estimate of effect includes both no effect and appreciable harm.<br/> <sup>4</sup>Downgraded two levels for very serious imprecision because the optimal information size (OIS) is not met, very small sample size, and the 95% CI around the estimate of effect includes both no effect and appreciable harm. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Fractional laser versus non‐fractional non‐ablative laser for acne scars</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/full#CD011946-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD011946-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Fractional laser versus radiofrequency for acne scars</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Fractional laser versus radiofrequency for acne scars</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with acne scars<br/> <b>Settings:</b> hospital‐based<br/> <b>Intervention:</b> fractional laser versus radiofrequency </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Fractional laser versus radiofrequency</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participant‐reported scar improvement (long‐term)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not measured</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participant‐reported scar improvement (short‐term)</b> <br/> N of participants with &gt; 50% improvement in acne scars<br/> Follow‐up: mean 8 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>450 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>351 per 1000</b> <br/> (162 to 756) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.78</b> <br/> (0.36 to 1.68) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011946-bbs2-0021" title="RongsaardN , RummaneethornP . Comparison of a fractional bipolar radiofrequency device and a fractional erbium‐doped glass 1,550‐nm device for the treatment of atrophic acne scars: a randomized split‐face clinical study. Dermatologic Surgery2014;40(1):14‐21. [PUBMED: 24267397] ">Rongsaard 2014</a> reported a mean improvement of 2.89 for the fractional laser and 2.74 for the radiofrequency </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Investigator‐assessed adverse events (short‐term)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear whether the reported higher events (erythema, oedema, PIH) with the laser are participant‐ or investigator‐assessed </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participant‐assessed adverse events (short‐term)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>More pain with fractional laser was noticed, <a href="./references#CD011946-bbs2-0021" title="RongsaardN , RummaneethornP . Comparison of a fractional bipolar radiofrequency device and a fractional erbium‐doped glass 1,550‐nm device for the treatment of atrophic acne scars: a randomized split‐face clinical study. Dermatologic Surgery2014;40(1):14‐21. [PUBMED: 24267397] ">Rongsaard 2014</a> and <a href="./references#CD011946-bbs2-0024" title="ZhangZ , FeiY , ChenX , LuW , ChenJ . Comparison of a fractional microplasma radio frequency technology and carbon dioxide fractional laser for the treatment of atrophic acne scars: a randomized split‐face clinical study. Dermatologic Surgery2013;39(4):559‐66. [PUBMED: 23379344] ">Zhang 2013</a> reported higher incidence of positive adverse events with fractional laser </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participant satisfaction</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011946-bbs2-0024" title="ZhangZ , FeiY , ChenX , LuW , ChenJ . Comparison of a fractional microplasma radio frequency technology and carbon dioxide fractional laser for the treatment of atrophic acne scars: a randomized split‐face clinical study. Dermatologic Surgery2013;39(4):559‐66. [PUBMED: 23379344] ">Zhang 2013</a> reported that 30/33 and 31/33 of participants were satisfied with laser and radiofrequency respectively with no significant difference </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not measured</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded by one level because of unclear allocation concealment and high blinding of participant and personnel.<br/> <sup>2</sup>Downgraded two levels for very serious imprecision because the optimal information size (OIS) is not met (should be around 620) and the 95% CI around the estimate of effect includes both no effect and appreciable benefit. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Fractional laser versus radiofrequency for acne scars</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/full#CD011946-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD011946-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Fractional laser versus combined chemical peeling plus needling for acne scars</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Fractional laser versus combined chemical peeling plus needling for acne scars</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with acne scars<br/> <b>Settings:</b> hospital‐based<br/> <b>Intervention:</b> fractional laser versus combined chemical peeling plus needling </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Fractional laser versus combined chemical peeling plus needling</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participant‐reported scar improvement (long‐term)</b> <br/> N of participants with &gt; 50% improvement in acne scars<br/> Follow‐up: mean 12 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>692 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>692 per 1000</b> <br/> (415 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1</b> <br/> (0.6 to 1.67) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participant‐reported scar improvement (short‐term)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not measured</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Investigator‐assessed adverse events (short‐term)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not measured</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participant‐assessed adverse events (short‐term)</b> <br/> N of participants with adverse events<br/> Follow‐up: mean 4 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>1000 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>1000 per 1000</b> <br/> (860 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1</b> <br/> (0.86 to 1.16) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participant satisfaction</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not measured</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not measured</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded by one level for high risk of bias regarding blinding of participants and personnel.<br/> <sup>2</sup>Downgraded two levels for very serious imprecision because the optimal information size (OIS) is not met (should be around 200), very small sample size, and the 95% CI around the estimate of effect includes both no effect and appreciable benefit.<br/> <sup>3</sup>Downgraded two levels for very serious imprecision because the optimal information size (OIS) is not met, very small sample size, and the 95% CI around the estimate of effect includes both no effect and appreciable harm. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Fractional laser versus combined chemical peeling plus needling for acne scars</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/full#CD011946-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD011946-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Chemical peeling versus placebo or no treatment for acne scars</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Chemical peeling versus placebo or no treatment for acne scars</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with acne scars<br/> <b>Settings:</b> out‐patient<br/> <b>Intervention:</b> chemical peeling versus placebo or no treatment </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Chemical peeling versus placebo or no treatment</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participant‐reported scar improvement (long‐term)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not measured</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participant‐reported scar improvement (short‐term)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not measured</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Investigator‐assessed adverse events (short‐term)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not measured</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participant‐assessed adverse events (short‐term)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Burning sensation and deep erythema were reported following frosting in some cases from the chemical peeling </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participant satisfaction</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not measured</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not measured</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious or severe adverse events</b> <br/> N of participants with positive severe adverse events<br/> Follow‐up: mean 6 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> <br/> (0 to 0) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 5.45</b> <br/> (0.33 to 90.14) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7/43 participants experienced serious adverse events with chemical peel but 0/15 in the placebo group </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded one level for high risk of attrition bias.<br/> <sup>2</sup>Downgraded two levels for very serious imprecision because the optimal information size (OIS) is far from met, extremely wide CI, due to low occurrence of events in control group and small sample size. 95% CI around the estimate of effect includes both no effect and appreciable harm. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Chemical peeling versus placebo or no treatment for acne scars</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/full#CD011946-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD011946-tbl-0005"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Chemical peeling versus combined chemical peeling plus any active intervention for acne scars</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Chemical peeling versus combined chemical peeling plus any active intervention for acne scars</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with acne scars<br/> <b>Settings:</b> hospital‐based<br/> <b>Intervention:</b> chemical peeling versus combined chemical peeling plus any active intervention </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Chemical peeling versus combined chemical peeling plus any active intervention</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participant‐reported scar improvement (long‐term)</b> <br/> N of participants with &gt; 50% improvement in acne scars<br/> Follow‐up: mean 8 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>800 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>992 per 1000</b> <br/> (696 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.24</b> <br/> (0.87 to 1.75) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participant‐reported scar improvement (short‐term)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not measured</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Investigator‐assessed adverse events (short‐term)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not measured</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participant‐assessed adverse events (short‐term)</b> <br/> N of participants with adverse events<br/> Follow‐up: mean 4 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>1000 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>1000 per 1000</b> <br/> (830 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1</b> <br/> (0.83 to 1.2) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participant satisfaction</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not measured</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not measured</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded by one level due to high risk of bias with regard to blinding of participants and personnel.<br/> <sup>2</sup>Downgraded two levels for very serious imprecision because the optimal information size (OIS) is not met (should be around 100), very small sample size, and the 95% CI around the estimate of effect includes both no effect and appreciable benefit.<br/> <sup>3</sup>Downgraded two levels for very serious imprecision because the optimal information size (OIS) is not met, very small sample size, and the 95% CI around the estimate of effect includes both no effect and appreciable harm. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Chemical peeling versus combined chemical peeling plus any active intervention for acne scars</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/full#CD011946-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD011946-tbl-0006"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Chemical peeling versus needling for acne scars</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Chemical peeling versus needling for acne scars</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with acne scars<br/> <b>Settings:</b> hospital‐based<br/> <b>Intervention:</b> chemical peeling versus needling </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Chemical peeling versus needling</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participant‐reported scar improvement (long‐term)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not measured</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participant‐reported scar improvement (short‐term)</b> <br/> N of participants with &gt; 50% improvement in acne scars<br/> Follow‐up: mean 1 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>667 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>747 per 1000</b> <br/> (460 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.13</b> <br/> (0.69 to 1.83) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Investigator‐assessed adverse events (short‐term)</b> <br/> N of participants with adverse events<br/> Follow‐up: mean 4 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>RR 16</b> <br/> (0.99 to 258.36) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>27<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p>6/12 participants experienced adverse events with chemical peel</p> <p>but 0/15 with needling</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> <br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Moderate</b> </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>0 per 1000</b> <br/> (0 to 0) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participant‐assessed adverse events (short‐term)</b> <br/> N of participants with positive adverse events<br/> Follow‐up: mean 4 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>1000 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>1000 per 1000</b> <br/> (870 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1</b> <br/> (0.87 to 1.15) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Patient satisfaction</b> <br/> N of satisfied participants<br/> Follow‐up: mean 4 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>667 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>747 per 1000</b> <br/> (460 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.13</b> <br/> (0.69 to 1.83) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not measured</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded by one level due to high risk of bias regarding blinding of participants and personnel.<br/> <sup>2</sup>Downgraded two levels for very serious imprecision because the optimal information size (OIS) is not met (should be around 250), very small sample size, and the 95% CI around the estimate of effect includes both no effect and appreciable benefit.<br/> <sup>3</sup>Downgraded two levels for very serious imprecision because the optimal information size (OIS) is not met, very small sample size, extremely wide CI, and the 95% CI around the estimate of effect includes both no effect and appreciable harm.<br/> <sup>4</sup>Downgraded two levels for very serious imprecision because the optimal information size (OIS) is not met, very small sample size, and the 95% CI around the estimate of effect includes both no effect and appreciable harm. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Chemical peeling versus needling for acne scars</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/full#CD011946-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD011946-tbl-0007"> <div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Injectable fillers versus placebo or no treatment for acne scars</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Injectable fillers versus placebo or no treatment for acne scars</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with acne scars<br/> <b>Settings:</b> outpatient<br/> <b>Intervention:</b> injectable fillers versus placebo or no treatment </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Injectable fillers versus placebo or no treatment</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participant‐assessed scar improvement (long‐term)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not measured</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participant‐reported scar improvement (short‐term)</b> <br/> N of participants with &gt; 50% improvement in acne scars<br/> Follow‐up: mean 6 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>420 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>773 per 1000</b> <br/> (550 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.84</b> <br/> (1.31 to 2.59) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>147<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011946-bbs2-0020" title="MunavalliGS , SmithS , MaslowskiJM , WeissRA . Successful treatment of depressed, distensible acne scars using autologous fibroblasts: a multi‐site, prospective, double blind, placebo‐controlled clinical trial. Dermatologic Surgery2013;39(8):1226‐36. [PUBMED: 23566237] ">Munavalli 2013</a> reported 43% vs 18% improvement with the dermal filler and placebo respectively </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participant satisfaction</b> <br/> N of satisfied participants<br/> Follow‐up: mean 6 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>520 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>848 per 1000</b> <br/> (640 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.63</b> <br/> (1.23 to 2.15) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>147<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Participant‐reported adverse events (short‐term)</b> <br/> N of participants with positive adverse events<br/> Follow‐up: mean 4 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>20 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>21 per 1000</b> <br/> (2 to 222) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.03</b> <br/> (0.1 to 11.1) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>147<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Investigator‐assessed adverse events (short‐term)</b> <br/> N of participants with positive adverse events<br/> Follow‐up: mean 4 weeks </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>260 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>174 per 1000</b> <br/> (94 to 330) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.67</b> <br/> (0.36 to 1.27) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>147<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011946-bbs2-0020" title="MunavalliGS , SmithS , MaslowskiJM , WeissRA . Successful treatment of depressed, distensible acne scars using autologous fibroblasts: a multi‐site, prospective, double blind, placebo‐controlled clinical trial. Dermatologic Surgery2013;39(8):1226‐36. [PUBMED: 23566237] ">Munavalli 2013</a> reported comparable incidence of events with dermal filler and placebo </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not estimable</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This outcome was not measured</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded one level for imprecision because the optimal information size (OIS) is not met (should be around 300), although the sample size is not that small.<br/> <sup>2</sup>Downgraded two levels for very serious imprecision because the optimal information size (OIS) is not met (should be around 1500), small sample size, and the 95% CI around the estimate of effect includes both no effect and appreciable harm.<br/> <sup>3</sup>Downgraded two levels for very serious imprecision because the optimal information size (OIS) is not met, and the 95% CI around the estimate of effect includes both no effect and appreciable harm. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Injectable fillers versus placebo or no treatment for acne scars</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/full#CD011946-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011946-tbl-0008"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Contacted authors</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Contact author</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Contact email</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Reply/did not reply</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011946-bbs2-0025" title="AhmedR , MohammedG , IsmailN , ElakhrasA . Randomized clinical trial of CO₂ LASER pinpoint irradiation technique versus chemical reconstruction of skin scars (CROSS) in treating ice pick acne scars. Journal of Cosmetic and Laser Therapy2014;16(1):8‐13. [EMBASE: 2014075366] ">Ahmed 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mohammed G</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a class="__cf_email__" data-cfemail="bedacce1d9d6dfdadf8989fed6d1cad3dfd7d290ddd1d3" href="/cdn-cgi/l/email-protection">[email protected]</a></p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Did not reply</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011946-bbs2-0002" title="AsilianA , SalimiE , FaghihiG , DehghaniF , TajmirriahiN , HosseiniSM . Comparison of Q‐Switched 1064‐nm Nd: YAG laser and fractional CO2 laser efficacies on improvement of atrophic facial acne scar. Journal of Research in Medical Sciences2011;16(9):1189‐95. [EMBASE: 2011598154] ">Asilian 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Salimi E</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a class="__cf_email__" data-cfemail="7e0d210d1f121713173e0c1b0d1b1a1b100a50130b17501f1d50170c" href="/cdn-cgi/l/email-protection">[email protected]</a></p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Did not reply</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011946-bbs2-0003" title="BernsteinEF , FerreiraM , AndersonD . A pilot investigation to subjectively measure treatment effect and side‐effect profile of non‐ablative skin remodeling using a 532 nm, 2 ms pulse‐duration laser. Journal of Cosmetic &amp; Laser Therapy2001;3(3):137‐41. [EMBASE: 2002362049] ">Bernstein 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Bernstein EF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a class="__cf_email__" data-cfemail="fd99988f909a8884bd959289909c9491d39e9290" href="/cdn-cgi/l/email-protection">[email protected]</a></p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Did not reply</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011946-bbs2-0004" title="ChaeWS , SeongJY , JungHN , KongSH , KimMH , SuhHS , et al. Comparative study on efficacy and safety of 1550 nm Er: Glass fractional laser and fractional radiofrequency microneedle device for facial atrophic acne scar. Journal of Cosmetic Dermatology2015;14(2):100‐6. [EMBASE: 2015071568] ">Chae 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Choi YS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a class="__cf_email__" data-cfemail="98ededf0fcfdeaf5f9d8f0f9f6f5f9f1f4b6f6fdec" href="/cdn-cgi/l/email-protection">[email protected]</a></p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Responded</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011946-bbs2-0005" title="ChoSB , LeeSJ , ChoS , OhSH , ChungWS , KangJM , et al. Non‐ablative 1550‐nm erbium‐glass and ablative 10 600‐nm carbon dioxide fractional lasers for acne scars: a randomized split‐face study with blinded response evaluation. Journal of the European Academy of Dermatology and Venereology2010;24(8):921‐5. [EMBASE: 2010378178] ">Cho 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kim DH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a class="__cf_email__" data-cfemail="daaebfa8b3b5a9e3e89ab2bbb4b7bbb3b6f4b4bfae" href="/cdn-cgi/l/email-protection">[email protected]</a></p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Did not reply</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011946-bbs2-0032" title="GadkariR , NayakC . A split‐face comparative study to evaluate efficacy of combined subcision and dermaroller against combined subcision and cryoroller in treatment of acne scars. Journal of Cosmetic Dermatology2014;13(1):38‐43. [PUBMED: 24641604] ">Gadkari 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gadkari R</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a class="__cf_email__" data-cfemail="5531272730263d38343234313e34273c153238343c397b363a38" href="/cdn-cgi/l/email-protection">[email protected]</a></p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Did not reply</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011946-bbs2-0008" title="HedelundL , MoreauKER , BeyerDM , NymannP , HaedersdalM . Fractional nonablative 1,540‐nm laser resurfacing of atrophic acne scars. A randomized controlled trial with blinded response evaluation. Lasers in Medical Science2010;25(5):749‐54. [EMBASE: 2010472544] ">Hedelund 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hedelund L</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a class="__cf_email__" data-cfemail="117d747f743f797475747d647f7551797e657c70787d3f727e7c" href="/cdn-cgi/l/email-protection">[email protected]</a></p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Did not reply</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011946-bbs2-0009" title="HedelundL , HaakCS , Togsverd‐BoK , BoghMK , BjerringP , HaedersdalM . Fractional CO2 laser resurfacing for atrophic acne scars: A randomized controlled trial with blinded response evaluation. Lasers in Surgery and Medicine2012;44(6):447‐52. [EMBASE: 2012412028] ">Hedelund 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hedelund L</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a class="__cf_email__" data-cfemail="aac6cfc4c2cfceead8c784cec1" href="/cdn-cgi/l/email-protection">[email protected]</a></p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Did not reply</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011946-bbs2-0010" title="KarnikJ , BaumannL , BruceS , CallenderV , CohenS , GrimesP , et al. A double‐blind, randomized, multicenter, controlled trial of suspended polymethylmethacrylate microspheres for the correction of atrophic facial acne scars. Journal of the American Academy of Dermatology2014;71(1):77‐83. [EMBASE: 2014426024] ">Karnik 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Smith SR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a class="__cf_email__" data-cfemail="cfbcbca2a6bba78fbcbbaeacb6bdbca2a6bba7a2abe1aca0a2" href="/cdn-cgi/l/email-protection">[email protected]</a></p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Did not reply</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011946-bbs2-0011" title="KimHJ , KimTG , KwonYS , ParkJM , LeeJH . Comparison of a 1,550 nm Erbium: glass fractional laser and a chemical reconstruction of skin scars (CROSS) method in the treatment of acne scars: a simultaneous split‐face trial. Lasers in Surgery and Medicine2009;41(8):545‐9. [PUBMED: 19639620] ">Kim 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lee JH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a class="__cf_email__" data-cfemail="264c534e4343665f534e55084745" href="/cdn-cgi/l/email-protection">[email protected]</a></p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Did not reply</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011946-bbs2-0036" title="KimS , ChoKH . Clinical trial of dual treatment with an ablative fractional laser and a nonablative laser for the treatment of acne scars in Asian patients. Dermatologic Surgery2009;35(7):1089‐98. [PUBMED: 19438689] ">Kim 2009a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kim S</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a class="__cf_email__" data-cfemail="f29bc69981b28b939a9d9ddc919d9f" href="/cdn-cgi/l/email-protection">[email protected]</a></p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Did not reply</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011946-bbs2-0012" title="LeeDH , ChoiYS , MinSU , YoonMY , SuhDH . Comparison of a 585‐nm pulsed dye laser and a 1064‐nm Nd:YAG laser for the treatment of acne scars: a randomized split‐face clinical study. Journal of the American Academy of Dermatology2009;60(5):801‐7. [PUBMED: 19217691] ">Lee 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Suh DH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a class="__cf_email__" data-cfemail="f195909499849fb1829f84df9092df9a83" href="/cdn-cgi/l/email-protection">[email protected]</a></p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Did not reply</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011946-bbs2-0013" title="LeeJW , KimBJ , KimMN , MunSK . The efficacy of autologous platelet rich plasma combined with ablative carbon dioxide fractional resurfacing for acne scars: a simultaneous split‐face trial. Dermatologic Surgery2011;37(7):931‐8. [PUBMED: 21635618] ">Lee 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kim BJ</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a class="__cf_email__" data-cfemail="f597909a989f9a9a9bb5809b9c819099db969adb9e87" href="/cdn-cgi/l/email-protection">[email protected]</a></p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Did not reply</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011946-bbs2-0017" title="LinknerRV , Jim OnS , HaddicanM , SingerG , Shim‐ChangH . Evaluating the efficacy of photodynamic therapy with 20% aminolevulinic acid and microdermabrasion as a combination treatment regimen for acne scarring: A split‐face, randomized, double‐blind pilot study. Journal of Clinical &amp; Aesthetic Dermatology2014;7(5):32‐5. [PUBMED: 24847407] ">Linkner 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Linkner RV</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a class="__cf_email__" data-cfemail="ce9ca7baafe082a7a0a5a0abbc8ea3a1bba0babda7a0afa7e0a1bca9" href="/cdn-cgi/l/email-protection">[email protected]</a></p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Did not reply</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011946-bbs2-0018" title="ManuskiattiW , IamphonratT , WanitphakdeedechaR , EimpunthS . Comparison of fractional Er:YAG and CO2 lasers in resurfacing of atrophic acne scars in Asians. 31st Annual Conference of the American Society for Laser Medicine and Surgery, ASLMS 2011 Grapevine, TX United States. Conference Start: 20110330 Conference End: 20110403. Lasers in Surgery and Medicine2011;43:938‐939. [EMBASE: 70640237] ManuskiattiW , IamphonratT , WanitphakdeedechaR , EimpunthS . Comparison of fractional erbium‐doped yttrium aluminum garnet and carbon dioxide lasers in resurfacing of atrophic acne scars in Asians. Dermatologic Surgery2013;39(1 Pt 1):111‐20. [EMBASE: 23205717] ">Manuskiatti 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Manuskiatti W</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a class="__cf_email__" data-cfemail="2f58405d4e5f4740414801424e416f424e47464b4043014e4c015b47" href="/cdn-cgi/l/email-protection">[email protected]</a></p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Did not reply</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011946-bbs2-0019" title="MinSU , ChoiYS , LeeDH , YoonMY , SuhDH . Comparison of a long‐pulse Nd:YAG laser and a combined 585/1,064‐nm laser for the treatment of acne scars: a randomized split‐face clinical study. Dermatologic Surgery2009;35(11):1720‐7. [PUBMED: 19250299] ">Min 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Suh DH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a class="__cf_email__" data-cfemail="472326222f322907342932692624692c35" href="/cdn-cgi/l/email-protection">[email protected]</a></p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Did not reply</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011946-bbs2-0040" title="MohammedG . Randomized clinical trial of CO2 laser pinpoint irradiation technique with/without needling for ice pick acne scars. Journal of Cosmetic and Laser Therapy2013;15(3):177‐82. [EMBASE: 2013337358] ">Mohammed 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mohammed G</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a class="__cf_email__" data-cfemail="c6a2b499a1aea7a2a7f1f186aea9b2aba7afaae8a5a9ab" href="/cdn-cgi/l/email-protection">[email protected]</a></p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Did not reply</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011946-bbs2-0020" title="MunavalliGS , SmithS , MaslowskiJM , WeissRA . Successful treatment of depressed, distensible acne scars using autologous fibroblasts: a multi‐site, prospective, double blind, placebo‐controlled clinical trial. Dermatologic Surgery2013;39(8):1226‐36. [PUBMED: 23566237] ">Munavalli 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Munavalli GS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a class="__cf_email__" data-cfemail="0d6a6078636c7b6c6161644d6e6c7f626164636c7e666463236e6260" href="/cdn-cgi/l/email-protection">[email protected]</a></p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Did not reply</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011946-bbs2-0041" title="NofalE , HelmyA , NofalA , AlakadR , NasrM . Platelet‐rich plasma versus CROSS technique with 100% trichloroacetic acid versus combined skin needling and platelet rich plasma in the treatment of atrophic acne scars: a comparative study. Dermatologic Surgery2014;40(8):864‐73. [PUBMED: 25006854] ">Nofal 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nofal E</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a class="__cf_email__" data-cfemail="4d2c25202c2923222b2c21780d252239202c2421632e2220" href="/cdn-cgi/l/email-protection">[email protected]</a></p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Did not reply</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011946-bbs2-0021" title="RongsaardN , RummaneethornP . Comparison of a fractional bipolar radiofrequency device and a fractional erbium‐doped glass 1,550‐nm device for the treatment of atrophic acne scars: a randomized split‐face clinical study. Dermatologic Surgery2014;40(1):14‐21. [PUBMED: 24267397] ">Rongsaard 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rongsaard N</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a class="__cf_email__" data-cfemail="1678796678776463736679647856717b777f7a3875797b" href="/cdn-cgi/l/email-protection">[email protected]</a></p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Responded</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011946-bbs2-0022" title="SageRJ , LopiccoloMC , LiuA , MahmoudBH , TierneyEP , KoubaDJ . Subcuticular incision versus naturally sourced porcine collagen filler for acne scars: a randomized split‐face comparison. Dermatologic Surgery2011;37(4):426‐31. [PUBMED: 21388487] ">Sage 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Kouba DJ</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a class="__cf_email__" data-cfemail="e0848b8f958281d1a088868893ce8f9287" href="/cdn-cgi/l/email-protection">[email protected]</a></p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Did not reply</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011946-bbs2-0023" title="TanziEL , AlsterTS . Comparison of a 1450‐nm diode laser and a 1320‐nm Nd:YAG laser in the treatment of atrophic facial scars: a prospective clinical and histologic study. Dermatologic Surgery2004;30(2 Pt 1):152‐7. [PUBMED: 14756642] ">Tanzi 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Alster TS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a class="__cf_email__" data-cfemail="a1d5c0cdd2d5c4d3e1d2cac8cfcdc0d2c4d38fc2cecc" href="/cdn-cgi/l/email-protection">[email protected]</a></p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Did not reply</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD011946-bbs2-0024" title="ZhangZ , FeiY , ChenX , LuW , ChenJ . Comparison of a fractional microplasma radio frequency technology and carbon dioxide fractional laser for the treatment of atrophic acne scars: a randomized split‐face clinical study. Dermatologic Surgery2013;39(4):559‐66. [PUBMED: 23379344] ">Zhang 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chen J</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a class="__cf_email__" data-cfemail="047c60676c616a4469616069656d682a676b692a676a" href="/cdn-cgi/l/email-protection">[email protected]</a></p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Did not reply</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Contacted authors</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/full#CD011946-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011946-tbl-0009"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Summary of research gaps</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Gap No.</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Reason(s) for Gap*</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> POPULATION</b> </p> <p><b> (P)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> INTERVENTION</b> </p> <p><b> (I)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> COMPARISON</b> </p> <p><b> (C)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> OUTCOMES</b> </p> <p><b> (O)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> SETTING</b> </p> <p><b> (S)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Free Text Gap</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>People with acne scars</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fractional Laser</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participant‐reported scar improvement (long‐term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospital‐based/outpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lack of a validated standardised improvement scale</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>2</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A1</p> <p>D4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>People with acne scars</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fractional Laser</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Non‐fractional non‐ablative laser</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participant‐reported scar improvement (long‐term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospital‐based/outpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lack of a validated standardised improvement scale</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>3</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A2</p> <p>A3</p> <p>A4</p> <p>B2</p> <p>C1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>People with acne scars</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fractional Laser</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Non‐fractional non‐ablative laser</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participant‐reported scar improvement (short‐term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospital‐based/outpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lack of a validated standardised improvement scale</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>4</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A1</p> <p>D4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>People with acne scars</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fractional Laser</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Radiofrequency</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participant‐reported scar improvement (long‐term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospital‐based/outpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lack of a validated standardised improvement scale</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>5</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A2</p> <p>A3</p> <p>B2</p> <p>C1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>People with acne scars</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fractional Laser</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Radiofrequency</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participant‐reported scar improvement (short‐term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospital‐based/outpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lack of a validated standardised improvement scale</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>6</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>People with acne scars</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fractional Laser</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chemical peeling</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participant‐reported scar improvement (short‐ and long‐term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospital‐based/outpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lack of a validated standardised improvement scale</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>7</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A2</p> <p>A3</p> <p>B2</p> <p>C1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>People with acne scars</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fractional Laser</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Combined chemical peeling plus needling</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participant‐reported scar improvement (long‐term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospital‐based/outpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lack of a validated standardised improvement scale</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>8</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>People with acne scars</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fractional Laser</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Combined chemical peeling plus needling</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participant‐reported scar improvement (short‐term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospital‐based/outpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lack of a validated standardised improvement scale</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>9</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>People with acne scars</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fractional Laser</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Microdermabrasion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participant‐reported scar improvement (short‐ and long‐term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospital‐based/outpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lack of a validated standardised improvement scale</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>10</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>People with acne scars</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fractional Laser</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Needling</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participant‐reported scar improvement (short‐ and long‐term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospital‐based/outpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lack of a validated standardised improvement scale</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>11</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>People with acne scars</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fractional Laser</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Injectible fillers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participant‐reported scar improvement (short‐ and long‐term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospital‐based/outpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lack of a validated standardised improvement scale</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>12</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A1</p> <p>D4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>People with acne scars</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chemical peeling</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo/no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participant‐reported scar improvement (long‐term and short‐term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospital‐based/outpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lack of a validated standardised improvement scale</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>13</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A2</p> <p>A3</p> <p>B2</p> <p>C1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>People with acne scars</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chemical peeling</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Combined chemical peeling with any active intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participant‐reported scar improvement (long‐term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospital‐based/outpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lack of a validated standardised improvement scale</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>14</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>People with acne scars</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chemical peeling</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Combined chemical peeling with any active intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participant‐reported scar improvement (short‐term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospital‐based/outpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lack of a validated standardised improvement scale</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>15</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A1</p> <p>D4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>People with acne scars</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chemical peeling</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Needling</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participant‐reported scar improvement (long‐term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospital‐based/outpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lack of a validated standardised improvement scale</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>16</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A2</p> <p>A3</p> <p>B2</p> <p>C1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>People with acne scars</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chemical peeling</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Needling</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participant‐reported scar improvement (short‐term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospital‐based/outpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lack of a validated standardised improvement scale</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>17</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A1</p> <p>D4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>People with acne scars</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Injectable fillers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo/no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participant‐reported scar improvement (long‐term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lack of a validated standardised improvement scale</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>18</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A2</p> <p>C1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>People with acne scars</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Injectable fillers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo/no treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participant‐reported scar improvement (short‐term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>lack of a validated standardised improvement scale</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>19</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>People with acne scars</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Injectable fillers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Autologous bone marrow stem‐cell transplant</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participant‐reported scar improvement (short‐ and long‐term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hospital‐based</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lack of a validated standardised improvement scale</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>20</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>People with acne scars</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Microdermabrasion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participant‐reported scar improvement (short‐ and long‐term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lack of a validated standardised improvement scale</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>21</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>People with acne scars</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Microdermabrasion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Needling</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participant‐reported scar improvement (short‐ and long‐term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lack of a validated standardised improvement scale</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>22</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>People with acne scars</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Microdermabrasion</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Subcision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participant‐reported scar improvement (short‐ and long‐term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lack of a validated standardised improvement scale</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>23</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>People with acne scars</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Needling</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participant‐reported scar improvement (short‐ and long‐term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lack of a validated standardised improvement scale</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>24</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>A1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>People with acne scars</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Needling</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Subcision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participant‐reported scar improvement (short‐ and long‐term)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Outpatient</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lack of a validated standardised improvement scale</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p><b>* Reasons for Gap </b> </p> <p><b>Insufficient or imprecise information: A1</b> = No studies; <b>A2</b> = Limited number of studies; <b>A3</b> = Sample sizes too small; <b>A4</b> = Estimate of effect is imprecise<br/> <b>Information at 'Risk of bias': B1</b> = Inappropriate study design; <b>B2</b> = Major methodological limitations in studies<br/> <b>Inconsistency or unknown consistency: C1</b> = Consistency unknown (only 1 study); <b>C2</b> = Inconsistent results across studies<br/> <b>Not the right information: D1</b> = Results not applicable to population of interest; <b>D2</b> = Inadequate duration of interventions/comparisons; <b>D3</b> = Inadequate duration of follow‐up; <b>D4</b> = Optimal/most important outcomes not addressed; <b>D5</b> = Results not applicable to setting of interest </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Summary of research gaps</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/full#CD011946-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011946-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Non‐fractional non‐ablative laser versus placebo or no treatment</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Within‐individual studies <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Non‐fractional non‐ablative laser versus placebo or no treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/references#CD011946-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011946-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Fractional laser versus non‐fractional non‐ablative laser</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Participant‐reported scar improvement (short‐term) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Investigator‐assessed scar improvement (short‐term) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Participant‐reported adverse events (short‐term) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Burning</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Investigator‐assessed adverse events (short‐term) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Hyperpigmentation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Fractional laser versus non‐fractional non‐ablative laser</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/references#CD011946-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011946-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Fractional laser versus placebo or no treatment</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Within‐individual studies <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Fractional laser versus placebo or no treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/references#CD011946-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011946-tbl-0013"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Fractional laser versus radiofrequency</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Participant‐reported scar improvement (short‐term) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Investigator‐assessed scar improvement (short‐term) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Within‐individual studies <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Fractional laser versus radiofrequency</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/references#CD011946-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011946-tbl-0014"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Fractional laser versus combined fractional laser plus any active intervention</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Within‐individual studies <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Fractional laser versus combined fractional laser plus any active intervention</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/references#CD011946-tbl-0014">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011946-tbl-0015"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Fractional laser versus chemical peeling</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Within‐individual studies <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Fractional laser versus chemical peeling</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/references#CD011946-tbl-0015">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011946-tbl-0016"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Fractional laser versus combined chemical peeling plus needling</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Participant‐reported scar improvement (12 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Investigator‐assessed scar improvement (12 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Participant‐reported adverse events (&lt; 4 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Fractional laser versus combined chemical peeling plus needling</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/references#CD011946-tbl-0016">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011946-tbl-0017"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Chemical peeling versus placebo or no treatment</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Serious or severe adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Chemical peeling versus placebo or no treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/references#CD011946-tbl-0017">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011946-tbl-0018"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Chemical peeling versus combined chemical peeling plus any active intervention</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Participant‐reported scar improvement (8 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Investigator‐assessed scar improvement (8 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Participant‐reported adverse events (&lt; 4 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Investigator‐assessed adverse events (8 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Chemical peeling versus combined chemical peeling plus any active intervention</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/references#CD011946-tbl-0018">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011946-tbl-0019"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">Chemical peeling versus needling</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Participant‐reported scar improvement (1 month) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Investigator‐assessed scar improvement (1 month) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Patient satisfaction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Participant‐reported adverse events (&lt; 4 weeks) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Investigator‐assessed adverse events (1 month) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Hyperpigmentation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Post‐procedure down time <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">Chemical peeling versus needling</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/references#CD011946-tbl-0019">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011946-tbl-0020"> <div class="table-heading"><span class="table-label">Comparison 11.</span> <span class="table-title">Needling versus placebo or no treatment</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Within‐individual studies <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 11.</span> <span class="table-title">Needling versus placebo or no treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/references#CD011946-tbl-0020">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011946-tbl-0021"> <div class="table-heading"><span class="table-label">Comparison 12.</span> <span class="table-title">Injectable fillers versus placebo or no treatment</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Participant‐reported scar improvement (short‐term) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Investigator‐assessed scar improvement (short‐term) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Participant satisfaction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Participant‐reported adverse events (short‐term) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Investigator‐assessed adverse events (short‐term) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Within‐individual studies <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 12.</span> <span class="table-title">Injectable fillers versus placebo or no treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/references#CD011946-tbl-0021">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011946-tbl-0022"> <div class="table-heading"><span class="table-label">Comparison 13.</span> <span class="table-title">Injectable fillers versus subcision</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Within‐individual studies <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 13.</span> <span class="table-title">Injectable fillers versus subcision</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/references#CD011946-tbl-0022">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011946-tbl-0023"> <div class="table-heading"><span class="table-label">Comparison 14.</span> <span class="table-title">Combined microdermabrasion plus ALA‐PDT versus combined microdermabrasion plus placebo‐PDT</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Within‐individual studies <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 14.</span> <span class="table-title">Combined microdermabrasion plus ALA‐PDT versus combined microdermabrasion plus placebo‐PDT</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011946.pub2/references#CD011946-tbl-0023">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD011946.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD011946-note-0001">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD011946-note-0006">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD011946-note-0007">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD011946-note-0005">Français</a> </li> <li class="section-language"> <a class="" href="ms#CD011946-note-0019">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD011946-note-0004">Polski</a> </li> <li class="section-language"> <a class="" href="ru#CD011946-note-0003">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD011946-note-0002">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011946\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011946\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011946\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011946\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011946\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011946\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011946\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011946\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011946\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011946\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011946\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011946\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011946\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011946\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011946\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011946\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011946\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011946\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=bzu3XIhG&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011946.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011946.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD011946.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD011946.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011946.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740727610089"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011946.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740727610093"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011946.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918eb042aa4c936d',t:'MTc0MDcyNzYxMC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 